脳神経内科学レビュー　2022-'23

出版社： 総合医学社
著者：
発行日： 2022-03-25
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784883784646
電子書籍版： 2022-03-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

17,600 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,600 円(税込)

購入する
特記事項：

商品紹介

脳神経内科分野のエキスパートによって厳選された、直近2年間を中心に国内外で発表された最新の文献レビューです。広く脳神経内科関連の最近のトピックスを把握でき、脳神経内科専門医だけでなく、専門医を目指す方にも必携の1冊です。

目次

  • I章　脳血管障害
    　1．脳梗塞，TIA，内頚動脈狭窄症
    　2．超急性期機械的血栓回収療法
    　3．高血圧性脳内出血
    　4．くも膜下出血，脳動脈瘤，慢性硬膜下血腫
    　5．もやもや病
    　6．脳動脈解離
    　7．脳静脈・静脈洞血栓症
    　8．脳アミロイドアンギオパチー
    　9. 高血圧性脳症
    　10．遺伝性脳血管疾患

    II章　認知症
    　11．アルツハイマー病，軽度認知機能障害
    　12．レビー小体型認知症（DLB）
    　13．前頭側頭型認知症（FTD）
    　14．大脳皮質基底核変性症（CBD）
    　15．原発性進行性失語症
    　16．血管性認知症
    　17．特発性正常圧水頭症（iNPH）
    　18．遺伝性白質脳症/認知症

    III章　運動系の障害
    　19．パーキンソン病
    　20．進行性核上性麻痺
    　21．本態性振戦
    　22．ハンチントン病
    　23．脊髄小脳変性症
    　24．痙性対麻痺
    　25．物質の脳沈着による神経変性（鉄，ヘモジデリン，カルシウム）

    IV章　運動神経疾患類縁
    　26．脊髄性筋萎縮症（SMA），球脊髄性筋萎縮症（SBMA）
    　27. 筋萎縮性側索硬化症
    　28. 若年性一側上肢筋萎縮症（平山病）

    V章　脱髄疾患
    29. 多発性硬化症（MS）
    30. 視神経脊髄炎スペクトラム
    31. MOG抗体関連疾患（MOGAD）
    32. 中枢末梢連合脱髄症（CCPD）

    VI章　自己免疫性脳炎・硬膜炎
    33. 自己免疫性脳炎およびその類縁疾患
    34. 肥厚性硬膜炎，サルコイドーシス

    VII章　末梢神経疾患
    　35. Guillain-Barré症候群，Fisher症候群
    　36. CIDPとその類縁疾患（MMN with conduction block
    　37. 免疫性ニューロパチー（POEMS症候群，MGUSニューロパチー，自己免疫性自律神経節障害）
    　38. その他のニューロパチー（糖尿病性，傍腫瘍性，薬剤性ニューロパチー）
    　39. 血管炎性ニューロパチー（EGPAも含む）
    　40. 圧迫性ニューロパチー（手根管症候群，肘管症候群）
    　41. 家族性アミロイドポリニューロパチー
    　42. 遺伝性ニューロパチー（CMT，HSAN）
    　43. 重症疾患多発ニューロパチー（CIP）

    VIII章　筋疾患
    　44. 重症筋無力症
    　45. Lambert-Eaton筋無力症候群
    　46. 炎症性筋疾患
    　47. 筋強直性ジストロフィー
    　48. 筋ジストロフィー
    　49. 遺伝性周期性四肢麻痺，非ジストロフィー性ミオトニー症候群
    　50. 先天性ミオパチー

    IX章　神経系感染症
    　51. 脳炎
    　52. 髄膜炎の診断と治療
    　53. ヒトTリンパ球向性ウイルス脊髄症（HAM）
    　54. プリオン病
    　55. 進行性多巣性白質脳症（PML）
    　56. COVID-19 神経感染症

    X章　代謝性疾患
    　57. ファブリー病
    　58. ミトコンドリア病
    　59. Wilson病

    XI章　頭　痛
    　60. 片頭痛
    　61. 緊張型頭痛
    　62. 群発頭痛と三叉神経・自律神経性頭痛
    　63. 低髄液圧症候群（脳脊髄液減少症，脳脊髄液漏出症）
    　64. 三叉神経痛
    　65. 可逆性後頭葉白質脳症（PRES），可逆性脳血管攣縮症候群（RCVS）

    XII章　てんかん
    66. てんかん

    XIII章　神経（脳神経内科）系疾患における新たな治療・新薬の動向
    67. 神経（脳神経内科）系疾患における新たな治療・新薬の動向

    XIV章　神経（脳神経内科）系疾患における新たな診断技術・臨床検査の動向
    68. 神経（脳神経内科）系疾患における新たな診断技術・臨床検査の動向

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 脳血管障害

P.2 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会編 : 脳卒中治療ガイドライン 2021. 協和企画, 東京, 2021
 
2) Thomalla G, Simonsen CZ, Boutitie F et al : MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 379 : 611-622, 2018
PubMed
3) Koga M, Yamamoto H, Inoue M et al : Thrombolysis with alteplase at 0.6 mg/kg for stroke with unknown time of onset : a randomized controlled trial. Stroke 51 : 1530-1538, 2020
 
P.3 掲載の参考文献
4) Toyoda K, Inoue M, Yoshimura S et al : Magnetic resonance imaging-guided thrombolysis (0.6 mg/kg) was beneficial for unknown onset stroke above a certain core size : THAWS RCT Substudy. Stroke 52 : 12-19, 2021
 
5) Pan Y, Elm JJ, Li H et al : Outcomes-associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack : a pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebro-vascular events (CHANCE) and plateletoriented inhibition in new TIA and minor ischemic stroke (POINT) Trials. JAMA Neurol 76 : 1466-1473, 2019
PubMed
6) Toyoda K, Uchiyama S, Yamaguchi T et al : Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan : a multicentre, open-label, randomised controlled trial. Lancet neurology 18 : 539-548, 2019
PubMed
P.4 掲載の参考文献
7) Johnston SC, Amarenco P, Albers GW et al : Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 375 : 35-43, 2016
 
8) Johnston SC, Amarenco P, Denison H et al : Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 383 : 207-217, 2020
 
9) Ogawa A, Toyoda K, Kitagawa K et al : Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke : a phase 3, randomised, noninferiority trial (PRASTRO-I). Lancet neurology 18 : 238-247, 2019
PubMed
P.5 掲載の参考文献
10) Kitazono T, Toyoda K, Kitagawa K et al : Efficacy and safety of prasugrel by stroke subtype : a sub-analysis of the PRASTRO-I randomized controlled trial. J Atheroscler Thromb 28 : 169-180, 2021
PubMed
11) Kitagawa K, Toyoda K, Kitazono T et al : Safety and efficacy of prasugrel in elderly/low body weight Japanese patients with ischemic stroke : randomized PRASTRO-II. Cerebro-vascular diseases 49 : 152-159, 2020
 
12) 北園孝成 : PRASTRO試験. 神経治療 38 : S144, 2021
Medical*Online
P.6 掲載の参考文献
13) Okumura K, Akao M, Yoshida T et al : Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 383 : 1735-1745, 2020
PubMed
14) Kitagawa K, Yamamoto Y, Arima H et al : Effect of standard vs intensive blood pressure control on the risk of recurrent stroke : a randomized clinical trial and meta-analysis. JAMA Neurol 76 : 1309-1318, 2019
PubMed
P.7 掲載の参考文献
15) Amarenco P, Kim JS, Labreuche J et al : Benefit of targeting a LDL (Low-Density Lipoprotein) cholesterol < 70 mg/dL during 5 years after ischemic stroke. Stroke 51 : 1231-1239, 2020
PubMed
P.9 掲載の参考文献
1) Requena M, Olive-Gadea M, Muchada M et al : Direct to angiography suite without stopping for computed tomography imaging for patients with acute stroke. JAMA Neurol 78 : 1099-1107, 2021
PubMed
2) Sarraji A, Goyal N, Chen M et al : Direct to angiography vs repeated imaging approaches in transferred patients undergoing endo-vascular thrombectomy. JAMA Neurol 78 : 916-926, 2021
 
3) Texakalidis P, Giannopoulos S, Karasavvidis T et al : Mechanical thrombectomy in acute ischemic stroke : a meta-analysis of stent retrievers vs direct aspiration vs a combined approach. Neurosurgery 86 : 464-477, 2020
 
P.10 掲載の参考文献
4) Mohammaden MH, Haussen DC, Pisani L et al : Stent-retriever alone vs. aspiration and stent-retriever combination in large vessel occlusion stroke : a matched analysis. Int J Stroke, 2021 [online ahead of print]
 
5) Yoo J, Lee SJ, Hong JH et al : Immediate effects of first-line thrombectomy devices for intracranial atherosclerosis-related occlusion : stent retriever versus contact aspiration. BMC Neurol 20 : 283, 2020
 
6) Suzuki K, Matsumaru Y, Takeuchi M et al : Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic Stroke : the SKIP randomized clinical trial. JAMA 325 : 244-253, 2021
PubMed
7) Yang P, Zhang Y, Zhang L et al : Endo-vascular thrombectomy with or without intravenous alteplase in acute stroke. N Engl J Med 382 : 1981-1993, 2020
PubMed
8) Zi W, Qiu Z, Li F et al : Effect of endo-vascular treatment alone vs intravenous alteplase plus endo-vascular treatment on functional independence in patients with acute ischemic stroke. JAMA 325 : 234-243, 2021
 
P.11 掲載の参考文献
9) Bouslama M, Barreira CM, Haussen DC et al : Endo-vascular reperfusion outcomes in patients with a stroke and low ASPECTS is highly dependent on baseline infarct volumes. J Neurointerv Surg, 2021 [online ahead of print]
 
10) Diestro JDB, Dmytriw AA, Broocks G et al : Endo-vascular thrombectomy for low ASPECTS large vessel occlusion ischemic stroke : a systematic review and meta-analysis. Can J Neurol Sci 47 : 612-619, 2020
 
11) Xing PF, Zhang YW, Zhang L et al : Higher baseline cortical score predicts good outcome in patients with low alberta stroke program early computed tomography score treated with endo-vascular treatment. Neurosurgery 88 : 612-618, 2021
 
12) Yoshimoto T, Inoue M, Tanaka K et al : Identifying large ischemic core volume ranges in acute stroke that can benefit from mechanical thrombectomy. J Neurointerv Surg, 2020 [online ahead of print]
 
P.12 掲載の参考文献
13) Volny O, Zerna C, Tomek A et al : Thrombectomy vs medical management in low NIHSS acute anterior circulation stroke. Neurology 95 : e3364-e3372, 2020
PubMed
14) Goyal N, Tsivgoulis G, Malhotra K et al : Medical management vs mechanical thrombectomy for mild strokes : an international multicenter study and systematic review and meta-analysis. JAMA Neurol 77 : 16-24, 2020
PubMed
15) Zhao Y, Song Y, Guo Y et al : Endo-vascular thrombectomy VS. medical treatment for mild stroke patients : a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 29 : 105258, 2020
 
16) Muszynski P, Anadani M, Richard S et al : Endo-vascular reperfusion of M2 occlusions in acute ischemic stroke reduced disability and mortality : ETIS registry results. J Neurointerv Surg, 2021 [online ahead of print]
 
17) Menon BK, Hill MD, Davalos A et al : Efficacy of endo-vascular thrombectomy in patients with M2 segment middle cerebral artery occlusions : meta-analysis of data from the HERMES Collaboration. J Neurointerv Surg 11 : 1065-1069, 2019
 
18) Vidale S, Romoli M, Agostoni EC : Endo-vascular treatment versus intravenous thrombolysis alone in isolated M2 occlusion : a meta-analysis. Neurol Sci 42 : 4221-4224, 2021
 
19) Wang J, Qian J, Fan L et al : Efficacy and safety of mechanical thrombectomy for M2 segment of middle cerebral artery : a systematic review and meta-analysis. J Neurol 268 : 2346-2354, 2020
PubMed
20) Langezaal LCM, van der Hoeven EJRJ, Mont'Alverne FJA et al : Endo-vascular therapy for stroke due to basilar-artery occlusion. N Engl J Med 384 : 1910-1920, 2021
 
21) Liu X, Dai Q, Ye R et al : Endo-vascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST) : an open-label, randomised controlled trial. Lancet Neurol 19 : 115-122, 2020
 
P.13 掲載の参考文献
22) Zhu F, Bracard S, Anxionnat R et al : Impact of emergent cervical carotid stenting in tandem occlusion strokes treated by thrombectomy : a review of the TITAN collaboration. Front Neurol 10 : 206, 2019
PubMed
P.14 掲載の参考文献
23) Anadani M, Marnat G, Consoli A et al : Endo-vascular therapy of anterior circulation tandem occlusions : pooled analysis from the TITAN and ETIS registries. Stroke 52 : 3097-3105, 2021
 
24) Li H, Zhang Y, Zhang L et al : Endo-vascular treatment of acute ischemic stroke due to intracranial atherosclerotic large vessel occlusion : a systematic review. Clin Neuroradiol 30 : 777-787, 2020
 
25) Yang W, Zhang Y, Li Z et al : Differences in safety and efficacy of endo-vascular treatment for acute ischemic stroke : a propensity score analysis of intracranial atherosclerosis-related occlusion versus embolism. Clin Neuroradiol 31 : 457-464, 2021
 
26) Yoo J, Kim YD, Park H et al : Immediate and long-term outcomes of reperfusion therapy in patients with cancer. Stroke 52 : 2026-2034, 2021
 
27) Fu CH, Chen CH, Lin YH et al : Fibrin and platelet-rich composition in retrieved thrombi hallmarks stroke with active cancer. Stroke 51 : 3723-3727, 2020
PubMed
28) Jeon Y, Baik SH, Jung C et al : Mechanical thrombectomy in patients with acute cancer-related stroke : is the stent retriever alone effective? J Neurointerv Surg 13 : 318-323, 2021
PubMed
P.15 掲載の参考文献
29) Fujita K, Tanaka K, Yamagami H et al : Outcomes of large vessel occlusion stroke in patients aged 90 years. Stroke 52 : 1561-1569, 2021
PubMed
30) Hendrix P, Killer-Oberpfalzer M, Broussalis E et al : Outcome following mechanical thrombectomy for anterior circulation large vessel occlusion stroke in the elderly. Clin Neuroradiol, 2021 [online ahead of print]
 
P.16 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会編 : III 脳出血. "脳卒中治療ガイドライン 2021". 協和企画, 東京, pp115-148, 2021
 
2) Moullaali T, Wang X, Martin RH et al : Blood pressure control and clinical outcomes in acute intracerebral haemorrhage : a preplanned pooled analysis of individual participant data. Lancet Neurol 18 : 857-864, 2019
PubMed
P.18 掲載の参考文献
3) Leasure AC, Qureshi AI, Murthy SB et al : Association of intensive blood pressure reduction with risk of hematoma expansion in patients with deep intracerebral hemorrhage. JAMA Neurol 76 : 949-955, 2019
PubMed
P.19 掲載の参考文献
4) Meretoja A, Yassi N, Wu TY et al : Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST) : a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 19 : 980-987, 2020
 
P.20 掲載の参考文献
5) Gladstone DJ, Aviv RI, Demchuk AM et al : Effect of recombinant activated coagulation factor VII on hemorrhage expansion among patients with spot sign-positive acute intracerebral hemorrhage : the SPOTLIGHT and STOP-IT randomized clinical trials. JAMA Neurol 76 : 1493-1501, 2019
PubMed
6) Li L, Poon MTC, Samarasekera NE et al : Risks of recurrent stroke and all serious-vascular events after spontaneous intracerebral haemorrhage : pooled analyses of two population-based studies. Lancet Neurol 20 : 437-447, 2021
PubMed
P.21 掲載の参考文献
7) Murthy SB, Zhang C, Diaz I et al : Association between intracerebral hemorrhage and subsequent arterial ischemic events in participants from 4 population-based cohort studies. JAMA Neurol 78 : 809-816, 2021
PubMed
8) Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J et al : Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with arterial fibrillation in the Netherlands (APACH-AF) : a randomized, open-label, phase 2 trial. Lancet Neurol 20 : 907-916, 2021
 
P.22 掲載の参考文献
9) SoSTART Collaboration : Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK : a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol 20 : 842-853, 2021
 
10) Salman RAS, Dennis MS, Sandercock PGA et al : Effects of antiplatelet therapy after stroke caused by intaracerebral hemorrhage : extended follow-up of the RESTART Randomized clinical trial. JAMA Neurol 78 : 1179-1186, 2021
 
P.23 掲載の参考文献
1) Etiminan N, Chang HS, Hackenberg K et al : Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population : a systematic review and meta-analysis. JAMA Neurology 76 : 588-597, 2019
 
P.24 掲載の参考文献
2) Ikawa F, Morita A, Nakayama T et al : A register-based SAH study in Japan : high incidence rate and recent decline trend based on lifestyle. J Neurosurg 134 : 983-991, 2021
 
3) Schatlo B, Gautschi OP, Friedrich CM et al : Association of single and multiple aneurysms with tobacco abuse : an @neurIST risk analysis. Neurosurgical Focus 47 : E9, 2019
PubMed
4) Korja M, Kaprio J : Controversies in epidemiology of intracranial aneurysms and SAH. Nat Rev Neurol 12 : 50-56, 2016
PubMed
5) Bianchi C, Ageron FX, Carron PN : Assessment of diagnostic strategies based on risk stratification for aneurysmal subarachnoid hemorrhage : a retrospective chart review. Eur J Emerg Med 28 : 355-362, 2021
PubMed
6) Kaneko J, Tagami T, Chie Tanaka et al : Ultra-early induction of general anesthesia for reducing rebleeding rates in patients with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 30 : 105926, 2021
PubMed
7) Chai CL, Jeon JP, Tsai YH et al : Endo-vascular intervention versus surgery in ruptured intracranial aneurysms in equipoise : a systematic review. Stroke 51 : 1703-1711, 2020
 
8) Van Donkelaar CE, Bakker NA, Birks J et al : Impact of treatment delay on outcome in the international subarachnoid aneurysm trial. Stroke 51 : 1600-1603, 2020
PubMed
9) Jiang Z, Chen Y, Zeng C et al : Neurosurgical clipping versus endo-vascular coiling for patients with intracranial aneurysmsa systematic review and meta-analysis. World Neurosurg 138 : e 191-222, 2020
 
P.25 掲載の参考文献
10) Ikawa F, Michihata N, Matsushige T et al : In-hospital mortality and poor outcome after surgical clipping and endo-vascular coiling for aneurysmal subarachnoid hemorrhage using nationwide databases : a systematic review and meta-analysis. Neurosurg Rev 43 : 655-667, 2020
 
11) Rumalla K, Lin M, Ding L et al : Risk factors for cerebral vasospasm in aneurysmal subarachnoid hemorrhage : a population-based study of 8346 patients. World Neurosurg 145 : e 233-241, 2021
 
12) Mayer SA, Aldrich EF, Bruder N et al : Thick and diffuse subarachnoid blood as a treatment effect modifier of clazosentan after subarachnoid hemorrhage. Stroke 50 : 2738-2744, 2019
PubMed
13) Higashida RT, Bruder N, Gupta R et al : Reversal of vasospasm with clazosentan after aneurysmal subarachnoid hemorrhage : a pilot study. World Neurosurg 128 : e 639-648, 2021
 
14) Shan T, Zhang T, Qian W et al : Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage : a systematic review and meta-analysis. J Neurol 267 : 1577-1584, 2020
 
15) Gao Y, Zhao C, Wang J et al : The potential biomarkers for the formation and development of intracranial aneurysm. J Clin Neurosci 81 : 270-278, 2020
PubMed
16) Hackenberg KAM, Oghaz HR, Dreier R et al : Collagen turnover in relation to risk factors and hemodynamics in human intracranial aneurysms. Stroke 51 : 1624-1628, 2020
 
P.26 掲載の参考文献
17) Woo HG, Chang YK, Lee JS et al : Association of periodontal disease with the occurrence of unruptured cerebral aneurysm among adults in Korea : a nationwide population-based cohort study. Medicina (Kaunas) 57 : 910, 2021
 
18) Hallikainen J, Lindgren A, Savolainen J et al : Periodontitis and gingival bleeding associate with intracranial aneurysms and risk of aneurysmal subarachnoid hemorrhage. Neurosurg Rev 43 : 669-679, 2019
PubMed
19) Li H, Xu H, Li Y et al : Alterations of gut microbiota contribute to the progression of unruptured intracranial aneurysms. Nat Commun 11 : 3218, 2020
 
20) Roa JA, Zanaty M, Ishii D et al : Decreased contrast enhancement on highresolutionvessel wall imaging of unruptured intracranial aneurysmsin patients taking aspirin. J Neurosurg 134 : 902-908, 2020
 
21) Feng X, Tong X, Chen J et al : External validation of the PHASES score in patients with multiple intracranial aneurysms. J Stroke Cerebrovasc Dis 30 : 105643, 2021
PubMed
P.27 掲載の参考文献
22) Shimizu K, Imamura H, Tani S et al : Candidate drugs for preventive treatment of unruptured intracranial aneurysms : a crosssectional study. PLoS One 16 : e0246865, 2021
PubMed
23) Algra AM, Lindgren A, Vergouwen MDI et al : Procedural clinical complications, case-fatality risks, and risk factors in endo-vascular and neurosurgical treatment of unruptured intracranial aneurysms : a systematic review and meta-analysis. JAMA Neurol 76 : 282-293, 2019
 
24) Hanel RA, Kallmes DF, Lopes DK et al : Prospective study on embolization of intracranial aneurysms with the pipeline device : the PREMIER study 1 year results. J Nerointerv Surgery 12 : 62-66, 2020
PubMed
25) Pierot L, Spelle L, Berge J et al : SAFE study (Safety and efficacy Analysis of FRED Embolic device in aneurysm treatment) : 1-year clinical and anatomical results. J Neurointerv Surg 11 : 184-189, 2019
PubMed
26) Arthur AS, Molyneux A, Coon AL et al ; WEB-IT Study investigators : The safety and effectiveness of the Woven Endo-Bridge (WEB) system for the treatment of wide-necked bifurcation aneurysms : final 12-month results of the pivotal WEB Intrasaccular Therapy (WEB-IT) Study. J Neurointerv Surg 11 : 924-930, 2019
 
P.28 掲載の参考文献
27) Toi H, Kinoshita K, Hirai S et al : Present epidemiology of chronic subdural hematoma in Japan : analysis of 63,358 cases recorded in a national administrative database. J Neurosurg 128 : 222-228, 2018
 
28) He C, Xia P, Xu J et al : Evaluation of the efficacy of atorvastatin in the treatment for chronic subdural hematoma : a meta-analysis. Neurosurg Rev 44 : 479-484, 2021
 
29) Todeschi J, Ferracci FX, Metayer T et al : Impact of discontinuation of antithrombotic therapy after surgery for chronic subdural hematoma. Neurochirurgie 66 : 195-202, 2020
PubMed
P.29 掲載の参考文献
30) Ironside N, Nguyen C, Do Q et al : Middle meningeal artery embolization for chronic subdural hematoma : a systematic review and meta-analysis. J Neurointerv Surg 13 : 951-957, 2021
PubMed
P.30 掲載の参考文献
1) Liu W, Morito D, Takashima S et al : Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 6 : e22542, 2011
PubMed
2) Miyamoto S, Yoshimoto T, Hashimoto N et al : Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease : results of the Japan Adult Moyamoya Trial. Stroke 45 : 1415-1421, 2014
PubMed
P.31 掲載の参考文献
3) Sato Y, Kazumata K, Nakatani E et al : Characteristics of moyamoya disease based on national registry data in Japan. Stroke 50 : 1973-1980, 2019
 
4) Sun Y, Zhou G, Feng J et al : Incidence and prevalence of moyamoya disease in urban China : a nationwide retrospective cohort study. Stroke Vasc Neurol, 2021
 
5) Mineharu Y, Miyamoto S : RNF213 and GUCY1A3 in moyamoya disease : key regulators of metabolism, inflammation, and vascular stability. Front Neurol 12 : 687088, 2021
PubMed
6) Matsuo M, Nadanaka S, Soga M et al : Vulnerability to shear stress caused by altered peri-endothelial matrix is a key feature of Moyamoya disease. Sci Rep 11 : 1552, 2021
PubMed
7) Lee WJ, Jeong SK, Han KS et al : Impact of endothelial shear stress on the bilateral progression of unilateral moyamoya disease. Stroke 51 : 775-783, 2020
PubMed
8) Ishigami D, Miyawaki S, Imai H et al : RNF213 p.Arg4810Lys heterozygosity in moyamoya disease indicates early onset and bilateral cerebro-vascular events. Transl Stroke Res, 2021
 
P.32 掲載の参考文献
9) Mineharu Y, Takagi Y, Koizumi A et al : Genetic and nongenetic factors for contralateral progression of unilateral moyamoya disease : the first report from the SUPRA Japan Study Group. J Neurosurg : 1-10, 2021
 
10) Hongo H, Miyawaki S, Imai H et al : Comprehensive investigation of RNF213 nonsynonymous variants associated with intracranial artery stenosis. Sci Rep 10 : 11942, 2020
PubMed
11) Eto F, Yoshimoto T, Okazaki S et al : RNF213 p.R4810K (c.14429G > A) variant determines anatomical variations of the circle of Willis in cerebro-vascular disease. Front Aging Neurosci 13 : 681743, 2021
 
12) Ozaki D, Endo H, Tashiro R et al : Association between RNF213 c.14576G > A variant (rs112735431) and peripheral pulmonary artery stenosis in moyamoya disease. Cerebrovasc Dis : 1-6, 2021
PubMed
13) Ya J, Zhou D, Ding J et al : High-resolution combined arterial spin labeling MR for identifying cerebral arterial stenosis induced by moyamoya disease or atherosclerosis. Ann Transl Med 8 : 87, 2020
PubMed
14) Yang S, Wang X, Liao W et al : High-resolution MRI of the vessel wall helps to distinguish moyamoya disease from atherosclerotic moyamoya syndrome. Clin Radiol 76 : 392e311-392e319, 2021
 
15) Lu M, Zhang H, Liu D et al : Association of intracranial vessel wall enhancement and cerebral hemorrhage in moyamoya disease : a high-resolution magnetic resonance imaging study. J Neurol, 2021
PubMed
16) Kathuveetil A, Sylaja PN, Senthilvelan S et al : Vessel wall thickening and enhancement in high-resolution intracranial vessel wall imaging : a predictor of future ischemic events in moyamoya disease. AJNR Am J Neuroradiol 41 : 100-105, 2020
PubMed
17) Choi EH, Lee H, Chung JW et al : Ring finger protein 213 variant and plaque characteristics, vascular remodeling, and hemodynamics in patients with intracranial atherosclerotic stroke : a high-resolution magnetic resonance imaging and hemodynamic study. J Am Heart Assoc 8 : e011996, 2019
 
18) Kim HJ, Choi EH, Chung JW et al : Role of the RNF213 variant in -vascular outcomes in patients with intracranial atherosclerosis. J Am Heart Assoc 10 : e017660, 2021
PubMed
P.33 掲載の参考文献
19) Hara S, Tanaka Y, Ueda Y et al : Detection of hemodynamic impairment on (15) O gas PET using visual assessment of arterial spin-labeling MR imaging in patients with moyamoya disease. J Clin Neurosci 72 : 258-263, 2020
PubMed
20) Setta K, Matsuda T, Sasaki M et al : Diagnostic accuracy of screening arterial spinlabeling MRI using hadamard encoding for the detection of reduced CBF in adult patients with ischemic moyamoya disease. AJNR Am J Neuroradiol 42 : 1403-1409, 2021
PubMed
21) Miyakoshi A, Funaki T, Fushimi Y et al : Cortical distribution of fragile periventricular anastomotic collateral vessels in moyamoya disease : an exploratory crosssectional study of Japanese patients with moyamoya disease. AJNR Am J Neuroradiol 41 : 2243-2249, 2020
PubMed
22) Funaki T, Takahashi JC, Houkin K et al : High rebleeding risk -associated with choroidal collateral vessels in hemorrhagic moyamoya disease : analysis of a nonsurgical cohort in the Japan Adult Moyamoya Trial. J Neurosurg 130 : 337-673, 2019
 
23) Funaki T, Takahashi JC, Houkin K et al : Effect of choroidal collateral vessels on de novo hemorrhage in moyamoya disease : analysis of nonhemorrhagic hemispheres in the Japan Adult Moyamoya Trial. J Neurosurg 132 : 408-414, 2019
 
24) Miyakoshi A, Funaki T, Fushimi Y et al : Identification of the bleeding point in hemorrhagic moyamoya disease using fusion images of susceptibility-weighted imaging and time-of-flight MRA. AJNR Am J Neuroradiol 40 : 1674-1680, 2019
PubMed
25) Yamamoto S, Funaki T, Fujimura M et al : Development of hemorrhage-prone anastomoses in asymptomatic moyamoya disease-a comparative study with Japan adult moyamoya trial. J Stroke Cerebrovasc Dis 28 : 104328, 2019
 
26) Pang CH, Cho WS, Kang HS et al : Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease. Sci Rep 11 : 19367, 2021
PubMed
27) Ye F, Li J, Wang T et al : Efficacy and safety of antiplatelet agents for adult patients with ischemic moyamoya disease. Front Neurol 11 : 608000, 2020
 
P.34 掲載の参考文献
28) Seo WK, Kim JY, Choi EH et al : Association of antiplatelet therapy, including cilostazol, with improved survival in patients with moyamoya disease in a nationwide study. J Am Heart Assoc 10 : e017701, 2021
 
29) Ando S, Tsutsui S, Miyoshi K et al : Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease : sub-analysis of a prospective cohort. Neurol Res 41 : 480-487, 2019
 
30) Aihara Y, Kashiwase S, Chiba K et al : Aspirin use and platelet aggregation in ischemic onset-type pediatric moyamoya patients with intractable headaches (moyaache). Childs Nerv Syst 37 : 1649-1657, 2021
PubMed
P.35 掲載の参考文献
1) 国循脳卒中データバンク2021編集委員会編 : 脳卒中データバンク 2021. 中山書店, 東京, 2021
 
P.36 掲載の参考文献
2) 日本脳卒中学会脳卒中ガイドライン委員会編 : 脳卒中治療ガイドライン 2021. 協和企画, 東京, pp202-210, 2021
 
3) Markus HS, Levi C, King A et al : Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection : the cervical artery dissection in stroke study (CADISS) randomized clinical trial final results. JAMA Neurol 76 : 657-664, 2019
PubMed
P.37 掲載の参考文献
4) Engelter ST, Traenka C, Gensicke H et al : Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD) : an open-label, randomised, non-inferiority trial. Lancet Neurol 20 : 341-350, 2021
PubMed
5) Bernardo F, Nannoni S, Strambo D et al : Intravenous thrombolysis in acute ischemic stroke due to intracranial artery dissection : a single-center case series and a review of literature. J Thromb Thrombolysis 48 : 679-684, 2019
 
P.38 掲載の参考文献
6) Kloss M, Kalashnikova L, Dobrynina L et al : Recurrent versus first cervical artery dissection-a retrospective study of clinical and -vascular characteristics. Eur J Neurol 27 : 2185-2190, 2020
PubMed
7) Brunser AM, Lavados PM, Cavada G et al : Transcranial Doppler as a predictor of ischemic events in vertebral artery dissection. J Neuroimaging 30 : 890-895, 2020
PubMed
P.39 掲載の参考文献
8) Rosati LM, Vezzetti A, Redd KT et al : Early anticoagulation or antiplatelet therapy is critical in craniocervical artery dissection : results from the COMPASS registry. Cerebrovasc Dis 49 : 369-374, 2020
PubMed
9) Vezzetti A, Rosati LM, Lowe FJ et al : Stenting as a treatment for cranio-cervical artery dissection : improved major adverse cardio-vascular event-free survival. Catheter Cardiovasc Interv, 2021 [online ahead of print]
 
P.40 掲載の参考文献
10) Korai M, Kanematsu Y, Yamaguchi I et al : Subarachnoid hemorrhage due to rupture of vertebral artery dissecting aneurysms : treatments, outcomes, and prognostic factors. World Neurosurg 152 : e86-e93, 2021
PubMed
11) Maybaum J, Henkes H, Aguilar-Perez M et al : Flow diversion for reconstruction of intradural vertebral artery dissecting aneurysms causing subarachnoid hemorrhage-A retrospective study from four neuro-vascular centers. Front Neurol 12 : 700164, 2021
 
P.42 掲載の参考文献
1) Al Rawahi B, Almegren M, Carrier M : The efficacy and safety of anticoagulation in cerebral vein thrombosis : a systematic review and meta-analysis Thromb Res 169 : 135-139, 2018
PubMed
2) Ferro JM, Bousser MG, Canhao P et al : European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis-endorsed by the European Academy of Neurology Eur J Neurol 24 : 1203-1213, 2017
PubMed
3) The Japan Stroke Society : Japanese Guidelines for the Management of Stroke 2021. Kyowa kikaku, Tokyo, pp225-227, 2021
 
4) Saposnik G, Barinagarrementeria F, Brown RD Jr et al : Diagnosis and management of cerebral venous thrombosis : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 : 1158-1192, 2011
PubMed
P.43 掲載の参考文献
5) Miranda B, Aaron S, Arauz A et al : The benefit of EXtending oral antiCOAgulation treatment (EXCOA) after acute cerebral vein thrombosis (CVT) : eXCOA-CVT cluster randomized trial protocol. Int J Stroke 13 : 771-774, 2018
PubMed
6) Ferro JM, Coutinho JM, Dentali F et al : Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis : a randomized clinical trial. JAMA Neurol 76 : 1457-1465, 2019
PubMed
7) Connor P, Sanchez van Kammen M et al : Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv 4 : 6250-6258, 2020
 
P.44 掲載の参考文献
8) Coutinho JM, Zuurbier SM, Bousser MG et al : Effect of endo-vascular treatment with medical management vs standard care on severe cerebral venous thrombosis : the TO-ACT randomized clinical trial. JAMA Neurol 77 : 966-973, 2020
 
9) Coutinho JM, Ferro JM, Stam J : Endo-vascular treatment for cerebral venous thrombosis. World Neurosurg 144 : 194-195, 2020
 
10) Fraiman P, Godeiro Junior C, Moro E et al : COVID-19 and cerebro-vascular diseases : a systematic review and perspectives for stroke management. Front Neurol 11 : 574694, 2020
 
P.45 掲載の参考文献
11) Mowla A, Shakibajahromi B, Shahjouei S et al : Cerebral venous sinus thrombosis associated with SARS-CoV-2 ; a multinational case series. J Neurol Sci 419 : 117183, 2020
 
12) Baldini T, Asioli GM, Romoli M et al : Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection : a systematic review and meta-analysis Eur J Neurol 28 : 3478-3490, 2021
PubMed
13) Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A et al : Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination ; a systematic review J Neurol Sci 428 : 117607, 2021
PubMed
14) Krzywicka K, Heldner MR, Sanchez van Kammen M et al : Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis : an analysis of cases notified to the European Medicines Agency. Eur J Neurol, 2021
 
P.46 掲載の参考文献
15) Furie KL, Cushman M, Elkind MSV et al : Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. stroke 52 : 2478-2482, 2021
PubMed
16) Cines DB, Bussel JB : SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 384 : 2254-2256, 2021
PubMed
P.48 掲載の参考文献
1) Jakel L, De Kort AM, Klijn CJM et al : Prevalence of cerebral amyloid angiopathy : a systematic review and meta-analysis. Alzheimers Dement, 2021 [online ahead of print]
 
2) Sakai K, Ueda M, Fukushima W et al : Nationwide survey on cerebral amyloid angiopathy in Japan. Eur J Neurol 26 : 1487-1493, 2019
PubMed
3) Greenberg SM, Charidimou A : Diagnosis of cerebral amyloid angiopathy : evolution of the Boston Criteria. stroke 49 : 491-497, 2018
PubMed
4) Rodrigues MA, Samarasekera N, Lerpiniere C et al : The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage -associated with cerebral amyloid angiopathy : model development and diagnostic test accuracy study. Lancet Neurol 17 : 232-40, 2018
PubMed
5) Etten ESv, Kaushik K, Zwet EWv et al : Sensitivity of the Edinburgh Criteria for lobar intracerebral hemorrhage in Hereditary Cerebral Amyloid Angiopathy. Stroke 51 : 3608-3612, 2020
 
6) Baron JC, Boulouis G, Benzakoun J et al : Cerebral amyloid angiopathy-related acute lobar intra-cerebral hemorrhage : diagnostic value of plain CT. J Neurol, 2021 [online ahead of print]
 
P.49 掲載の参考文献
7) Kozberg MG, Perosa V, Gurol ME et al : A practical approach to the management of cerebral amyloid angiopathy. Int J Stroke 16 : 356-369, 2021
 
8) Charidimou A, Boulouis G, Greenberg SM et al : Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy. Neurology 93 : e2192, 2019
PubMed
9) Yilmaz P, Ikram MA, Ikram MK et al : Application of an imaging-based sum score for cerebral amyloid Angiopathy to the general population : risk of major neurological diseases and mortality. Front Neurol 10 : 1276, 2019
 
10) Matsuda K, Shindo A, Ii Y et al : Investigation of hypertensive arteriopathy-related and cerebral amyloid angiopathy-related small vessel disease scores in patients from a memory clinic : a prospective single-centre study. BMJ open 11 : e042550, 2021
 
P.50 掲載の参考文献
11) Smith EE, Charidimou A, Ayata C et al : Cerebral amyloid angiopathy-related transient focal neurologic episodes. Neurology 97 : 231-238, 2021
PubMed
12) Auriel E, Charidimou A, Gurol ME et al : Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol 73 : 197-202, 2016
PubMed
13) Regenhardt RW, Thon JM, Das AS et al : Association between immunosuppressive treatment and outcomes of cerebral amyloid angiopathy-related inflammation. JAMA Neurol 77 : 1261-1269, 2020
PubMed
P.51 掲載の参考文献
14) Antolini L, DiFrancesco JC, Zedde M et al : Spontaneous ARIA-like events in cerebral amyloid angiopathy-related inflammation : a multicenter prospective longitudinal cohort study. Neurology 97 : e1809-e1822, 2021
PubMed
15) Weller JM, Enkirch SJ, Bogs C et al : Endo-vascular treatment for acute stroke in cerebral amyloid angiopathy. Stroke 2 : e581-e585, 2021
 
16) Derraz I, Cagnazzo F, Gaillard N et al : Microbleeds, cerebral hemorrhage, and functional outcome after endo-vascular thrombectomy. Neurology 96 : e1724-e1731, 2021
 
P.52 掲載の参考文献
17) Al-Shahi Salman R, Dennis MS, Sandercock PAG et al : Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART) : a randomised, open-label trial. Lancet 393 : 2613-2623, 2019
PubMed
18) Al-Shahi Salman R, Minks DP, Mitra D et al : Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases : subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurol 18 : 643-652, 2019
 
19) Biffi A, Urday S, Kubiszewski P et al : Combining imaging and genetics to predict recurrence of anticoagulation-associated intracerebral hemorrhage. Stroke 51 : 2153-2160, 2020
PubMed
20) Schrag M, Mac Grory B, Nackenoff A et al : Left atrial appendage closure for patients with cerebral amyloid angiopathy nd atrial fibrillation : the LAA-CAA cohort. Transl Stroke Res 12 : 259-265, 2021
 
P.53 掲載の参考文献
21) Banerjee G, Adams ME, Jaunmuktane Z et al : Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. Ann Neurol 85 : 284-290, 2019
PubMed
22) Hamaguchi T, Komatsu J, Sakai K et al : Cerebral hemorrhagic stroke associated with cerebral amyloid angiopathy in young adults about 3 decades after neurosurgeries in their infancy. J Neurolo Sci 399 : 3-5, 2019
 
23) Yamada M, Hamaguchi T, Sakai K : Chapter Six-Acquired cerebral amyloid angiopathy : an emerging concept. In "Progress in molecular biology and translational science" Teplow DB, ed, Academic Press, Massachusetts, pp85-95, 2019
 
P.54 掲載の参考文献
1) Oppenheimer BS, Fishberg AM : Hypertensive encephalopathy. Arch Intern Med 41 : 264-278, 1928
 
2) Dominedo C, D'Avino E, Martinotti A et al : A rare pheochromocytoma complicated by cardiogenic shock and posterior reversible encephalopathy syndrome : case report. Eur Heart J Case Rep 5 : ytaa513, 2021
PubMed
P.55 掲載の参考文献
3) Auer LM : The pathogenesis of hypertensive encephalopathy : experimental data and their clinical relevance with special reference to neurosurgical patients. Acta Neurochir Suppl (Wien) 27 : 1-111, 1978
PubMed
4) Kontos HA, Wei EP, Navari RM et al : Responses of cerebral arteries and arterioles to acute hypotension and hypertension. Am J Physiol 234 : H371-383, 1978
PubMed
5) MacKenzie ET, Strandgaard S, Graham DI et al : Effects of acutely induced hypertension in cats on pial arteriolar caliber, local cerebral blood flow, and the blood-brain barrier. Circ Res 39 : 33-41, 1976
PubMed
6) Vaughan CJ, Delanty N : Hypertensive emergencies. Lancet 356 : 411-417, 2000
PubMed
7) Astarita A, Covella M, Vallelonga F et al : Hypertensive emergencies and urgencies in emergency departments : a systematic review and meta-analysis. J Hypertens 38 : 1203-1210, 2020
PubMed
8) Lochner P, Lesmeister M, Nardone R et al : Posterior reversible encephalopathy syndrome : role of transorbital ultrasound. Neurol Sci 42 : 1171-1174, 2021
PubMed
P.56 掲載の参考文献
9) Peixoto AJ : Acute severe hypertension. N Engl J Med 381 : 1843-1852, 2019
PubMed
10) van den Born BH, Lip GYH, Brguljan-Hitij J et al : ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother 5 : 37-46, 2019
PubMed
11) Miller JB, Suchdev K, Jayaprakash N et al : New developments in hypertensive encephalopathy. Curr Hypertens Rep 20 : 13, 2018
PubMed
12) Delgado MG, Bogousslavsky J : Cerebral hyperperfusion syndrome and -related conditions. Eur Neurol 83 : 453-457, 2020
PubMed
13) Alshami A, Al-Bayati A, Douedi S et al : Clinical characteristics and outcomes of patients admitted to hospitals for posterior reversible encephalopathy syndrome : a retrospective cohort study. BMC Neurol 21 : 107, 2021
 
14) Pal R, Dutta A, Agrawal K et al : Primary hyperparathyroidism presenting as posterior reversible encephalopathy syndrome : a report of two cases. J Clin Res Pediatr Endocrinol 12 : 432-438, 2020
 
15) Maramattom BV : Cough headache as a presenting feature of posterior reversible encephalopathy syndrome (PRES). Clin Med (Lond) 21 : e237-e238, 2021
PubMed
16) Tan YY, Tan K : Hypertensive brainstem encephalopathy : a diagnosis often overlooked. Clin Med (Lond) 19 : 511-513, 2019
 
17) Gall E, Chaudhuri A, South AM : Peak blood pressure and prediction of posterior reversible encephalopathy syndrome in children. Pediatr Nephrol 35 : 1967-1975, 2020
PubMed
18) Langlo KAR, Silva GJJ, Overrein TS et al : Circulating microRNAs may serve as biomarkers for hypertensive emergency end-organ injuries and address underlying pathways in an animal model. Front Cardiovasc Med 7 : 626699, 2021
 
P.57 掲載の参考文献
19) Williams B, Mancia G, Spiering W et al : 2018 ESC/ESH Guidelines for the management of arterial hypertension : The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension : The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 36 : 1953-2041, 2018
 
20) Williams B, Mancia G, Spiering W et al : 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology : ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 36 : 2284-2309, 2018
 
21) Immink RV, van den Born BJ, van Montfrans GA et al : Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension. Hypertension 52 : 236-240, 2008
PubMed
22) Peacock WF, Varon J, Baumann BM et al : CLUE : a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care 15 : R157, 2011
PubMed
23) Liu-DeRyke X, Levy PD, Parker D Jr et al : A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. Neurocrit Care 19 : 41-47, 2013
 
24) Peacock WF 4th, Hilleman DE, Levy PD et al : A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med 30 : 981-993, 2012
PubMed
P.58 掲載の参考文献
25) Watanabe K, Hamada T, Shimada K et al : Efficacy of renin-angiotensin-aldosterone system blockades for acute phase hypertensive emergencies in patient complicating severe acute kidney injury. CEN Case Rep, 2021
PubMed
26) Strandgaard S : Autoregulation of cerebral circulation in hypertension. Acta Neurol Scand Suppl 66 : 1-82, 1978
PubMed
27) Strandgaard S : Autoregulation of cerebral blood flow in hypertensive patients. The modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension. Circulation 53 : 720-727, 1976
 
28) Zhang R, Witkowski S, Fu Q et al : Cerebral hemodynamics after short- and long-term reduction in blood pressure in mild and moderate hypertension. Hypertension 49 : 1149-1155, 2007
 
29) Amraoui F, Van Der Hoeven NV, Van Valkengoed IG et al : Mortality and cardio-vascular risk in patients with a history of malignant hypertension : a case-control study. J Clin Hypertens (Greenwich) 16 : 122-126, 2014
 
30) Vlcek M, Bur A, Woisetschlager C et al : Association between hypertensive urgencies and subsequent cardio-vascular events in patients with hypertension. J Hypertens 26 : 657-662, 2008
 
P.59 掲載の参考文献
1) Mancusoa M, Arnoldb M, Bersanoc A et al : Monogenic cerebral small-vessel diseases : diagnosis and therapy. Consensus recommendations of the European Academy of Neurology. Eur J Neurol 27 : 909-927, 2020
 
2) Guey S, Lesnik Oberstein SAJ Tournier-Lasserve E et al : Hereditary cerebral small vessel diseases and stroke : a guide for diagnosis and management. Stroke 52 : 3025-3032, 2021
PubMed
3) Bakker MK, van der Spek RAA, van Rheenen W et al : Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors. Nat Genet 52 : 1303-1313, 2020
PubMed
4) Malik R, Chauhan G, Traylor M et al : Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 50 : 524-537, 2018. Erratum in : Nat Genet 51 : 1192-1193, 2019
 
P.60 掲載の参考文献
5) Shindo A, Tabei KI, Taniguchi A et al : A nationwide survey and multicenter registry-based database of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy in Japan. Front Aging Neurosci 12 : 216, 2020
PubMed
P.61 掲載の参考文献
6) Rutten JW, Hack RJ, Duering M et al : Broad phenotype of cysteine-altering NOTCH3 variants in UK Biobank : CADASIL to nonpenetrance. Neurology 95 : e1835-e1843, 2020
PubMed
7) Watanabe-Hosomi A, Mizuta I, Koizumi T et al : Effect of lomerizine hydrochloride on preventing strokes in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Clin Neuropharmacol 43 : 146-150, 2020
PubMed
8) Ihara M, Washida K, Yoshimoto T et al : Adrenomedullin : a vasoactive agent for sporadic and hereditary vascular cognitive impairment. Cerebral Circulation-Cognition and Behavior 2 : 100007, 2021
 
9) Uemura M, Nozaki H, Kato T et al : HTRA1-related cerebral small vessel disease : a review of the literature. Front Neurol 11 : 545, 2020
PubMed
10) Coste T, Herve D, Neau JP et al : Heterozygous HTRA1 nonsense or frameshift mutations are pathogenic. Brain, 2021 [Epub ahead of print]
PubMed
11) Mishra A, Chauhan G, Violleau MH et al : Association of variants in HTRA1 and NOTCH3 with MRI-defined extremes of cerebral small vessel disease in older subjects. Brain 142 : 1009-1023, 2019
PubMed
12) Liu G, Zhang H, Liu B et al : Rs2293871 regulates HTRA1 expression and affects cerebral small vessel stroke and Alzheimer's disease. Brain 142 : e61, 2019
PubMed
13) Saito R, Nozaki H, Kato T et al : Retinal vasculopathy with cerebral leukodystrophy : clinicopathologic features of an autopsied patient with a heterozygous TREX 1 mutation. J Neuropathol Exp Neurol 78 : 181-186, 2019
PubMed
P.62 掲載の参考文献
14) Hoogeveen ES, Pelzer N, Ghariq E et al : Cerebro-vascular reactivity in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. J Cereb Blood Flow Metab 41 : 831-840, 2021
 
15) Tan RYY, Traylor M, Megy K et al : How common are single gene mutations as a cause for lacunar stroke? a targeted gene panel study. Neurology 93 : e2007-e2020, 2019
PubMed
16) Traylor M, Persyn E, Tomppo L et al : Genetic basis of lacunar stroke : a pooled analysis of individual patient data and genome-wide association studies. Lancet Neurol 20 : 351-361, 2021
PubMed
17) Grami N, Chong M, Lali R et al : Global assessment of Mendelian stroke genetic prevalence in 101 635 individuals from 7 ethnic groups. Stroke 51 : 1290-1293, 2020
PubMed
18) Adham S, Billon C, Legrand A et al : Spontaneous cervical artery dissection in vascular Ehlers-Danlos syndrome : a cohort study. Stroke 52 : 1628-1635, 2021
PubMed
P.63 掲載の参考文献
19) Kamimura T, Okazaki S, Morimoto T et al : Prevalence of RNF213 p.R4810K variant in early-onset stroke with intracranial arterial stenosis. Stroke 50 : 1561-1563, 2019
PubMed
20) Kuveljic J, Djuric T, Stankovic A et al : PHACTR1 haplotypes are -associated with carotid plaque presence and affect PHACTR1 mRNA expression in carotid plaque tissue. Gene 710 : 273-278, 2019
PubMed
21) Okazaki S, Morimoto T, Kamatani Y et al : Moyamoya disease susceptibility variant RNF213 p.R4810K increases the risk of ischemic stroke attributable to largeartery atherosclerosis. Circulation 139 : 295-298, 2019
PubMed
22) Hongo H, Miyawaki S, Imai H et al : Comprehensive investigation of RNF213 nonsynonymous variants -associated with intracranial artery stenosis. Sci Rep 10 : 11942, 2020
PubMed
23) Uemura M, Kanazawa M, Yamagishi T et al : Role of RNF213 p.4810K variant in the development of intracranial arterial disease in patients treated with nilotinib. J Neurol Sci 408 : 116577, 2020
PubMed
P.64 掲載の参考文献
24) 堤佐斗志, 萩野郁子, 近藤聡英他 : 家族性海綿状血管腫の臨床像と予後. Neurosurg Emerg 24 : 14-19, 2019
 
25) Lanfranconi S, Piergallini L, Ronchi D et al : Clinical, neuroradiological and genetic findings in a cohort of patients with multiple cerebral cavernous malformations. Metab Brain Dis, 2021 [Epub ahead of print]
 
26) Much CD, Schwefel K, Skowronek D et al : Novel pathogenic variants in a cassette exon of CCM2 in patients with cerebral cavernous malformations. Front Neurol 10 : 1219, 2019
 
27) Peyre M, Miyagishima D, Bielle F et al : Somatic PIK3CA mutations in sporadic cerebral cavernous malformations. N Engl J Med 385 : 996-1004, 2021
PubMed
28) Faughnan ME, Mager JJ, Hetts SW et al : Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med 173 : 989-1001, 2020
PubMed
P.65 掲載の参考文献
29) Hong T, Yan Y, Li J et al : High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain 142 : 23-34, 2019
 
30) Bameri O, Salarzaei M, Parooie F : KRAS/BRAF mutations in brain arteriovenous malformations : a systematic review and meta-analysis. Interv Neuroradiol. 1591019920982810, 2021 [Epub ahead of print]
 
31) Yamada Y, Kato K, Oguri M et al : Identification of nine genes as novel susceptibility loci for early-onset ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage. Biomed Rep 9 : 8-20, 2018
 

II章 認知症

P.68 掲載の参考文献
1) Gauthier S, Rosa-Neto P, Morais J et al : World Alzheimer Report 2021 https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf (2021年9月21日閲覧)
 
2) Wortmann M : Dementia : a global health priority-highlights from an ADI and World Health Organization report. Alzheimers Res Ther 4 : 40, 2012
PubMed
3) Wu Y-T, Beiser AS, Breteler MMB et al : The changing prevalence and incidence of dementia over time-current evidence. Nature Reviews Neurology 13 : 327-U379, 2017
PubMed
4) Roehr S, Pabst A, Luck T et al : Is dementia incidence declining in high-income countries? a systematic review and meta-analysis. Clin Epidemiol 10 : 1233-1247, 2018
PubMed
5) Ohara T, Hata J, Yoshida D et al : Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology 88 : 1925-1932, 2017
 
P.69 掲載の参考文献
6) Yu JT, Xu W, Tan C et al : Evidence-based prevention of Alzheimer's disease : systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry 91 : 1201-1209, 2020
PubMed
7) Kivipelto M, Helkala EL, Laakso MP et al : Midlife -vascular risk factors and Alzheimer's disease in later life : longitudinal, population based study. BMJ 322 : 1447-1451, 2001
PubMed
8) Jack CR Jr, Wiste HJ, Weigand SD et al : Age-specifc and sex-specifc prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years : a cross-sectional study. Lancet Neurol 16 : 435-444, 2017
 
9) Bannai T, Mano T, Chen X et al : Chronic cerebral hypoperfusion shifts the equilibrium of amyloid β oligomers to aggregation-prone species with higher molecular weight. Sci Rep 9 : 2827, 2019
 
10) Ding J, Davis-Plourde KL, Sadaghat S et al : Antihypertensive medications and risk for incident dementia and Alzheimer's disease : a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol 19 : 61-70, 2020
 
11) Ohara T, Ninomiya T, Hata J et al : Midlife and late-life smoking and risk of dementia in the community : the Hisayama study. J Am Geriatr Soc 63 : 2332-2339, 2015
PubMed
12) Cheng J, Liu H, Lee C et al : Matrix metalloproteinase 14 modulates diabetes and Alzheimer's disease cross-talk : a meta-analysis. Neurol Sci 39 : 267-274, 2018
 
P.70 掲載の参考文献
13) Niu H, Qu Y, Li Z et al : Smoking and risk for Alzheimer disease : a meta-analysis -based on both case-control and cohort study. J Nerv Ment Dis 206 : 680-685, 2018
 
14) Lucchetta RC, Mata BPM, Mastroianni PC : Association between development of dementia and use of benzodiazepines : a systematic review and meta-analysis. Pharmacotherapy 38 : 1010-1020, 2018
PubMed
15) Dyer AH, Murphy C, Lawlor B et al : Cognitive outcomes of long-term benzodiazepine and -related drug (BDZR) use in people living with mild to moderate Alzheimer's disease : results from NILVAD. J Am Med Dir Assoc 21 : 194-200, 2020
PubMed
P.71 掲載の参考文献
16) Nafti M, Sirois C, Kroger E et al : Is benzodiazepine use associated with the risk of dementia and cognitive impairment-not dementia in older persons? the Canadian study of health and aging. Ann Pharmacother 54 : 219-225, 2020
 
17) Meziab O, Kirby KA, Williams B et al : Prisoner of war status, post-traumatic stress disorder, and dementia in older veterans. Alzheimers Dement 10 (3 Suppl) : S236-241, 2014
 
18) Weiner MW, Veitch DP, Hayes J et al : Effects of traumatic brain injury and post-traumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 10 (3 Suppl) : S226-235, 2014
 
19) Doblhammer G, Fink A, Zylla S et al : Compression or expansion of dementia in Germany? an observational study of shortterm trends in incidence and death rates of dementia between 2006/07 and 2009/10 based on German health insurance data. Alzheimers Res Ther 7 : 66, 2015
PubMed
20) Kuring JK, Mathias JL, Ward L : Prevalence of depression, anxiety and PTSD in people with dementia : a systematic review and meta-analysis. Neuropsychol Rev 28 : 393-416, 2018
PubMed
21) Bonanni L, Franciotti R, Martinotti G et al : Post traumatic stress disorder heralding the onset of semantic frontotemporal dementia. Alzheimers Dis 63 : 203-215, 2018
PubMed
22) Kuring JK, Mathias JL, Ward L : Risk of dementia in persons who have previously experienced clinically-significant depression, anxiety, or PTSD : a systematic review and meta-analysis. J Affect Disord : 247-261, 2020
PubMed
P.72 掲載の参考文献
23) Wang T, Kuang W, Chen W et al : A phase II randomized trial of sodium oligomannate in Alzheimer's dementia. Alzheimers Res Ther 12 : 110, 2020
 
24) Kondo T, Bannno H, Okunomiya T et al : Repurposing bromocriptine for A β metabolism in Alzheimer's disease (REBRAnD) study : randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. BMJ Open 11 : e051343, 2021
 
25) Grossberg GT, Kohegyi E, Mergel V et al : Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia : two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry 28 : 383-400, 2020
PubMed
P.73 掲載の参考文献
1) Arnaoutoglou NA, O'Brien JT, Underwood BR : Dementia with Lewy bodies-from scientific knowledge to clinical insights. Nat Rev Neurol 15 : 103-112, 2019
PubMed
2) McKeith IG, Boeve BF, Dickson DW et al : Diagnosis and management of dementia with Lewy bodies : fourth consensus report of the DLB Consortium. Neurology 89 : 88-100, 2017
PubMed
P.74 掲載の参考文献
3) Outeiro TF, Koss DJ, Erskine D et al : Dementia with Lewy bodies : an update and outlook. Mol Neurodegener 14 : 5, 2019
PubMed
4) Gan J, Liu S, Wang X et al : Clinical characteristics of Lewy body dementia in Chinese memory clinics. BMC Neurol 21 : 144, 2021
PubMed
5) Matar E, Shine JM, Halliday GM : Cognitive fluctuations in Lewy body dementia : towards a pathophysiological framework. Brain 143 : 31-46, 2020
PubMed
6) Eversfield CL, Orton LD : Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies : a systematic review and meta-analysis. Psychol Med 49 : 2342-2353, 2019
PubMed
7) 吉崎崇仁 : レビー小体型認知症. "最新ガイドラインに基づく神経疾患診療指針 2021-'22" 鈴木則宏編. 総合医学社, 東京, pp84-90, 2021
 
8) Chan PC, Lee HH, Hong CT et al : REM Sleep Behavior Disorder (RBD) in Dementia with Lewy Bodies (DLB). Behav Neurol 2018 : 9421098, 2018
PubMed
9) Risacher SL, Saykin AJ : Neuroimaging in aging and neurologic diseases. Handb Clin Neurol 167 : 191-227, 2019
PubMed
P.75 掲載の参考文献
10) Yousaf T, Dervenoulas G, Valkimadi PE et al : Neuroimaging in Lewy body dementia. J Neurol 266 : 1-26, 2019
PubMed
11) Berman SB, Miller-Patterson C : PD and DLB : brain imaging in Parkinson's disease and dementia with Lewy bodies. Prog Mol Biol Transl Sci 165 : 167-185, 2019
PubMed
12) Orad RI, Shiner T : Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia : an update on imaging modalities. J Neurol, 2021 [online ahead of print]
 
13) Trost M, Perovnik M, Pirtosek Z : Correlations of neuropsychological and metabolic brain changes in Parkinson's disease and other α-synucleinopathies. Front Neurol 10 : 1204, 2019
 
14) Pardini M, Nobili F, Arnaldi D et al : 123I-FP-CIT SPECT validation of nigroputaminal MRI tractography in dementia with Lewy bodies. Eur Radiol Exp 4 : 27, 2020
 
15) Chin KS, Teodorczuk A, Watson R : Dementia with Lewy bodies : challenges in the diagnosis and management. Aust N Z J Psychiatry 53 : 291-303, 2019
PubMed
16) van der Zande JJ, Gouw AA, van Steenoven I et al : Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. Neurology 95 : e662-e670, 2020
PubMed
17) Law ZK, Todd C, Mehraram R et al : The role of EEG in the diagnosis, prognosis and clinical correlations of dementia with Lewy bodies-a systematic review. Diagnostics (Basel) 10 : 616, 2020
PubMed
P.76 掲載の参考文献
18) Hershey LA, Coleman-Jackson R : Pharmacological management of dementia with Lewy bodies. Drugs Aging 36 : 309-319, 2019
PubMed
19) Sezgin M, Bilgic B, Tinaz S et al : Parkinson's disease dementia and Lewy body disease. Semin Neurol 39 : 274-282, 2019
PubMed
20) Monfared AAT, Desai M, Hughes R et al : Treatment options for dementia with Lewy bodies : a network meta-analysis of randomised control trials. Neurol Ther 9 : 521-534, 2020
 
P.77 掲載の参考文献
21) Kyle K, Bronstein JM : Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies : a review. Parkinsonism Relat Disord 75 : 55-62, 2020
PubMed
22) Liu J, Cooper CA, Weintraub D et al : Pharmacological treatment of apathy in Lewy body disorders : a systematic review. Parkinsonism Relat Disord 60 : 14-24, 2019
PubMed
23) Taylor JP, McKeith IG, Burn DJ et al : New evidence on the management of Lewy body dementia. Lancet Neurol 19 : 157-169, 2020
 
24) van der Perren A, Gelders G, Fenyi A et al : The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol 139 : 977-1000, 2020
 
25) Olfati N, Shoeibi A, Litvan I : Progress in the treatment of Parkinson-Plus syndromes. Parkinsonism Relat Disord 59 : 101-110, 2019
PubMed
P.78 掲載の参考文献
26) Lee CY, Cheng SJ, Lin HC et al : Quality of life in patients with dementia with Lewy bodies. Behav Neurol. eCollection 2018 : 8320901, 2018
 
27) Mueller C, Soysal P, Rongve A et al : Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis : a meta-analysis of longitudinal studies. Ageing Res Rev 50 : 72-80, 2019
PubMed
P.80 掲載の参考文献
1) Scarioni M, Gami-Patel P, Timar Y et al : Frontotemporal dementia : correlations between psychiatric symptoms and pathology. Ann Neurol 87 : 950-961, 2020
PubMed
2) Kawakami I, Arai T, Shinagawa S et al : Distinct early symptoms in neuropathologically proven frontotemporal lobar degeneration. Int J Geriatr Psychiatry 36 : 38-45, 2021
PubMed
P.81 掲載の参考文献
3) Panza F, Lozupone M, Seripa D et al : Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol 16 : 213-228, 2020
PubMed
4) Moore KM, Nicholas J, Grossman M et al : Age at symptom onset and death and disease duration in genetic frontotemporal dementia : an international retrospective cohort study. Lancet Neurol 19 : 145-156, 2020
 
5) Greaves CV, Rohrer JD : An update on genetic frontotemporal dementia. J Neurol 266 : 2075-2086, 2019
PubMed
6) 渡辺亮平, 新井哲明 : 前頭側頭葉変性症の臨床-病理-遺伝子相関. BRAIN and NERVE 72 : 575-583, 2020
 
7) Swift IJ, Sogorb-Esteve A, Heller C et al : Fluid biomarkers in frontotemporal dementia : past, present and future. J Neurol Neurosurg Psychiatry 92 : 204-215, 2021
PubMed
P.82 掲載の参考文献
8) van der Ende EL, Meeter LH, Poos JM et al : Serum neurofilament light chain in genetic frontotemporal dementia : a longitudinal, multicentre cohort study. Lancet Neurol 18 : 1103-1111, 2019
PubMed
9) Sellami L, Rucheton B, Ben Younes I et al : Plasma progranulin levels for frontotemporal dementia in clinical practice : a 10-year French experience. Neurobiology of Aging 91 : 167.e1-167.e9, 2020
 
P.83 掲載の参考文献
10) Thijssen EH, La Joie R, Strom A et al : Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration : a retrospective diagnostic performance study. Lancet Neurol 20 : 739-752, 2021
PubMed
11) Tagai K, Ono M, Kubota M et al : High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies. Neuron 109 : 42-58, 2021
PubMed
P.84 掲載の参考文献
12) 桝田道人, 渡辺宏久, 勝野雅央 他 : FTLD-Jからみたわが国におけう前頭側頭型認知症の臨床特徴. 老年精神医学雑誌 30 : 1107-1113, 2019
 
P.85 掲載の参考文献
1) Shimohata T, Aiba I, Nishizawa M : [Diagnoses of corticobasal syndrome and corticobasal degeneration]. Rinsho Shinkeigaku 56 : 149-157, 2016
PubMed
2) Armstrong MJ, Litvan I, Lang AE et al : Criteria for the diagnosis of corticobasal degeneration. Neurology 80 : 496-503, 2013
PubMed
P.86 掲載の参考文献
3) Lang AE, Stebbins GT, Wang P et al : The Cortical Basal ganglia Functional Scale (CBFS) : Development and preliminary validation. Parkinsonism Relat Disord 79 : 121-126, 2020
PubMed
4) Tsai RM, Miller Z, Koestler M et al : Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome : a randomized clinical trial. JAMA Neurol 77 : 215-224, 2020
PubMed
5) Valentino RR, Koga S, Walton RL et al : MAPT subhaplotypes in corticobasal degeneration : assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathol Commun 8 : 218, 2020
PubMed
P.87 掲載の参考文献
6) Maruyama M, Shimada H, Suhara T et al : Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 : 1094-1108, 2013
 
7) Goodheart AE, Locascio JJ, Samore WR et al : 18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. Brain 144 : 266-277, 2021
PubMed
8) Palleis C, Brendel M, Finze A et al : Cortical [18F] PI-2620 binding differentiates corticobasal syndrome subtypes. Mov Disord 36 : 2104-2115, 2021
 
9) Tezuka T, Takahata K, Seki M et al : Evaluation of [18F] PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun 3 : fcab190, 2021
PubMed
P.88 掲載の参考文献
10) Brendel M, Barthel H, van Eimeren T et al : Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol 77 : 1408-1419, 2020
PubMed
11) Tagai K, Ono M, Kubota M et al : High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies. Neuron 109 : 42-58 e8, 2021
 
12) Pardini M, Huey ED, Spina S et al : FDG-PET patterns -associated with underlying pathology in corticobasal syndrome. Neurology 92 : e1121-e1135, 2019
PubMed
P.89 掲載の参考文献
13) Zhang W, Tarutani A, Newell KL et al : Novel tau filament fold in corticobasal degeneration. Nature 580 : 283-287, 2020
PubMed
14) Shi Y, Zhang W, Yang Y et al : Structure-based classification of tauopathies. Nature 598 : 359-363, 2021
 
15) Koga S, Ghayal NB, Dickson DW : Deep learning-based image classification in differentiating tufted astrocytes, astrocytic plaques, and neuritic plaques. J Neuropathol Exp Neurol 80 : 306-312, 2021
PubMed
16) Koga S, Zhou X, Dickson DW : Machine learning-based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration. Neuropathol Appl Neurobiol, 2021
PubMed
P.91 掲載の参考文献
17) Sabater L, Gaig C, Gelpi E et al : A novel non-rapid-eye movement and rapid-eyemovement parasomnia with sleep breathing disorder -associated with antibodies to IgLON5 : a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13 : 575-586, 2014
 
18) Gelpi E, Hoftberger R, Graus F et al : Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 132 : 531-543, 2016
PubMed
19) Gaig C, Graus F, Compta Y et al : Clinical manifestations of the anti-IgLON5 disease. Neurology 88 : 1736-1743, 2017
PubMed
20) Fuseya K, Kimura A, Yoshikura N et al : Corticobasal syndrome in a patient with anti-IgLON5 antibodies. Mov Disord Clin Pract 7 : 557-559, 2020
 
P.92 掲載の参考文献
1) Gorno-Tempini ML, Hillis AE, Weintraub S et al : Classification of primary progressive aphasia and its variants. Neurology 76 : 1006-1014, 2011
PubMed
2) Ferrari C, Polito C, Vannucchi S et al : Primary progressive aphasia : natural history in an Italian cohort. Alzheimer Dis Assoc Disord 33 : 42-46, 2019
 
P.93 掲載の参考文献
3) Mesulam MM, Weintraub S, Rogalski EJ et al : Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. Brain 137 : 1176-1192, 2014
PubMed
4) Tee BL, Gorno-Tempini ML : Primary progressive aphasia : a model for neurodegenerative disease. Curr Opin Neurol 32 : 255-265, 2019
 
5) Vinceti G, Olney N, Mandelli ML et al : Primary progressive aphasia and the FTD-MND spectrum disorders : clinical, pathological, and neuroimaging correlates. Amyotroph Lateral Scler Frontotemporal Degener 20 : 146-158, 2019
PubMed
6) Bergeron D, Gorno-Tempini ML, Rabinovici GD et al : Prevalence of amyloid-beta pathology in distinct variants of primary progressive aphasia. Ann Neurol 84 : 729-740, 2018
PubMed
7) Snowden JS, Kobylecki C, Jones M et al : Association between semantic dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 90 : 115-117, 2019
PubMed
8) Johnson JCS, Jiang J, Bond RL et al : Impaired phonemic discrimination in logopenic variant primary progressive aphasia. Ann Clin Transl Neurol 7 : 1252-1257, 2020
PubMed
9) Boes S, Botha H, Machulda M et al : Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. Neurocase 26 : 259-263, 2020
PubMed
10) Josephs KA, Martin PR, Botha H et al : [18F] AV-1451 tau-PET and primary progressive aphasia. Ann Neurol 83 : 599-611, 2018
 
P.94 掲載の参考文献
11) Mazzeo S, Polito C, Polito C et al : Linguistic profiles, brain metabolic patterns and rates of amyloid-beta biomarker positivity in patients with mixed primary progressive aphasia. Neurobiol Aging 96 : 155-164, 2020
PubMed
12) Utianski RL, Botha H, Martin PR et al : Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain Lang 197 : 104676, 2019
PubMed
13) Steinacker P, Semler E, Anderl-Straub S et al : Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology 88 : 961-969, 2017
PubMed
14) Matias-Guiu JA, Gomez-Pinedo U, Forero L et al : Plasma neurofilament light chain in primary progressive aphasia and -related disorders : clinical significance and metabolic correlates. J Alzheimers Dis 72 : 773-782, 2019
PubMed
15) Bonakdarpour B, Hurley RS, Wang AR et al : Perturbations of language network connectivity in primary progressive aphasia. Cortex 121 : 468-480, 2019
PubMed
16) Mandelli ML, Vilaplana E, Brown JA et al : Healthy brain connectivity predicts atrophy progression in non-fluent variant of primary progressive aphasia. Brain 139 : 2778-2791, 2016
PubMed
17) Whitwell JL, Jones DT, Duffy JR et al : Working memory and language network dysfunctions in logopenic aphasia : a taskfree fMRI comparison with Alzheimer's dementia. Neurobiol Aging 36 : 1245-1252, 2015
PubMed
P.95 掲載の参考文献
18) Guo CC, Gorno-Tempini ML, Gesierich B et al : Anterior temporal lobe degeneration produces widespread network-driven dysfunction. Brain 136 : 2979-299, 2013
PubMed
19) Tao Y, Ficek B, Rapp B et al : Different patterns of functional network reorganization across the variants of primary progressive aphasia : a graph-theoretic analysis. Neurobiol Aging 96 : 184-196, 2020
PubMed
20) Hardy CJD, Frost C, Sivasathiaseelan H et al : Findings of impaired hearing in patients with nonfluent/agrammatic variant primary progressive aphasia. JAMA Neurol 76 : 607-611, 2019
PubMed
P.96 掲載の参考文献
21) Tsapkini K, Webster KT, Ficek BN et al : Electrical brain stimulation in different variants of primary progressive aphasia : a randomized clinical trial. Alzheimers Dement (NY) 4 : 461-472, 2018
 
22) de Aguiar V, Zhao Y, Faria A et al : Brain volumes as predictors of tDCS effects in primary progressive aphasia. Brain Lang 200 : 104707, 2020
PubMed
P.98 掲載の参考文献
1) Yakushiji Y, Wilson D, Ambler G et al : Distribution of cerebral microbleeds in the East and West : individual participant meta-analysis. Neurology 92 : e1086-e1097, 2019
 
2) Yakushiji Y, Tanaka J, Wilson D et al : Proportion of intracerebral haemorrhage due to cerebral amyloid angiopathy in the East and West : comparison between single hospital centres in Japan and the United Kingdom. J Neurol Sci 416 : 117037, 2020
 
3) Wolters FJ, Tinga LM, Dhana K et al : Life expectancy with and without dementia : a population-based study of dementia burden and preventive potential. Am J Epidemiol 188 : 372-381, 2019
PubMed
4) Licher S, Darweesh SKL, Wolters FJ et al : Lifetime risk of common neurological diseases in the elderly population. J Neurol Neurosurg Psychiatry 90 : 148-156, 2019
PubMed
5) Pendlebury ST, Rothwell PM : Incidence and prevalence of dementia -associated with transient ischaemic attack and stroke : analysis of the population-based Oxford Vascular Study. Lancet Neurol 18 : 248-258, 2019
PubMed
6) Mok VC, Lam BY, Wong A et al : Earlyonset and delayed-onset poststroke dementia-revisiting the mechanisms. Nat Rev Neurol 13 : 148-159, 2017
PubMed
P.99 掲載の参考文献
7) van Middelaar T, Argillander TE, Schreuder F et al : Effect of antihypertensive medication on cerebral small vessel disease : a systematic review and meta-analysis. Stroke 49 : 1531-1533, 2018
PubMed
8) Chang-Quan H, Hui W, Chao-Min W et al : The association of antihypertensive medication use with risk of cognitive decline and dementia : a meta-analysis of longitudinal studies. Int J Clin Pract 65 : 1295-1305, 2011
PubMed
9) Group SMIftSR, Williamson JD, Pajewski NM et al : Effect of intensive vs standard blood pressure control on probable dementia : a randomized clinical trial. JAMA 321 : 553-561, 2019
PubMed
10) Noguchi-Shinohara M, Yuki-Nozaki S, Abe C et al : Diabetes mellitus, elevated hemoglobin A1c, and glycated albumin are associated with the presence of all cause dementia and Alzheimer's disease : the JPSC-AD Study. J Alzheimers Dis 2021 [online ahead of print]
 
11) Poly TN, Islam MM, Walther BA et al : Association between use of statin and risk of dementia : a meta-analysis of observational studies. Neuroepidemiology 54 : 214-226, 2020
PubMed
12) Yang Z, Wang H, Edwards D et al : Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke : a systematic review and meta-analysis. Ageing Res Rev 57 : 100962, 2020
PubMed
13) Ryan J, Storey E, Murray AM et al : Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology 95 : e320-e331, 2020
PubMed
14) Papanastasiou CA, Theochari CA, Zareifopoulos N et al : Atrial fibrillation is associated with cognitive impairment, allcause dementia, vascular dementia, and Alzheimer's disease : a systematic review and meta-analysis. J Gen Intern Med 36 : 3122-3135, 2021
PubMed
P.100 掲載の参考文献
15) Mongkhon P, Fanning L, Lau WCY et al : Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation : a population-based cohort study. Heart Rhythm 17 : 706-713, 2020
PubMed
16) Jacobs V, May HT, Bair TL et al : Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol 118 : 210-214, 2016
PubMed
17) Piccini JP, Todd DM, Massaro T et al : Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation. Heart 106 : 1919-1926, 2020
PubMed
18) Bunch TJ : Atrial fibrillation and dementia. Circulation 142 : 618-620, 2020
PubMed
19) Samieri C, Perier MC, Gaye B et al : Association of cardio-vascular health level in older age with cognitive decline and incident dementia. JAMA 320 : 657-664, 2018
 
20) Ngandu T, Lehtisalo J, Solomon A et al : A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) : a randomised controlled trial. Lancet 385 : 2255-2263, 2015
 
21) Stephen R, Solomon A, Ngandu T et al : White matter changes on diffusion tensor imaging in the FINGER randomized controlled trial. J Alzheimers Dis 78 : 75-86, 2020
PubMed
22) Stephen R, Liu Y, Ngandu T et al : Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimers Res Ther 11 : 53, 2019
PubMed
P.101 掲載の参考文献
23) Blumenthal JA, Smith PJ, Mabe S et al : Lifestyle and neurocognition in older adults with cognitive impairments : a randomized trial. Neurology 92 : e212-e223, 2019
PubMed
24) Blumenthal JA, Smith PJ, Mabe S et al : Longer term effects of diet and exercise on neurocognition : 1-year follow-up of the ENLIGHTEN trial. J Am Geriatr Soc 68 : 559-568, 2020
 
25) Smith PJ, Mabe SM, Sherwood A et al : Metabolic and neurocognitive changes following lifestyle modification : examination of biomarkers from the ENLIGHTEN randomized clinical trial. J Alzheimers Dis 77 : 1793-1803, 2020
PubMed
P.102 掲載の参考文献
26) Kim JO, Lee SJ, Pyo JS : Effect of acetylcholinesterase inhibitors on post-stroke cognitive impairment and vascular dementia : a meta-analysis. PLoS One 15 : e0227820, 2020
PubMed
27) Liao Z, Bu Y, Li M et al : Remote ischemic conditioning improves cognition in patients with subcortical ischemic vascular dementia. BMC Neurol 19 : 206, 2019
 
P.103 掲載の参考文献
1) Zaccaria V, Bacigalupo I, Gervasi G et al : A systematic review on the epidemiology of normal pressure hydrocephalus. Acta Neurol Scand 141 : 101-114, 2020
PubMed
P.104 掲載の参考文献
2) Akiba C, Gyanwali B, Villaraza S et al : The prevalence and clinical associations of disproportionately enlarged subarachnoid space hydrocephalus (DESH), an imaging feature of idiopathic normal pressure hydrocephalus in community and memory clinic based Singaporean cohorts. J Neurol Sci 408 : 116510, 2020
PubMed
3) Kimihira L, Iseki C, Takahashi Y et al : A multi-center, prospective study on the progression rate of asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus on magnetic resonance imaging to idiopathic normal pressure hydrocephalus. J Neurol Sci 419 : 117166, 2020
 
4) Skalicky P, Mladek A, Vlasak A et al : Normal pressure hydrocephalus-an overview of pathophysiological mechanisms and diagnostic procedures. Neurosurg Rev 43 : 1451-1464, 2020
PubMed
5) Yamada S, Ishikawa M, Nozaki K : Exploring mechanisms of ventricular enlargement in idiopathic normal pressure hydrocephalus : a role of cerebrospinal fluid dynamics and motile cilia. Fluids Barriers CNS 18 : 20, 2021
PubMed
6) Leinonen V, Kuulasmaa T, Hiltunen M : iNPH-the mystery resolving. EMBO Mol Med 13 : e13720, 2021
PubMed
7) Reeves BC, Karimy JK, Kundishora AJ et al : Glymphatic system impairment in Alzheimer's disease and idiopathic normal pressure hydrocephalus. Trends Mol Med 26 : 285-295, 2020
PubMed
8) Eide PK, Valnes LM, Pripp AH et al : Delayed clearance of cerebrospinal fluid tracer from choroid plexus in idiopathic normal pressure hydrocephalus. J Cereb Blood Flow Metab 40 : 1849-1858, 2020
PubMed
P.105 掲載の参考文献
9) Mantovani P, Albini-Riccioli L, Giannini G et al ; BOLOGNAPRO-HYDRO Study Group : Anterior callosal angle : a new marker of idiopathic normal pressure hydrocephalus? World Neurosurg 139 : e548-e552, 2020
 
10) Miyazaki K, Hanaoka K, Kaida H et al : Changes in cerebral glucose metabolism caused by morphologic features of prodromal idiopathic normal pressure hydrocephalus. EJNMMI Res 9 : 111, 2019
PubMed
11) Griffa A, Bommarito G, Assal F et al : Dynamic functional networks in idiopathic normal pressure hydrocephalus : alterations and reversibility by CSF tap test. Hum Brain Mapp 42 : 1485-1502, 2021
PubMed
12) Eleftheriou A, Blystad I, Tisell A et al : Indication of thalamo-cortical circuit dysfunction in idiopathic normal pressure hydrocephalus : a tensor imaging study. Sci Rep 10 : 6148, 2020
PubMed
13) Agerskov S, Arvidsson J, Ziegelitz D et al : MRI diffusion and perfusion alterations in the mesencephalon and pons as markers of disease and symptom reversibility in idiopathic normal pressure hydrocephalus. PLoS One 15 : e0240327, 2020
PubMed
P.106 掲載の参考文献
14) Kang K, Han J, Lee SW et al : Abnormal cortical thickening and thinning in idiopathic normal-pressure hydrocephalus. Sci Rep 10 : 21213, 2020
PubMed
15) Nakajima M, Kawamura K, Akiba C et al : Differentiating comorbidities and predicting prognosis in idiopathic normal pressure hydrocephalus using cerebrospinal fluid biomarkers : a review. Croat Med J 62 : 387-398, 2021
PubMed
16) Lolansen SD, Rostgaard N, Oernbo EK et al : Inflammatory markers in cerebrospinal fluid from patients with hydrocephalus : a systematic literature review. Dis Markers 2021 : 8834822, 2021
PubMed
17) Vanninen A, Nakajima M, Miyajima M et al : Elevated CSF LRG and decreased Alzheimer's disease biomarkers in idiopathic normal pressure hydrocephalus. J Clin Med 10 : 1105, 2021
PubMed
18) Mao C, Sha L, Liu C et al : Cerebrospinal fluid Alzheimer's biomarkers and neurofilament light profile of idiopathic normal pressure hydrocephalus in China : a PUMCH cohort study. Neurodegener Dis 2 : 1-8, 2021
 
P.107 掲載の参考文献
19) Hua R, Liu C, Liu X et al : Predictive value of cerebrospinal fluid biomarkers for tap test responsiveness in patients with suspected idiopathic normal pressure hydrocephalus. Front Aging Neurosci 13 : 665878, 2021
 
20) Torretta E, Arosio B, Barbacini P et al : Novel insight in idiopathic normal pressure hydrocephalus (iNPH) biomarker discovery in CSF. Int J Mol Sci 22 : 8034, 2021
PubMed
21) Ko PW, Lee HW, Lee M et al : Increased plasma levels of chitinase 3-like 1 (CHI3L1) protein in patients with idiopathic normal-pressure hydrocephalus. J Neurol Sci 423 : 117353, 2021
PubMed
22) Nakajima M, Yamada S, Miyajima M et al : Research committee of idiopathic normal pressure hydrocephalus : Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition) : Endorsed by the Japanese Society of Normal Pressure Hydrocephalus. Neurol Med Chir (Tokyo) 61 : 63-97, 2021
PubMed
P.108 掲載の参考文献
23) Thavarajasingam SG, El-Khatib M, Rea M et al : Clinical predictors of shunt response in the diagnosis and treatment of idiopathic normal pressure hydrocephalus : a systematic review and meta-analysis. Acta Neurochir (Wien), 2021
PubMed
24) Mallon DH, Malhotra P, Naik M et al : The role of amyloid PET in patient selection for extra-ventricular shunt insertion for the treatment of idiopathic normal pressure hydrocephalus : a pooled analysis. J Clin Neurosci 90 : 325-331, 2021
PubMed
25) Migliorati K, Panciani PP, Pertichetti M et al : P-Tau as prognostic marker in long term follow up for patients with shunted iNPH. Neurol Res 43 : 78-85, 2021
PubMed
26) Grasso G, Torregrossa F, Leone L et al : Long-term efficacy of shunt therapy in idiopathic normal pressure hydrocephalus. World Neurosurg 129 : e458-e463, 2019
PubMed
27) Cui W, Sun T, Wu K et al : Comparison of ventriculoperitoneal shunt to lumboperitoneal shunt in the treatment of idiopathic : a monocentric, assessor-blinded, randomized controlled trial. Medicine (Baltimore) 100 : e26691, 2021
PubMed
P.109 掲載の参考文献
28) Mostile G, Portaro G, Certo F et al : iNPH with parkinsonism : response to umbar CSF drainage and ventriculoperitoneal shunting. J Neurol 268 : 1254-1265, 2021
 
29) Todisco M, Zangaglia R, Minafra B et al : Clinical outcome and striatal dopaminergic function after shunt surgery in patients with idiopathic normal pressure hydrocephalus. Neurology 96 : e2861-e2873, 2021
PubMed
30) Del Gamba C, Bruno A, Frosini D et al : Is DAT imaging abnormality in normal pressure hydrocephalus always suggestive of degeneration? Neurol Sci 42 : 723-726, 2021
PubMed
P.110 掲載の参考文献
1) Rademakers R, Baker M, Nicholson AM et al : Mutations in the colony stimulating factor 1 receptor (CSF-1R) gene cause hereditary diffuse leukoencephalopathy with spheroid. Nat Genet 44 : 200-205, 2012
 
P.111 掲載の参考文献
2) 難病情報センター : 神経軸索スフェロイド形成を伴う遺伝性びまん性白質脳症 (指定難病125) nanbyou.or.jp/entry/4499 (2021年10月1日閲覧)
 
3) Saitoh BY, Yamasaki R, Hiwatashi A et al : Discriminative clinical and neuroimaging features of motor-predominant hereditary diffuse leukoencephalopathy with axonal spheroids and primary progressive multiple sclerosis : a preliminary crosssectional study. Mult Scler Relat Disord 31 : 22-31, 2019
PubMed
4) Stoiloudis P, Parissis D, Smyrni N et al : Hereditary diffuse leukoencephalopathy with spheroids mimicking primary progressive aphasia : report of a Greek case Neurol Sci 42 : 3431-3433, 2021
PubMed
5) Sharma R, Graff-Radford J, Rademakers R et al : CSF1R mutation presenting as dementia with Lewy bodies. Neurocase 25 : 17-20, 2019
PubMed
6) Wang M, Zhang X : A novel CSF-1R mutation in a family with hereditary diffuse leukoencephalopathy with axonal spheroids misdiagnosed as hydrocephalus. Neurogenetics 20 : 155-160, 2019
 
7) Sone J, Tanaka F, Koike H et al : Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease. Neurology 76 : 1372-1376, 2011
PubMed
8) Sone J, Mitsuhashi S, Fujita A et al : Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. Nat Genet 51 : 1215-1221, 2019
PubMed
9) Morimoto S, Hatsuta H, Komiya T et al : Simultaneous skin-nerve-muscle biopsy and abnormal mitochondrial inclusions in intranuclear hyaline inclusion body disease. J Neurol Sci 372 : 447-449, 2017
 
P.112 掲載の参考文献
10) Sone J, Kitagawa N, Sugawara E et al : Neuronal intranuclear inclusion disease cases with leukoencephalopathy diagnosed via skin biopsy. J Neurol Neurosurg Psychiatry 85 : 354-356, 2014
PubMed
11) Okubo M, Doi H, Fukai R et al : GGC repeat expansion of NOTCH2NLC in adult patients with leukoencephalopathy. Ann Neurol 86 : 962-968, 2019
PubMed
12) 曽根淳 : 神経核内封入体病 (Neuronal intranuclear inclusion disease ; NIID). 臨床神経学 60 : 653-662, 2020
 
13) Paloneva J, Autti T, Hakola P et al : Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. University of Washington, Seattle, updated 2020
 
P.113 掲載の参考文献
14) Satoh JI, Kino Y, Yanaizu M et al : Microglia express TMEM119 in the brains of Nasu-Hakola disease. Intractable Rare Dis Res 8 : 260-265, 2019
PubMed
15) Satoh JI, Kino Y, Yanaizu M et Al : Microglia express GPNMB in the brains of Alzheimer's disease and Nasu-Hakola disease. Intractable Rare Dis Res 8 : 120-128, 2019
PubMed
16) Huffnagel IC, Laheji FK, Aziz-Bose R et al : The natural history of adrenal insufficiency in X-linked adrenoleukodystrophy : an international collaboration. J Clin Endocrinol Metab 104 : 118-126, 2019
 
17) Huffnagel IC, Dijkgraaf MG, Janssens GE et al : Disease progression in women with X-linked adrenoleukodystrophy is slow. Orphanet J Rare Dis 14 : 30, 2019
PubMed
18) Lee DK, Long NP, Jung J et al : Integrative lipidomic and transcriptomic analysis of X-linked adrenoleukodystrophy reveals distinct lipidome signatures between adrenomyeloneuropathy and childhood cerebral adrenoleukodystrophy. Biochem Biophys Res Commun 508 : 563-569, 2019
PubMed
19) Coppa A, Guha S, Fourcade S et al : The peroxisomal fatty acid transporter ABCD1/PMP-4 is required in the C. elegans hypodermis for axonal maintenance : a worm model for adrenoleukodystrophy. Free Radic Biol Med 152 : 797-809, 2020
 
20) Casasnovas C, Ruiz M, Schluter A et al : Biomarker identification, Safety, and efficacy of high-dose antioxidants for adrenomyeloneuropathy : a Phase II pilot study. Neurotherapeutics 16 : 1167-1182, 2019
PubMed
21) van de Beek MC, Dijkstra IM, Nagtzaam L et al : Redirecting very chain fatty acid synthesis in adrenoleukodystrophy. Personal Communication.
 
P.114 掲載の参考文献
22) Madaan P, Jauhari P, Chakrabarty B et al : Saposin B-deficient metachromatic leukodystrophy mimicking acute flaccid paralysis. Neuropediatrics 50 : 318-321, 2019
PubMed
23) Kolnikova M, Jungova P, Skopkova M et al : Late infantile metachromatic leukodystrophy due to novel pathogenic variants in the PSAP gene. J Mol Neurosci 67 : 559-563, 2019
 
24) Bergner CG, van der Meer F, Winkler A et al : Microglia damage precedes major myelin breakdown in X-linked adrenoleukodystrophy and metachromatic leukodystrophy. Glia 67 : 1196-209, 2019
 
25) Beerepoot S, Nierkens S, Boelens JJ et al : Peripheral neuropathy in metachromatic leukodystrophy : current status and future perspective. Orphanet J Rare Dis 14 : 240, 2019
PubMed
26) Harrington M, Whalley D, Twiss J et al : Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis 14 : 89, 2019
PubMed
27) Elgun S, Waibel J, Kehrer C et al : Phenotypic variation between siblings with metachromatic leukodystrophy. Orphanet J Rare Dis 14 : 136, 2019
PubMed
28) Pajarola S, Weissenberg C, Baysal F et al : Measurement of recombinant human arylsulfatase A and leukocyte sulfatase activities by analytical isotachophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 1124 : 109-113, 2019
PubMed
29) Hong X, Kumar AB, Daiker J et al : Leukocyte and dried blood spot arylsulfatase A assay by tandem mass spectrometry. Anal Chem 92 : 6341-6348, 2020
PubMed
30) Ashrafi MR, Amanat M, Garshasbi M et al : An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies. Expert Rev Neurother 20 : 65-84, 2020
PubMed

III章 運動系の障害

P.116 掲載の参考文献
1) ハルロピRテープ医薬品インタビューフォーム 第3版 https://medical.kyowakirin.co.jp/site/drugpdf/interv/hrp_in.pdf (2021年11月10日閲覧)
 
2) Hattori N, Mochizuki H, Hasegawa K et al : Ropinirole patch versus placebo, ropinirole extended-release tablet in advanced Parkinson's disease. Mov Disord 35 : 1565-1573, 2020
PubMed
P.117 掲載の参考文献
3) Binda C, Wang J, Pisani L et al : Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors : safinamide and coumarin analogs. J Med Chem 50 : 5848-5852, 2007
PubMed
4) Hattori N, Tsubiu Y, Yamamoto A et al : Efficacy and safety of safinamide as an add-on therapy to L-DOPA for T patients with Parkinson's disease : a randomized, double-blind, placebo-controlled, phase II/III study. Parkinsonism Relat Disord 75 : 17-23, 2020
 
5) Abbruzzese G, Kulisevsky J, Bergmans B et al : A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice : the SYNAPSES trial. J Parkinsons Dis 11 : 187-198, 2021
 
6) Giossi R, Carrara F, Mazzari M et al : Overall efficacy and safety of safinamide in Parkinson's disease : a systematic review and a meta-analysis. Clin Drug Investig 41 : 321-339, 2021
 
7) Rascol O, Brooks DJ, Melamed E et al : Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Lancet 365 : 947-954, 2015
 
P.118 掲載の参考文献
8) Cattaneo C, Jost WH, Bonizzoni E : Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson's disease patients. J Parkinson Disease 10 : 89-97, 2020
 
9) Cattaneo C, Barone P, Bonizzoni E et al : Effects of safinamide on pain in fluctuating Parkinson's disease patients : a post-hoc analysis. J Parkinsons Dis 7 : 95-101, 2017
PubMed
10) Stocchi F, Rascol O, Kieburtz K et al : Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease : the STRIDE-PD study. Ann Neurol 68 : 18-27, 2010
PubMed
11) Liao X, Wu N, Liu D et al : Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease : a meta-analysis. Neurol Sci 41 : 2045-2054, 2020
PubMed
12) Takeda A, Takahashi R, Tsuboi Y et al : Randomized, controlled study of opicapone in Japanese Parkinson's patients with motor fluctuations. Mov Disord 36 : 415-423, 2021
PubMed
13) Takeda A, Takahashi R, Tsuboi Y et al : Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations. J Neural Transm (Vienna) 128 : 337-344, 2021
PubMed
14) Reichmann H, Lees A, Rocha JF et al : Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations : the OPTIPARK open-label study. Transl Neurodegener 9 : 9, 2020
 
P.119 掲載の参考文献
15) Tsuboi Y, Nakamura M, Maruyama H et al : Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia : post hoc analysis of phase 2 and phase 3 clinical trials. J Neurol Sci 430 : 120026, 2021
PubMed
16) Suzuki K, Fujita H, Matsubara T et al : Zonisamide effects on sleep problems and depressive symptoms in Parkinson's disease. Brain Behav 11 : e02026, 2021
PubMed
17) Antonini A, Stoessl AJ, Kleinman L et al : Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease : a multi-country Delphi-panel approach. Curr Med Res Opin 34 : 2063-2073, 2018
 
18) Aldred J, Anca-Herschkovitsch M, Antoni A et al : Application of the '5-2-1' screening criteria in advanced Parkinson's disease : interim analysis of DUOGLOBE. Neurodegener Dis Manag 10 : 309-323, 2020
 
19) Kulisevsky J, Bejr-Kasem H, Martinez-Horta S et al : Subclinical affective and cognitive fluctuations in Parkinson's disease : a randomized double-blind doubledummy study of Oral vs. Intrajejunal Levodopa. J Neurol 267 : 3400-3410, 2020
PubMed
P.120 掲載の参考文献
20) Elkouzi A, Ramirez-Zamora A, Zeilman P et al : Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation. Ann Clin Transl Neurol 6 : 1989-1995, 2019
PubMed
21) Bautista JMP, Oyama G, Nuermaimaiti M et al : Rescue levodopa/carbidopa intestinal gel for secondary deep brain stimulation failure. J Mov Disord 13 : 57-61, 2020
PubMed
22) Picillo M, Phokaewvarangkul O, Poon YY et al : Levodopa versus dopamine agonist after subthalamic stimulation in Parkinson's disease. Mov Disord 36 : 672-680, 2021
PubMed
23) Hacker ML, Turchan M, Heusinkveld LE et al : Deep brain stimulation in earlystage Parkinson disease Five-year outcomes. Neurology 95 : e393-401, 2020
PubMed
24) Olanow CW, Espay AJ, Stocchi F et al : Continuous subcutaneous levodopa delivery for Parkinson's disease : a randomized study. J Parkinsons Dis 11 : 177-186, 2021
PubMed
P.121 掲載の参考文献
1) 中島健二, 饗場郁子, 足立正他 : 進行性核上性麻痺 (PSP) 診療ガイドライン 2020. 神経治療学 37 : 435-493, 2020
 
P.122 掲載の参考文献
2) Litvan I, Agid Y, Calne D et al : Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop. Neurology 47 : 1-9, 1996
PubMed
3) Hoglinger GU, Respondek G, Stamelou M et al : Clinical diagnosis of progressive supranuclear palsy : the movement disorder society criteria. Mov Disord 32 : 853-864, 2017
PubMed
4) 神経変性疾患領域の基盤的調査研究班 : 進行性核上性麻痺の臨床診断 : Movement Disorder Societyによる基準 Clinical Diagnosis of Progressive Supranuclear Palsy : The Movement Disorder Society Criteria. 2019
 
5) Ogawa T, Hatano T, Oyama G et al : Graphic summary of movement disorders society criteria for progressive supranuclear palsy and multiple allocations eXtinction rules. Mov Disord Clin Pract 7 : 240-242, 2020
PubMed
6) Ali F, Martin PR, Botha H et al : Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov Disord 34 : 1144-1153, 2019
PubMed
P.123 掲載の参考文献
7) Grimm MJ, Respondek G, Stamelou M et al : Clinical conditions" suggestive of progressive supranuclear palsy" -diagnostic performance. Mov Disord 35 : 2301-2313, 2020
PubMed
8) Grotsch MT, Respondek G, Colosimo C et al : A modified progressive supranuclear palsy rating scale. Mov Disord 36 : 1203-1215, 2021
PubMed
9) Jabbari E, Holland N, Chelban V et al : Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol 77 : 377-387, 2020
PubMed
10) Piot I, Schweyer K, Respondek G et al : The progressive supranuclear palsy clinical deficits scale. Mov Disord 35 : 650-661, 2020
PubMed
P.124 掲載の参考文献
11) Oliveira MCB, Ling H, Lees AJ et al : Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 90 : 555-561, 2019
PubMed
12) van Gerpen JA, Al-Shaikh RH, Tipton PW et al : Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension. Neurology 93 : e1339-e1347, 2019
 
13) Painous C, Marti MJ, Simonet C et al : Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy : the step-back PSP study. Parkinsonism Relat Disord 74 : 67-73, 2020
PubMed
P.125 掲載の参考文献
14) Amboni M, Ricciardi C, Picillo M et al : Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages. Sci Rep 11 : 9297, 2021
PubMed
15) Malpetti M, Passamonti L, Rittman T et al : Neuroinflammation and tau Colocalize in vivo in progressive supranuclear palsy. Ann Neurol 88 : 1194-1204, 2020
PubMed
16) Malpetti M, Passamonti L, Jones PS et al : Neuroinflammation predicts disease progression in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 92 : 769-775, 2021
PubMed
17) Brendel M, Barthel H, van Eimeren T et al : Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol 77 : 1408-1419, 2020
PubMed
P.126 掲載の参考文献
18) Fujioka S, Morishita T, Takano K et al : A novel diagnostic marker for progressive supranuclear palsy targeting atrophy of the subthalamic nucleus. J Neurol Sci 423 : 117366, 2021
 
19) Quattrone A, Antonini A, Vaillancourt DE et al : A new MRI measure to early differentiate progressive supranuclear palsy from de novo Parkinson's disease in clinical practice : an international study. Mov Disord 36 : 681-689, 2021
 
20) Terao Y, Tokushige SI, Inomata-Terada S et al : Deciphering the saccade velocity profile of progressive supranuclear palsy : a sign of latent cerebellar/brainstem dysfunction? Clin Neurophysiol, 2021
 
21) Dam T, Boxer AL, Golbe LI et al : Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy : a phase 2, randomized, placebo-controlled trial. Nat Med 27 : 1451-1457, 2021
PubMed
22) Hoglinger GU, Litvan I, Mendonca N et al : Safety and efficacy of tilavonemab in progressive supranuclear palsy : a phase 2, randomised, placebo-controlled trial. Lancet Neurol 20 : 182-192, 2021
PubMed
P.127 掲載の参考文献
23) Takamatsu Y, Aiba I : Skeletal muscle loss and body composition in progressive supranuclear palsy : a retrospective crosssectional study. PLoS One 16 : e0253079, 2021
PubMed
24) 高橋哲哉 : 各種難病の最新治療情報進行性核上性麻痺の転倒と体重減少について. 難病と在宅ケア 26 : 32-36, 2020
 
25) 五十嵐中, 饗場郁子, 正路章子他 : 進行性核上性麻痺の社会的・経済的負担に関する推計. 薬理と治療 48 : 911-926, 2020
Medical*Online
P.128 掲載の参考文献
1) Bhatia KP, Bain P, Bajaj N et al : Consensus statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord 33 : 75-87, 2018
PubMed
2) Ferreira JJ, Mestre TA, Lyons KE et al : MDS evidence-based review of treatments for essential tremor. Mov Disord 34 : 950-958, 2019
PubMed
3) 日本神経治療学会治療指針作成委員会 : 標準的神経治療 : 本態性振戦. 神経治療 28 : 295-325, 2011
Medical*Online
P.129 掲載の参考文献
4) Louis ED, McCreary M : How common is essential tremor? Update on the worldwide prevalence of essential tremor. Tremor Other Hyperkinet Mov (NY) 11 : 28, 2021
 
5) Sun QY, Xu Q, Tian Y et al : Expansion of GGC repeat in the human-specific NOTCH2NLC gene is -associated with essential tremor. Brain 143 : 222-233, 2020
PubMed
P.130 掲載の参考文献
6) Yau WY, O'Connor E, Chen Z et al : GGC repeat expansion in NOTCH2NLC is rare in European patients with essential tremor. Brain 143 : e57, 2020
PubMed
7) Ng ASL, Lim WK, Xu Z et al : NOTCH2NLC GGC repeat expansions are associated with sporadic essential tremor : variable disease expressivity on long-term follow-up. Ann Neurol 88 : 614-618, 2020
PubMed
8) Louis ED, Bares M, Benito-Leon J et al : Essential tremor-plus : a controversial new concept. Lancet Neurol 19 : 266-270, 2020
 
9) Huang H, Yang X, Zhao Q et al : Clinical characteristics of patients with essential tremor or essential tremor plus. Acta Neurol Scand 141 : 335-341, 2020
PubMed
10) Louis ED, Huey ED, Cosentino S : Features of "ET plus" correlate with age and tremor duration : "ET plus"may be a disease stage rather than a subtype of essential tremor. Parkinsonism Relat Disord 21 : 42-47, 2021
 
11) Bellows ST, Jankovic J : Phenotypic features of isolated essential tremor, essential tremor plus, and essential tremor-Parkinson's disease in a movement disorders clinic. Tremor Other Hyperkinet Mov (NY) 11 : 12, 2021
 
P.131 掲載の参考文献
12) Mostile G, Terranova R, Rascuna C et al : Clinical-instrumental patterns of neurodegeneration in essential tremor : a datadriven approach. Parkinsonism Relat Disord 87 : 124-129, 2021
PubMed
13) Bologna M, Paparella G, Colella D et al : Is there evidence of bradykinesia in essential tremor? Eur J Neurol 27 : 1501-1509, 2020
PubMed
14) Bugalho P, Salavisa M, Borbinha C et al : REM sleep behavior disorder in essential tremor : a polysomnographic study. J Sleep Res 30 : e13050, 2021
PubMed
P.132 掲載の参考文献
15) Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E et al : Sleep disorders in patients with essential tremor. Curr Neurol Neurosci Rep 21 : 23, 2021
 
16) Kaya D, Aydin AE, Isik AT : Orthostatic hypotension in elderly patients with essential tremor. Clin Interv Aging 16 : 155-160, 2021
 
17) Radler KH, Chapman S, Zdrodowska MA et al : Physical activity as a predictor of cognitive decline in an elderly essential tremor cohort : a prospective, longitudinal study. Front Neurol 12 : 658527, 2021
 
18) Becktepe JS, Busse J, Jensen-Kondering U et al : White matter hyperintensities are associated with severity of essential tremor in the elderly. Front Neurol 12 : 694286, 2021
 
P.133 掲載の参考文献
19) Jog M, Lee J, Scheschonka A et al : Tolerability and efficacy of customized incobotulinumtoxinA injections for essential tremor : a randomized, double-blind, placebo-controlled study. Toxins (Basel) 12 : 807, 2020
PubMed
20) Dallapiazza RF, Lee DJ, De Vloo P et al : Outcomes from stereotactic surgery for essential tremor. J Neurol Neurosurg Psychiatry 90 : 474-482, 2019
PubMed
P.134 掲載の参考文献
21) Harary M, Segar DJ, Hayes MT et al : Unilateral thalamic deep brain stimulation versus focused ultrasound thalamotomy for essential tremor. World Neurosurg 126 : e144-e152, 2019
PubMed
22) Kim MJ, Chang KW, Park SH et al : Stimulation-induced side effects of deep brain stimulation in the ventralis intermedius and posteriorsubthalamic area for essential tremor. Front Neurol 12 : 678592, 2021
PubMed
23) Veerappan V, Anderson S, Safarpour D et al : Role of directional configuration in deep brain stimulation for essential tremor : a single center experience. Tremor Other Hyperkinet Mov (NY) 11 : 47, 2021
 
24) Kruger MT, Avecillas-Chasin JM, Tamber MS et al : Tremor and quality of life in patients with advanced essential tremor before and after replacing their standard deep brain stimulation with a directional system. Neuromodulation 24 : 353-360, 2021
PubMed
25) Steffen JK, Jergas H, Petry-Schmelzer JN et al : Thalamic deep brain stimulation in essential tremor plus is as effective as in essential tremor. Brain Sci 10 : 970, 2020
PubMed
P.135 掲載の参考文献
26) Tsuboi T, Wong JK, Eisinger RS et al : Comparative connectivity correlates of dystonic and essential tremor deep brain stimulation. Brain 144 : 1774-1786, 2021
PubMed
27) Park YS, Jung NA, Na YC et al : Four-year follow-up results of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. Mov Disord 34 : 727-734, 2019
PubMed
28) Abe K, Horisawa S, Yamaguchi T et al : Focused ultrasound thalamotomy for refractory essential tremor : a Japanese multicenter single-arm study. Neurosurgery 88 : 751-757, 2021
PubMed
29) Pineda-Pardo JA, Urso D, Martinez-Fernandez R et al : Transcranial magnetic resonance-guided focused ultrasound thalamotomy in essential tremor : a comprehensive lesion characterization. Neurosurgery 87 : 256-265, 2020
PubMed
30) Iorio-Morin C, Yamamoto K, Sarica C et al : Bilateral focused ultrasound thalamotomy for essential tremor (BEST-FUS Phase 2 Trial). Mov Disord 36 : 2653-2662, 2021
PubMed
P.136 掲載の参考文献
1) Warby SC, Visscher H, Collins JA et al : HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet 19 : 561-566, 2011
 
2) Crowell V, Houghton R, Tomar A et al : Modeling manifest Huntington's disease prevalence using diagnosed incidence and survival time. Neuroepidemiology 55 : 361-368, 2021
PubMed
3) Despotov K, Zadori D, Veres G et al : Genetic epidemiological characteristics of a Hungarian subpopulation of patients with Huntington's disease. BMC Neurol 21 : 79, 2021
PubMed
4) Kounidas G, Cruickshank H, Kastora S et al : The known burden of Huntington disease in the North of Scotland : prevalence of manifest and identified pre-symptomatic gene expansion carriers in the molecular era. J Neurol 268 : 4170-4177, 2021
PubMed
5) Volpi E, Terenzi F, Bagnoli S et al : Lateonset Huntington disease : an Italian cohort. J Clin Neurosci 86 : 58-63, 2021
 
P.137 掲載の参考文献
6) Sathe S, Ware J, Levey J et al : Enroll-HD : an integrated clinical research plat-form and worldwide observational study for Huntington's disease. Front Neurol 12 : 667420, 2021
 
7) van Duijn E, Fernandes AR, Abreu D et al : Incidence of completed suicide and suicide attempts in a global prospective study of Huntington's disease. BJPsych Open 7 : e158, 2021
 
8) McAllister B, Gusella JF, Landwehrmeyer GB et al : Timing and impact of psychiatric,cognitive,and motor abnormalities in Huntington disease. Neurology 96 : e2395-e2406, 2021
PubMed
P.138 掲載の参考文献
9) Hirano M, Iritani S, Fujishiro H et al : Clinicopathological differences between the motor onset and psychiatric onset of Huntington's disease, focusing on the nucleus accumbens. Neuropathology 39 : 331-341, 2019
PubMed
10) Morozko EL, Smith-Geater C, Monteys AM et al : PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease. Proc Natl Acad Sci USA 118 : e2021836118, 2021
 
11) Scahill RI, Zeun P, Osborne-Crowley K et al : Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS) : a cross-sectional analysis. Lancet Neurol 19 : 502-512, 2020
 
12) Parkin GM, Corey-Bloom J, Snell C et al : Plasma neurofilament light in Huntington's disease : a marker for disease onset, but not symptom progression. Parkinsonism Relat Disord 87 : 32-38, 2021
 
13) Wijeratne PA, Garbarino S, Gregory S et al : Revealing the timeline of structural MRI changes in premanifest to manifest Huntington disease. Neurol Genet 7 : e617, 2021
PubMed
14) Schneider F, Stamler D, Bradbury M et al : Pharmacokinetics of deutetrabenazine and tetrabenazine : dose proportionality and food effect. Clin Pharmacol Drug Dev 10 : 647-659, 2021
PubMed
15) Efficacy, safety, and tolerability of valbenazine for the treatment of chorea associated with Huntington disease (KINECT-HD) https://clinicaltrials.gov/ct2/show/NCT04102579 (2021年11月12日閲覧)
 
16) PRidopidine's outcome on function in Huntington disease, PROOF-HD https://clinicaltrials.gov/ct2/show/NCT04556656 (2021年11月12日閲覧)
 
17) Mimura Y, Funayama M, Oi H et al : Effectiveness of brexpiprazole in the treatment in a patient with Huntington's disease. Psychiatry Clin Neurosci 74 : 278-279, 2020
 
18) A study to evaluate the efficacy and safety of intrathecally administered RO7234292 (RG6042) in participants with manifest Huntington's disease https://clinicaltrials.gov/ct2/show/NCT03761849 (2021年11月12日閲覧)
 
P.139 掲載の参考文献
19) Tabrizi SJ, Leavitt BR, Landwehrmeyer GB et al : Targeting huntingtin expression in patients with Huntington's disease. N Engl J Med 380 : 2307-2316, 2019
PubMed
20) Nakamori M, Panigrahi GB, Lanni S et al : A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo. Nat Genet 52 : 146-159, 2021
 
21) 中村勝哉 : 遺伝性疾患の発症前診断の現状. 信州医学雑誌 68 : 125-130, 2020
Medical*Online
22) Huntington 病の診断, 治療, 療養の手引きガイドライン作成委員会編 : Huntington 病の診断, 治療, 療養の手引き. 神経治療学 37 : 61-104, 2020
 
P.140 掲載の参考文献
1) 日本神経学会・厚生労働省「運動失調症の医療基盤に関する調査研究班」監 : 脊髄小脳変性症・多系統萎縮症診療ガイドライン 2018. 2018
 
P.141 掲載の参考文献
2) Yoshida K, Kuwabara S, Nakamura K et al : Idiopathic cerebellar ataxia (IDCA) : diagnostic criteria and clinical analyses of 63 Japanese patients. J Neurol Sci 384 (Supplement C) : 30-35, 2018
 
3) Schmahmann JD, Sherman JC : The cerebellar cognitive affective syndrome. Brain 121 (Pt 4) : 561-579, 1998
 
4) Hoche F, Guell X, Vangel MG et al : The cerebellar cognitive affective/Schmahmann syndrome scale. Brain 141 : 248-270, 2018
PubMed
5) Ahmadian N, van Baarsen K, van Zandvoort M et al : The cerebellar cognitive affective syndrome-a meta-analysis. Cerebellum 18 : 941-950, 2019
PubMed
6) Argyropoulos GPD, van Dun K, Adamaszek M et al : The cerebellar cognitive affective/Schmahmann syndrome : a task force paper. Cerebellum 19 : 102-125, 2020
 
7) Maas R, Killaars S, van de Warrenburg BPC et al : The cerebellar cognitive affective syndrome scale reveals early neuropsychological deficits in SCA3 patients. J Neurology 268 : 3456-3466, 2021
PubMed
P.142 掲載の参考文献
8) Mizusawa H : Cerebellum as a CNS Hub (Contemporary Clinical Neuroscience). Springer, Berlin, 2021
 
9) Palvadeau R, Kaya-Gulec ZE, Simsir G et al : Cerebellar cognitive-affective syndrome preceding ataxia -associated with complex extrapyramidal features in a Turkish SCA48 family. Neurogenetics 21 : 51-58, 2020
 
10) Cortese A, Simone R, Sullivan R et al : Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. Nat Genet 51 : 649-658, 2019
PubMed
11) Scriba CK, Beecroft SJ, Clayton JS et al : A novel RFC1 repeat motif (ACAGG) in two Asia-Pacific CANVAS families. Brain 143 : 2904-2910, 2020
 
12) Tsuchiya M, Nan H, Koh K et al : RFC1 repeat expansion in Japanese patients with late-onset cerebellar ataxia. J Hum Genet 65 : 1143-1147, 2020
PubMed
13) Curro R, Salvalaggio A, Tozza S et al : RFC1 expansions are a common cause of idiopathic sensory neuropathy. Brain 144 : 1542-1550, 2021
PubMed
14) Sullivan R, Yau WY, Chelban V et al : RFC1-related ataxia is a mimic of early multiple system atrophy. J Neurol Neurosurg Psychiatry 92 : 444-446, 2021
PubMed
15) Traschutz A, Cortese A, Reich S et al : Natural history, phenotypic spectrum, and discriminative features of multisystemic RFC1 disease. Neurology 96 : e1369, 2021
PubMed
P.143 掲載の参考文献
16) Jacobi H, du Montcel ST, Romanzetti S et al : Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA) : a longitudinal cohort study. Lancet Neurol 19 : 738-747, 2020
 
P.144 掲載の参考文献
17) Reetz K, Dogan I, Hilgers RD et al : Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) : a 4-year cohort study. Lancet Neurol 20 : 362-372, 2021
 
P.145 掲載の参考文献
18) Wirth T, Jacques Namer I, Monga B et al : Progression of nigrostriatal denervation in cerebellar multiple system atrophy : a prospective study. Neurology, 2021 [online ahead of print]
 
19) Shin HR, Moon J, Lee WJ et al : Serum neurofilament light chain as a severity marker for spinocerebellar ataxia. Sci Rep 11 : 13517, 2021
 
P.146 掲載の参考文献
20) Peng Y, Zhang Y, Chen Z et al : Association of serum neurofilament light and disease severity in patients with spino-cerebellar ataxia type 3. Neurology 95 : e2977, 2020
 
21) Zhang L, Cao B, Hou Y et al : Neurofilament light chain predicts disease severity and progression in multiple system atrophy. Mov Disord, 2021 [online ahead of print]
 
22) Singer W, Schmeichel AM, Shahnawaz M et al : Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann Neurol 89 : 1212-1220, 2021
PubMed
P.147 掲載の参考文献
23) Kobayashi N, Sato N, Fujimura Y et al : Discovery of the orally effective thyrotropin-releasing hormone mimetic : 1-｛N- [(4S,5S) - (5-Methyl-2-oxooxazolidine-4-yl) carbonyl] -3- (thiazol-4-yl) -l-alanyl｝- (2R) -2-methylpyrrolidine trihydrate (rovatirelin hydrate). ACS Omega 3 : 13647-13666, 2018
 
24) Nishizawa M, Onodera O, Hirakawa A et al : Effect of rovatirelin in patients with cerebellar ataxia : two randomised double-blind placebo-controlled phase 3 trials. J Neurol Neurosurg Psychiatry 91 : 254-262, 2020
PubMed
P.148 掲載の参考文献
1) 日本神経学会監 : 脊髄小脳変性症・多系統萎縮症診療ガイドライン 2018. 南江堂, 東京, 2018
 
P.149 掲載の参考文献
2) Koh K, Ishiura H, Tsuji S et al : JASPAC : Japan Spastic Paraplegia Research Consortium. Brain Sci 8 : 153, 2018
 
3) Suero GO, Abildua MJA, Munuera CS et al : Epidemiology of ataxia and hereditary spastic paraplegia in Spain : a crosssectional study. Neurologia, 2021
 
4) Hellberg C, Alinder E, Jaraj D et al : Nationwide prevalence of primary dystonia, progressive ataxia and hereditary spastic paraplegia. Parkinsonism Relat Disord 69 : 79-84, 2019
PubMed
P.150 掲載の参考文献
5) ERN-RND, Diagnostic flowchart for Hereditary Spastic Paraplegia https://www.ern-rnd.eu/wp-content/uploads/2019/02/ERN-RND-Diagnostic-Flowchart-HSP_final-1.pdf (2021年11月9日閲覧)
 
P.151 掲載の参考文献
6) Pascual B, de Bot ST, Daniels MR et al : "Ears of the Lynx" MRI sign is associated with SPG11 and SPG15 hereditary spastic paraplegia. AJNR Am J Neuroradiol 40 : 199-203, 2019
PubMed
7) Servelhere KR, Casseb RF, de Lima FD et al : Spinal cord gray and white matter damage in different hereditary spastic paraplegia subtypes. AJNR Am J Neuroradiol 42 : 610-615, 2021
PubMed
8) Mohammad A, Adriana R, Elena B et al : Truncating mutations in UBAP1 cause hereditary spastic paraplegia. Am J Hum Genet 104 : 767-773, 2019
 
P.152 掲載の参考文献
9) Nan H, Ichinose Y, Tanaka M et al : UBAP1 mutations cause juvenile-onset hereditary spastic paraplegias (SPG80) and impair UBAP1 targeting to endosomes. J Hum Genet 64 : 1055-1065, 2019
PubMed
10) Husain RA, Grimmel M, Wagner M et al : Bi-allelic HPDL variants cause a neurodegenerative disease ranging from neonatal encephalopathy to adolescent-onset spastic paraplegia. Am J Hum Genet 107 : 364-373, 2020
 
11) Wiessner M, Maroofian R, Ni MY et al : Biallelic variants in HPDL cause pure and complicated hereditary spastic paraplegia. Brain 144 : 1422-1434, 2021
PubMed
12) Bellofatto M, De Michele G, Iovino A et al : Management of hereditary spastic paraplegia : a systematic review of the literature. Front Neurol 10 : 3, 2019
PubMed
P.153 掲載の参考文献
13) Kessler C, Serna-Higuita LM, Rattay TW et al : Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia. Ann Clin Transl Neurol 8 : 1122-1131, 2021
PubMed
14) Nakazeki F, Tsuge I, Horie T et al : MiR-33a is a therapeutic target in SPG4-related hereditary spastic paraplegia human neurons. Clin Sci (Lond) 133 : 583-595, 2019
PubMed
P.155 掲載の参考文献
1) 宮嶋裕明 : 過剰な鉄沈着による神経変性症. 生化学 90 : 272-278, 2018
 
2) Stelten BML, van Ommen W, Keizer K : Neurodegeneration with brain iron accumulation : a novel mutation in the ceruloplasmin gene. JAMA Neurol 76 : 229-230, 2019
PubMed
3) Vroegindeweij LHP, Wielopolski PA, Boon AJW et al : MR imaging for the quantitative assessment of brain iron in aceruloplasminemia : a postmortem validation study. Neuroimage 245 : 118752, 2021
PubMed
P.156 掲載の参考文献
4) Zanardi A, Conti A, Cremonesi M et al : Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia. EMBO Mol Med 10 : 91-106, 2018
 
5) Wilson JL, Gregory A, Kurian MA et al : Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration. Dev Med Child Neurol 63 : 1402-1409, 2021
PubMed
6) Nishioka K, Oyama G, Yoshino H et al : High frequency of beta-propeller protein-associated neurodegeneration (BPAN) among patients with intellectual disability and young-onset parkinsonism. Neurobiol Aging 36 : 2004.e9-2004.e15, 2015
 
7) Aring L, Choi EK, Kopera H et al : A neurodegeneration gene, WDR45, links impaired ferritinophagy to iron accumulation. J Neurochem, 2021 [online ahead of print]
 
8) Thakur N, Klopstock T, Jackowski S et al : Rational design of novel therapies for pantothenate kinase-associated neurodegeneration. Mov Disord 36 : 2005-2016, 2021
PubMed
P.157 掲載の参考文献
9) Klopstock T, Tricta F, Neumayr L et al : Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration : a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol 18 : 631-642, 2019
 
10) Klopstock T, Videnovic A, Bischoff AT et al : Fosmetpantotenate randomized controlled trial in pantothenate kinase-associated neurodegeneration. Mov Disord 36 : 1342-1352, 2020
PubMed
11) Lin G, Zhu F, Kanaan NM et al : Clioquinol decreases levels of phosphorylated, truncated, and oligomerized tau protein. Int J Mol Sci 22 : 1263, 2021
 
12) Finkelstein DI, Billings JL, Adlard PA et al : The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun 5 : 53, 2017
PubMed
13) Heras-Garvin A, Refolo V, Schmidt C : ATH434 reduces α-synuclein-related neurodegeneration in a murine model of multiple system atrophy. Mov Disord 36 : 2605-2614, 2021
 
P.158 掲載の参考文献
14) 高尾昌樹 : 脳表ヘモジデリン沈着症のオーバービュー. 神経治療 38 : 80-82, 2021
 
15) 難病情報センター : 脳表ヘモジデリン沈着症 (指定難病122). 2020年8月 http://www.nanbyou.or.jp/entry/4811 (2022年1月20日閲覧)
 
16) Ohira M, Takao M : Nationwide epidemiological survey of superficial hemosiderosis in Japan. J Neurol Sci 404 : 106-111, 2019
PubMed
17) Salloway S, Chalkias S, Barkhof F et al : Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 22 : e214161, 2021
PubMed
18) Arishima H, Higashino Y, Yamada S et al : Spinal endoscopy combined with selective CT myelography for dural closure of the spinal dural defect with superficial siderosis : technical note. J Neurosurg Spine 28 : 96-102, 2018
PubMed
P.159 掲載の参考文献
19) 保住功 : 脳内石灰化症診療の手引き 2021. 診断と治療社, 東京, 2021
 
20) Nishii K, Shimogawa R, Kurita H et al : Partial reduced Pi transport function of PiT-2 might not be sufficient to induce brain calcification of idiopathic basal ganglia calcification. Sci Rep 9 : 17288, 2019
 

IV章 運動神経疾患類縁

P.163 掲載の参考文献
1) Coratti G, Messina S, Lucibello S et al : Clinical variability in spinal muscular atrophy type III. Ann Neurol 88 : 1109-1117, 2020
PubMed
2) Pera MC, Coratti G, Mazzone ES et al : Revised upper limb module for spinal muscular atrophy : 12 month changes. Muscle Nerve 59 : 426-430, 2019
PubMed
3) Trucco F, Ridout D, Scoto M et al : Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study. Neurology 96 : e587-e599, 2021
PubMed
4) Annoussamy M, Seferian AM, Daron A et al : Natural history of type 2 and 3 spinal muscular atrophy : 2-year NatHis-SMA study. Ann Clin Transl Neurol 8 : 359-373, 2021
PubMed
5) Chambers GM, Settumba SN, Carey KA et al : Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology 95 : e1-e10, 2020
PubMed
P.164 掲載の参考文献
6) Weng WC, Hsu YK, Chang FM et al : CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients : lessons learned from newborn screening. Genet Med 23 : 415-420, 2021
PubMed
7) Alves CRR, Zhang R, Johnstone AJ et al : Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy. Muscle Nerve 62 : 351-357, 2020
PubMed
8) Pane M, Coratti G, Sansone VA et al : Nusinersen in type 1 spinal muscular atrophy : twelve-month real-world data. Ann Neurol 86 : 443-451, 2019
PubMed
9) Maggi L, Bello L, Bonanno S et al : Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91 : 1166-1174, 2020
PubMed
10) De Vivo DC, Bertini E, Swoboda KJ et al : Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy : interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 29 : 842-856, 2019
PubMed
P.165 掲載の参考文献
11) Kirschner J, Butoianu N, Goemans N et al : European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Pedieatr Neurol 28 : 38-43, 2020
 
12) Day JW, Finkel RS, Chiriboga CA et al : Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE) : an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20 : 284-293, 2021
PubMed
13) Mercuri E, Muntoni F, Baranello G et al : Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU) : an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20 : 832-841, 2021
PubMed
14) Chand DH, Zaidman C, Arya K et al : Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy : a case series. J Pediatr 231 : 265-268, 2021
 
P.166 掲載の参考文献
15) Baranello G, Darras BT, Day JW et al : Risdiplam in type 1 spinal muscular atrophy. N Engl J Med 384 : 915-923, 2021
PubMed
16) Darras BT, Masson R, Mazurkiewicz-Beldzinska M et al : Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385 : 427-435, 2021
PubMed
P.167 掲載の参考文献
17) Laskaratos A, Breza M, Karadima G et al : Wide range of reduced penetrance alleles in spinal and bulbar muscular atrophy : a model-based approach. J Med Genet 58 : 385-391, 2021
 
18) Langenbruch L, Perez-Mengual S, Glatz C : Disorders of sleep in spinal and bulbar muscular atrophy (Kennedy's disease). Sleep Breath 25 : 1399-1405, 2021
PubMed
19) Shibuya K, Misawa S, Uzawa A et al : Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy. J Neurol Neurosurg Psychiatry 91 : 1189-1194, 2021
 
P.168 掲載の参考文献
20) Gwak DW, Jung SH, Min YS et al : Correlation between maximal tongue pressure and swallowing function in spinal and bulbar muscular atrophy. Front Neurol 1 : 704788, 2021
 
21) Millere E, Rots D, Glazere I et al : Clinical phenotyping and biomarkers in spinal and bulbar muscular atrophy. Front Neurol 11 : 586610, 2021
PubMed
22) Lombardi V, Querin G, Ziff OJ et al : Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology 92 : e1205-e1211, 2019
 
23) Guo H, Lu M, Ma Y et al : Myoglobin : a new biomarker for spinal and bulbar muscular atrophy? Int J Neurosci 131 : 1209-1214, 2021
 
24) Kang MG, Gwak DW, Cho HJ et al : Effect of leuprorelin in bulbar function of spinal and bulbar muscular atrophy patients : observational study for 1 year. J Neurol 268 : 3344-3351, 2021
PubMed
25) Heje K, Andersen G, Buch A et al : High-intensity training in patients with spinal and bulbar muscular atrophy. J Neurol 266 : 1693-1697, 2019
PubMed
P.169 掲載の参考文献
26) Hijikata Y, Hashizume A, Yamada S et al : Long-term effects of androgen deprivation in a patient with spinal and bulbar muscular atrophy-a case report with 14 years of follow-up. Intern Med 58 : 2231-2234, 2019
 
P.171 掲載の参考文献
1) Geevasinga N, Loy CT, Menon P et al : Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis : a systematic review using individual patient data. Clin Neurophysiol 127 : 2684-2691, 2016
PubMed
2) Shefner JM, Al-Chalabi A, Baker MR et al : A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 131 : 1975-1978, 2020
PubMed
3) Pugdahl K, Camdessanche J-P, Cengiz B et al : Gold Coast diagnostic criteria increase sensitivity in amyotrophic lateral sclerosis. Clinical Neurophysiology 132 : 3183-3189, 2021
PubMed
4) Watanabe Y, Ogino M, Ichikawa H et al : The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) for Japanese ALS and FTD patients. Amyotroph Lateral Scler Frontotemporal Degener, 2020
PubMed
P.172 掲載の参考文献
5) Sobue G, Ishigaki S, Watanabe H : Pathogenesis of frontotemporal lobar degeneration : insights from loss of function theory and early involvement of the caudate nucleus. Front Neurosci 12 : 473, 2018
PubMed
6) Canosa A, Moglia C, Manera U et al : Metabolic brain changes across different levels of cognitive impairment in ALS : a (18) F-FDG-PET study. J Neurol Neurosurg Psychiatry, 2020
 
7) Christidi F, Karavasilis E, Ferentinos P et al : Investigating the neuroanatomical substrate of pathological laughing and crying in amyotrophic lateral sclerosis with multimodal neuroimaging techniques. Amyotroph Lateral Scler Frontotemporal Degener 19 : 12-20, 2018
 
8) Ogura A, Watanabe H, Kawabata K et al : Semantic deficits in ALS -related to right lingual/fusiform gyrus network involvement. EBioMedicine 47 : 506-517, 2019
PubMed
9) Tazelaar GHP, Boeynaems S, De Decker M et al : ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Commun 2 : fcaa064, 2020
PubMed
10) Dewan R, Chia R, Ding J et al : Pathogenic Huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron, 2020
PubMed
11) de Boer EMJ, van Rheenen W, Goedee HS et al : Genotype-phenotype correlations of KIF5A stalk domain variants. Amyotroph Lateral Scler Frontotemporal Degener 22 : 561-570, 2021
PubMed
12) Dobson-Stone C, Hallupp M, Shahheydari H et al : CYLD is a causative gene for frontotemporal dementia-amyotrophic lateral sclerosis. Brain 143 : 783-799, 2020
PubMed
13) Witzel S, Frauhammer F, Steinacker P et al : Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis : development and validation of a prediction model to improve interventional trials. Translational Neurodegeneration 10 : 31, 2021
PubMed
14) Delaby C, Alcolea D, Carmona-Iragui M et al : Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep 10 : 9161, 2020
 
P.173 掲載の参考文献
15) Yamada S, Hashizume A, Hijikata Y et al : Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 92 : 1072-1079, 2021
PubMed
16) Cheng Y, Chen Y, Shang H : Aberrations of biochemical indicators in amyotrophic lateral sclerosis : a systematic review and meta-analysis. Transl Neurodegener 10 : 3, 2021
 
17) Miller T, Cudkowicz M, Shaw PJ et al : Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 aLS. N Engl J Med 383 : 109-119, 2020
 
18) Kim G, Gautier O, Tassoni-Tsuchida E et al : ALS genetics : gains, losses, and implications for future therapies. Neuron 108 : 822-842, 2020
PubMed
19) Amado DA, Davidson BL : Gene therapy for ALS : a review. Mol Ther 29 : 3345-3358, 2021
 
20) Paganoni S, Macklin EA, Hendrix S et al : Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 383 : 919-930, 2020
PubMed
P.174 掲載の参考文献
21) Paganoni S, Hendrix S, Dickson SP et al : Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate- taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve 63 : 31-39, 2021
 
22) Mora JS, Bradley WG, Chaverri D et al : Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther Adv Neurol Disord 14 : 17562864211030365, 2021
PubMed
23) 漆谷真 : "神経難病をクスリで治す" 筋萎縮性側索硬化症に対する創薬開発の現状と展望. Brain Nerve. 71 : 13-23, 2019
 
24) Steyn FJ, Ioannides ZA, van Eijk RPA et al : Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry 89 : 1016-1023, 2018
PubMed
25) Nakamura R, Kurihara M, Ogawa N et al : Prognostic prediction by hypermetabolism varies depending on the nutritional status in early amyotrophic lateral sclerosis. Sci Rep 11 : 17943, 2021
PubMed
26) Gabery S, Ahmed RM, Caga J et al : Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 47 : 979-989, 2021
 
27) Ludolph AC, Dorst J, Dreyhaupt J et al : Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol 87 : 206-216, 2020
PubMed
28) Dorst J, Schuster J, Dreyhaupt J et al : Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 91 : 1007-1009, 2020
PubMed
29) Ho WY, Chang JC, Lim K et al : TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination. J Cell Biol 220 : e201910213, 2021
PubMed
30) Ingre C, Chen L, Zhan Y et al : Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology 94 : e1835-e1844, 2020
PubMed
P.175 掲載の参考文献
1) 平山惠造 : 臨床症候. "平山病-発見から半世紀の歩み-診断・治療・病態機序" 平山惠造, 田代邦雄. 文光堂, 東京, pp13-30, 2013
 
P.176 掲載の参考文献
2) Hung ND, Duc NM, Van NT et al : Vietnamese case series of Hirayama disease. In Vivo 34 : 2153-2157, 2020
PubMed
3) Lolli VE, Sarbu N, Pezzullo M et al : Flexion MRI in a case of Hirayama disease. Radiology Case Reports 15 : 1701-1704, 2020
 
4) Fustes OH, Kay CSK, Lorenzoni PJ et al : Somatosensory evoked potentials in Hirayama disease : a Brazilian study. Surg Neurol Int 11 : 464, 2020
PubMed
5) Rosliakova A, Zakroyshchikova I, Bakulin I et al : Hirayama disease : analysis of cases in Russia. Neurological Sciences 40 : 105-112, 2019
PubMed
6) Lyu F, Zheng C, Wang H et al : Establishment of a clinician-led guideline on the diagnosis and treatment of Hirayama disease using a modified Delphi technique. Clinical Neurophysiology 131 : 1311-1319, 2020
PubMed
P.177 掲載の参考文献
7) No S-W, Sung DH, Kim DHK : Significance of sufficient neck flexion during magnetic resonance imaging in the diagnosis of Hirayama disease : report of two cases. Ann Rehabil Med 43 : 615-620, 2019
 
8) Ojha R, Shahi S, Nepal G et al : The diagnostic quandary of magnetic resonance imaging-negative Hirayama disease : a case report. J Med Case Rep14 : 133, 2020
 
9) 得丸幸夫, 平山惠造 : 若年性一側上肢筋萎縮症における下部頚髄硬膜管後壁の前方移動について. 臨床神経 29 : 1237-1243, 1989
 
10) Xu H, Shao M, Zhang F et al : Snake-eyes appearance on MRI occurs during the late stage of Hirayama disease and indicates poor prognosis. Biomed Res Int, 2019
PubMed
11) Yokote A, Fukuhara K, Tsugawa J et al : Juvenle muscular atrophy of the proximal upper extremity as so-called proximal type Hirayama disease : case report and review of the literature. Case Rep Neurol 11 : 106-111, 2019
PubMed
12) 都築雨佳, 安藤哲朗, 杉浦真他 : 頸部回旋が病態に関与した近位型平山病の1症例. 臨床神経 61 : 120-126, 2021
 
13) 得丸幸夫, 平山惠造 : 若年性一側上肢筋萎縮症 (平山病) の頸椎カラー療法-38例での治療成績-. 臨床神経 41 : 173-178, 2001
 
14) Kuo Y-H, Kuo C-H, Huang W-C et al : Anterior cervical discectomy and fusion for Hiraya disease : a case report and literature review. Neurospine 16 : 626-630, 2019
 
15) 福武敏夫 : 平山病の病態機序に関する新しい仮説, 免疫異常に由来する頚部後部硬膜の椎弓への固定不全による. Brain and Nerve 72 : 1371-1381, 2020
 

V章 脱髄疾患

P.181 掲載の参考文献
1) Lebrun-Frenay C, Kantarci O, Siva A et al : Radiologically isolated syndrome : 10-year risk estimate of a clinical event. Ann Neurol 88 : 407-417, 2020
PubMed
2) Makhani N, Tremlett H : The multiple sclerosis prodrome. Nat Rev Neurol 17 : 515-521, 2021
PubMed
3) Yusuf FLA, Ng BC, Wijnands JMA et al : A systematic review of morbidities suggestive of the multiple sclerosis prodrome. Expert Rev Neurother 20 : 799-819, 2020
PubMed
P.182 掲載の参考文献
4) Brownlee WJ, Altmann DR, Prados F et al : Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 142 : 2276-2287, 2019
PubMed
5) Chung KK, Altmann D, Barkhof F et al : A 30-year clinical and magnetic resonance imaging observational study of multiple sclerosis and clinically isolated syndromes. Ann Neurol 87 : 63-74, 2020
PubMed
6) Malpas CB, Manouchehrinia A, Sharmin S et al : Early clinical markers of aggressive multiple sclerosis. Brain 143 : 1400-1413, 2020
PubMed
P.183 掲載の参考文献
7) Bjornevik K, Munger KL, Cortese M et al : Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol 77 : 58-64, 2020
PubMed
8) Thebault S, Abdoli M, Fereshtehnejad SM et al : Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep 10 : 10381, 2020
PubMed
9) Canto E, Barro C, Zhao C et al : Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol 76 : 1359-1366, 2019
PubMed
10) Koch-Henriksen N, Magyari M : Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol 17 : 676-688, 2021
PubMed
11) Tintore M, Cobo-Calvo A, Carbonell P et al : Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with clinically isolated syndrome. Neurology 97 : e1641-e1652, 2021.
PubMed
P.184 掲載の参考文献
12) Kalincik T, Diouf I, Sharmin S et al : Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years. Neurology 96 : e783-e797, 2021
 
13) Brown JWL, Coles A, Horakova D et al : Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321 : 175-187, 2019
PubMed
14) He A, Merkel B, Brown JWL et al : Timing of high-efficacy therapy for multiple sclerosis : a retrospective observational cohort study. Lancet Neurol 19 : 307-316, 2020
 
15) Spelman T, Magyari M, Piehl F et al : Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis : data from 2 different national strategies. JAMA Neurol 78 : 1197-1204, 2021
PubMed
P.185 掲載の参考文献
16) Hauser SL, Bar-Or A, Cohen JA et al : Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383 : 546-557, 2020
PubMed
17) Kira J-I, Nakahara J, Sazonov DV et al : Efficacy and safety of ofatumumab versus placebo in relapsing multiple sclerosis patients in japan and russia : results from the phase 2 apolitos study. Mult Scler 26 : 219, 2020
 
18) Montalban X, Arnold DL, Weber MS et al : Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med 380 : 2406-2417, 2019
PubMed
19) Reich DS, Arnold DL, Vermersch P et al : Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis : a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol 20 : 729-738, 2021
PubMed
P.186 掲載の参考文献
20) Louapre C, Collongues N, Stankoff B et al : Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 77 : 1079-1088, 2020
PubMed
21) Sormani MP, De Rossi N, Schiavetti I et al : Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89 : 780-789, 2021
PubMed
22) Simpson-Yap S, De Brouwer E, Kalincik T et al : Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology 97 : e1870-e1885, 2021
PubMed
23) Di Filippo M, Cordioli C, Malucchi S et al : mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry 18 : jnnp-2021-327200, 2021
PubMed
24) Achiron A, Dolev M, Menascu S et al : COVID-19 vaccination in patients with multiple sclerosis : what we have learnt by February 2021. Mult Scler 27 : 864-870, 2021
PubMed
25) Sormani MP, Inglese M, Schiavetti I et al : Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 72 : 103581, 2021
PubMed
26) Achiron A, Mandel M, Dreyer-Alster S et al : Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy diseasemodifying therapies. Ther Adv Neurol Disord 14 : 17562864211012835, 2021
PubMed
27) Brill L, Rechtman A, Zveik O et al : Humoral and T-Cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol 23 : e213599, 2021
 
28) Apostolidis SA, Kakara M, Painter MM et al : Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27 : 1990-2001, 2021
PubMed
P.187 掲載の参考文献
1) 日本神経学会監 : 多発性硬化症・視神経脊髄炎診療ガイドライン 2017. 医学書院, 東京, 2017
 
P.188 掲載の参考文献
2) Yang SK, Hong M, Baek J et al : A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 46 : 1017-1020, 2014.
 
3) Kakuta Y, Naito T, Onodera M et al : NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J 16 : 280-285, 2016
PubMed
4) Kakuta Y, Kawai Y, Okamoto D et al : NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease : a multicenter study. J Gastroenterol 53 : 1065-1078, 2018
PubMed
5) Pittock SJ, Berthele A, Fujihara K et al : Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381 : 614-625, 2019
PubMed
6) Namatame C, Misu T, Takai Y et al : CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder. Heliyon 7 : e058992021, 2021
PubMed
7) McNamara LA, Topaz N, Wang X et al : High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep 66 : 734-737, 2017
PubMed
P.189 掲載の参考文献
8) Yamamura T, Kleiter I, Fujihara K et al : Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381 : 2114-2124, 2019
PubMed
9) Cree BAC, Bennett JL, Kim HJ et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019
PubMed
10) Traboulsee A, Greenberg BM, Bennett JL et al : Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder : a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19 : 402-412, 2020
 
P.190 掲載の参考文献
11) Cree BA, Lamb S, Morgan K et al : An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 : 1270-1272, 2005
PubMed
12) Kim SH, Kim W, Li XF et al : Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68 : 1412-1420, 2011
 
13) Tahara M, Oeda T, Okada K et al : Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study) : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19 : 298-306, 2020
 
14) Akaishi T, Nakashima I, Takahashi T et al : Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm 7 : e640, 2019
PubMed
P.191 掲載の参考文献
15) Takai Y, Kuroda H, Misu T et al : Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord 49 : 102750, 2021
PubMed
16) Hor JY, Asgari N, Nakashima I et al : Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 11 : 501, 2020
PubMed
P.193 掲載の参考文献
1) Azumagawa K, Nakashima I, Kaneko K et al : A nation-wide survey of Japanese pediatric MOG antibody-associated diseases. Brain Dev 43 : 705-713, 2021
PubMed
P.194 掲載の参考文献
2) Ferilli MAN, Valeriani M, Papi C et al : Clinical and neuroimaging characteristics of MOG autoimmunity in children with acquired demyelinating syndromes. Mult Scler Relat Disord 50 : 102837, 2021
PubMed
3) Xu J, Liu L, Xiong J et al : The Clinical, radiologic, and prognostic differences between pediatric and adult patients with myelin Oligodendrocyte glycoprotein antibody-associated encephalomyelitis. Front Neurol 12 : 679430, 2021
PubMed
4) Bruijstens AL, Breu M, Wendel EM et al : E.U. paediatric MOG consortium consensus : Part 4-Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29 : 32-40, 2020
PubMed
5) Bruijstens AL, Lechner C, Flet-Berliac L et al : E.U. paediatric MOG consortium consensus : Part 1-Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29 : 2-13, 2020
PubMed
P.195 掲載の参考文献
6) Ishikawa H, Kezuka T, Shikishima K et al : Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology 126 : 1385-1398, 2019
PubMed
7) Akaishi T, Himori N, Takeshita T et al : Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease. Mult Scler Relat Disord 56 : 103222, 2021
PubMed
8) Masuda H, Mori M, Yokouchi H et al : Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders. J Neurol, 2021
PubMed
9) Takai Y, Misu T, Kaneko K et al : Myelin oligodendrocyte glycoprotein antibody-associated disease : an immunopathological study. Brain 143 : 1431-1446, 2020
PubMed
10) Matsumoto Y, Misu T, Mugikura S et al : Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases. J Neurol Neurosurg Psychiatry, 2020
PubMed
P.196 掲載の参考文献
11) Sechi E, Buciuc M, Pittock SJ et al : Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody Testing. JAMA Neurol 78 : 741-746, 2021
PubMed
12) Held F, Kalluri SR, Berthele A et al : Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. Mult Scler J Exp Transl Clin 7 : 20552173211022767, 2021
 
13) Bruijstens AL, Wendel EM, Lechner C et al : E.U. paediatric MOG consortium consensus : Part 5-Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29 : 41-53, 2020
 
14) Fadda G, Armangue T, Hacohen Y et al : Paediatric multiple sclerosis and antibody-associated demyelination : clinical, imaging and biological considerations for diagnosis and care. Lancet Neurol 20 : 136-149, 2021
PubMed
P.197 掲載の参考文献
15) Klein da Costa B, Banwell BL, Sato DK : Treatment of MOG-IgG -associated disease in paediatric patients : a systematic review. Mult Scler Relat Disord 56 : 103216, 2021
PubMed
16) Epstein SE, Levin S, Onomichi K et al : Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease : the difficulty of predicting relapses. Mult Scler Relat Disord 56 : 103229, 2021
PubMed
17) Deschamps R, Pique J, Ayrignac X et al : The long-term outcome of MOGAD : an observational national cohort study of 61 patients. Eur J Neurol 28 : 1659-1664, 2021
 
18) Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS et al : Treatment of MOG-IgG-associated disorder with rituximab : an international study of 121 patients. Mult Scler Relat Disord 44 : 102251, 2020
 
19) Bai P, Zhang M, Yuan J et al : A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination : a meta-analysis. Mult Scler Relat Disord 53 : 103044, 2021
 
20) Liu J, Mori M, Zimmermann H et al : Anti-MOG antibody-associated disorders : differences in clinical profiles and prognosis in Japan and Germany. J Neurol Neurosurg Psychiatry, 2020
 
21) Marignier R, Hacohen Y, Cobo-Calvo A et al : Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20 : 762-772, 2021
PubMed
P.198 掲載の参考文献
1) Lambrianides S, Kinnis E, Cleanthous M et al : A case of combined central and peripheral demyelination -associated with antineurofascin 155 antibodies and paternal history of multiple sclerosis. Neurologist 26 : 156-159, 2021
PubMed
P.199 掲載の参考文献
2) Ogata H, Matsuse D, Yamasaki R et al : A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry 87 : 29-36, 2016
PubMed
3) Nomura E, Kawahara Y, Omote Y et al : The oldest Japanese case of combined central and peripheral demyelination, which developed nine years after the first instance of optic neuritis. Intern Med 60 : 305-308, 2021
PubMed
4) Cortese A, Franciotta D, Alfonsi E et al : Combined central and peripheral demyelination : clinical features, diagnostic findings, and treatment. J Neurol Sci 363 : 182-187, 2016
PubMed
5) Wang YQ, Chen H, Zhuang WP et al : The clinical features of combined central and peripheral demyelination in Chinese patients. J Neuroimmunol 317 : 32-36, 2018
PubMed
6) Kawamura N, Yamasaki R, Yonekawa T et al : Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 81 : 714-722, 2013
PubMed
7) Kira JI : Anti-neurofascin 155 antibodypositive chronic inflammatory demyelinating polyneuropathy/combined central and peripheral demyelination : strategies for diagnosis and treatment based on thedisease mechanism. Front Neurol 212 : 665136, 2021
 
8) Ogata H, Zhang X, Inamizu S et al : Optic, trigeminal, and facial neuropathy -related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol 7 : 2297-2309, 2020
PubMed
9) Verghese A, Krishnan D, Chia YK et al : Optic nerve demyelination in IgG4 antineurofascin 155 antibody-positive combined central and peripheral demyelination syndrome. J Cent Nerv Syst Dis 13 : 11795735211039913, 2021
PubMed
10) Rinaldi S, Davies A, Fehmi J et al : Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurol Neuroimmunol Neuroinflamm 8, 2021
PubMed
11) Sundaram S, Nair SS, Jaganmohan D et al : Relapsing lumbosacral myeloradiculitis : an unusual presentation of MOG antibody disease. Mult Scler (Houndmills, Basingstoke, England) 26 : 509-511, 2020
 
12) Nakamura M, Fujimori J, Kobayashi M et al : Refractory case of myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis with lumbosacral radiculitis. Clin Exp Neuroimmunol 11 : 126-130, 2020
 
P.200 掲載の参考文献
13) Nakamura T, Kaneko K, Watanabe G et al : Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy. Neurol Sci 42 : 1135-1138, 2021
PubMed
14) Sokmen O, Demirci M, Tan E : A case with Neurofascin-155 IgG antibody-associated combined central and peripheral demyelination : successfully treated with anti-CD20 monoclonal antibody. Clin Neurol Neurosurg 210 : 106961, 2021
 
15) Makkawi S, Yonbawi F, Qari Y et al : Combined central and peripheral demyelinating disease with good response to B-cell depleting therapy. Cureus 13 : e14690, 2021
 
16) Farag M, Sibtain N, Burge J et al : Atypical inflammatory demyelinating syndrome with central and peripheral nerve involvement. Mult Scler Relat Disord 51 : 102926, 2021
PubMed

VI章 自己免疫性脳炎・硬膜炎

P.202 掲載の参考文献
1) Graus F, Titulaer MJ, Balu R et al : A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15 : 391-404, 2016
PubMed
P.203 掲載の参考文献
2) Cellucci T, Van Mater H, Graus F et al : Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm 7 : e663, 2020
 
3) Mattozzi S, Sabater L, Escudero D et al : Hashimoto encephalopathy in the 21st century. Neurology 94 : e217-e224, 2020
PubMed
P.204 掲載の参考文献
4) Kikuchi A, Yoneda M, Hasegawa T et al : High prevalence of serum anti-NH2-terminal of α-enolase antibodies in patients with multiple system atrophy and corticobasal syndrome. J Neurol 268 : 4291-4295, 2021
 
5) Sugiyama A, Suzuki M, Suichi T et al : Gerstmann's syndrome in a patient double-positive for antibodies against the N-methyl-D-aspartate receptor and NH2-terminal of α-enolase. Intern Med 60 : 1463-1468, 2021
 
6) Dubey D, Pittock SJ, McKeon A : Antibody prevalence in epilepsy and encephalopathy score : increased specificity and applicability. Epilepsia 60 : 367-369, 2019
PubMed
7) Geis C, Planaguma J, Carreno M et al : Autoimmune seizures and epilepsy. J Clin Invest 12 : 926-940, 2019
 
8) Steriade C, Britton J, Dale RC et al : Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy : conceptual definitions. Epilepsia 61 : 1341-1351, 2020
PubMed
P.205 掲載の参考文献
9) Hirsch LJ, Gaspard N, van Baalen A et al : Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and -related conditions. Epilepsia 59 : 739-744, 2018
PubMed
10) Iizuka T, Kanazawa N, Kaneko J et al : Cryptogenic NORSE : its distinctive clinical features and response to immunotherapy. Neurol Neuroimmunol Neuroinflamm 4 : e396, 2017
PubMed
11) Yanagida A, Kanazawa N, Kaneko J et al : Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus. Neurol Neuroimmunol Neuroinflamm 7 : e849, 2020
PubMed
12) Sabater L, Gaig C, Gelpi E et al : A novel non-rapid-eye movement and rapid-eyemovement parasomnia with sleep breathing disorder associated with antibodies to IgLON5 : a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13 : 575-586, 2014
 
P.206 掲載の参考文献
13) Honorat JA, Komorowski L, Josephs KA et al : IgLON5 antibody : neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4 : e385, 2017
PubMed
14) Fuseya K, Kimura A, Yoshikura N et al : Corticobasal syndrome in a patient with anti-IgLON5 antibodies. Mov Disord Clin Pract 7 : 557-559, 2020
 
15) Landa J, Gaig C, Plaguma J et al : Effects of IgLON5 antibodies on neuronal cytoskeleton : a link between autoimmunity and neurodegeneration. Ann Neurol 88 : 1023-1027, 2020
PubMed
16) Fang B, McKeon A, Hinson SR et al : Autoimmune glial fibrillary acidic protein JAMA Neurol 73 : 1297-1307, 2016
PubMed
17) Flanagan EP, Hinson SR, Lennon VA et al : Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy : analysis of 102 patients. Ann Neurol 81 : 298-309, 2017
PubMed
18) Martinez-Hernandez E, Guasp M, Garcia-Serra A et al : Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology 94 : e2302-e2310, 2020
PubMed
19) Yamakawa M, Hogan KO, Leever J et al : Autopsy case of meningoencephalomyelitis associated with glial fibrillary acidic protein antibody. Neurol Neuroimmunol Neuroinflamm 8 : e1081, 2021
PubMed
20) Mandel-Brehm C, Dubey D, Kryzer TJ et al : Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med 381 : 47-54, 2019
PubMed
21) Maudes E, Landa J, Munoz-Lopetegi A et al : Clinical significance of Kelch-like protein 11 antibodies. Neurol Neuroimmunol Neuroinflamm 7 : e666, 2020
PubMed
22) Zekeridou A, Kryzer T, Guo Y et al : Phosphodiesterase 10A IgG : a novel biomarker of paraneoplastic neurologic autoimmunity. Neurology 93 : e815-e822, 2019
PubMed
23) Ruiz-Garcia R, Martinez-Hernandez E, Joubert B et al : Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol Neuroimmunol Neuroinflamm 7 : e658, 2019
 
24) Landa J, Guasp M, Miguez-Cabello F et al : Encephalitis with autoantibodies against the glutamate kainate receptors GluK2. Ann Neurol 90 : 101-117, 2021
PubMed
P.207 掲載の参考文献
25) Amano E, Machida A, Kanazawa N et al : Cerebrospinal fluid MOG-antibodies in anti-NMDA receptor encephalitis with leptomeningeal enhancement. Neurol Sci 41 : 2635-2638, 2020
PubMed
26) Joubert B, Garcia-Serra A, Planaguma J et al : Pregnancy outcomes in anti-NMDA receptor encephalitis : case series. Neurol Neuroimmunol Neuroinflamm 7 : e668, 2020
PubMed
P.208 掲載の参考文献
27) Armangue T, Spatola M, Vlagea A et al : Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis : a prospective observational study and retrospective analysis. Lancet Neurol 17 : 760-772, 2018
PubMed
28) Dechelotte B, Muniz-Castrillo S, Joubert B et al : Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 7 : e701, 2020
 
29) Ruiz-Garcia R, Martinez-Hernandez E, Saiz A et al : The diagnostic value of onconeural antibodies depends on how they are tested. Front Immunol 11 : 1482, 2020
 
30) Nosadini M, Thomas T, Eyre M et al : International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm 8 : e1052, 2021
PubMed
P.209 掲載の参考文献
1) Ueno T, Kon T, Kaneko K et al : Contrast enhancement of hypertrophic dura mater in MOG antibody-associated disease. Neurology 93 : 271-272, 2019
PubMed
P.210 掲載の参考文献
2) Papathanasiou A, Yeo JM, Humberstone M et al : MOG-antibody-associated hypertrophic pachymeningitis. Mult Scler Relat Disord 42 : 102074, 2020
PubMed
3) Suzuki H, Kitada M, Ueno S et al : Anti-NMDAR encephalitis preceded by dura mater lesions. Neurol Sci 34 : 1021-1022, 2013
PubMed
4) Jia H, Xie X, Qi F et al : Anti-NMDAR encephalitis with simultaneous hypertrophic pachymeningitis in a 68-year-old male : a rare case report. BMC Neurol 19 : 215, 2019
 
5) Imafuku A, Sawa N, Kawada M et al : Incidence and risk factors of new-onset hypertrophic pachymeningitis in patients with anti-neutrophil antibody-associated vasculitis : using logistic regression and classification tree analysis. Clin Rheumatol 38 : 1039-1046, 2019
PubMed
6) Ikeda J, Shimojima Y, Usami Y et al : Cerebrospinal fluid biomarkers implicated in the pathogenesis of anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis. Clin Rheumatol 39 : 1803-1811, 2020
PubMed
7) Shimojima Y, Kishida D, Nomura S et al : Cerebrospinal fluid levels of BAFF and APRIL as direct indicators of disease activity in anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis. Clin Rheumatol 39 : 3145-3148, 2020
PubMed
P.211 掲載の参考文献
8) Kobayashi K, Nakagomi D, Furuta S et al : Efficacy of rituximab for antineutrophil cytoplasmic antibody-associated hypertrophic pachymeningitis : a case series. Clin Exp Rheumatol 38 (Suppl. 124) : S176-S181, 2020
 
9) Levraut M, Cohen M, Bresch S et al : Immunoglobulin G4-related hypertrophic pachymeningitis : a case-oriented review. Neurol Neuroimmunol Neuroinflamm 6 : e568, 2019
PubMed
10) Wallace ZS, Naden RP, Chari S et al : The 2019 American College of Rheumatology/european league against rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 72 : 7-19, 2020
PubMed
11) Umehara H, Okazaki K, Kawa S et al : The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31 : 529-533, 2021
PubMed
12) Della-Torre E, Campochiaro C, Cassione EB et al : Intrathecal rituximab for IgG 4-related hypertrophic pachymeningitis. J Neurol Neurosurg Psychiatry 89 : 441-444, 2018
PubMed
13) Soares C, Martins DF, Pestana-Silva R : Intrathecal rituximab in immunoglobulin G4-hypertrophic pachymeningitis. J Neuroimmunol 334 : 576997, 2019
 
P.212 掲載の参考文献
14) Ramos-Casals M, Perez-Alvarez R, Kostov B et al : Clinical characterization and outcomes of 85 patients with neurosarcoidosis. Sci Rep 11 : 13735, 2021
 
15) Murphy OC, Salazar-Camelo A, Jimenez JA et al : Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol Neuroimmunol Neuroinflamm 7 : e722, 2020
PubMed
P.213 掲載の参考文献
16) Dieudonne Y, Allenbach Y, Benveniste O et al : Granulomatosis-associated myositis : high prevalence of sporadic inclusion body myositis. Neurology 94 : e910-e920, 2020
PubMed
17) Arun T, Pattison L, Palace J : Distinguishing neurosarcoidosis from multiple sclerosis-based on CSF analysis : a retrospective study. Neurology 94 : e2545-e2554, 2020
PubMed
18) Otto C, Wengert O, Unterwalder N et al : Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm 7 : e725, 2020
PubMed
19) Lord J, Paz Soldan MM, Galli J et al : Neurosarcoidosis : Longitudinal experience in a single-center, academic healthcare system. Neurol Neuroimmunol Neuroinflamm 7 : e743, 2020
 
P.214 掲載の参考文献
20) Kidd DP : Sarcoidosis of the central nervous system : Safety and efficacy of treatment, and experience of biological therapies. Clin Neurol Neurosurg 194 : 105811, 2020
PubMed
21) Arun T, Palace J : Effects of immunotherapies and clinical outcomes in neurosarcoidosis : a retrospective cohort study. J Neurol 268 : 2466-2472, 2021
PubMed
P.215 掲載の参考文献
22) Fritz D, Timmermans WMC, van Laar JAM et al : Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm 7 : e847, 2020
PubMed
23) Kidd DP, Galloway M, Wilhelm T : Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar. Neurology 94 : 991-993, 2020
PubMed
24) Hutto SK, Kyle K, Cavanagh JJ et al : Adalimumab for CNS sarcoidosis : single-center experience and literature review. J Neurol, 2021 [online ahead of print]
 

VII章 末梢神経疾患

P.218 掲載の参考文献
1) Kaida K, Kusunoki S : Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome : mini-review. J Neuroimmunol 223 : 5-12, 2010
PubMed
2) Kaida K, Morita D, Kanzaki M et al : Antiganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 182 : 212-218, 2007
PubMed
P.219 掲載の参考文献
3) Morikawa M, Kuwahara M, Ueno R et al : Serological study using glycoarray for detecting antibodies to glycolipids and glycolipid complexes in immune-mediated neuropathies. J Neuroimmunol 301 : 35-40, 2016
PubMed
4) Yoshikawa K, Kuwahara M, Morikawa M et al : Varied antibody reactivities and clinical relevance in anti-GQlb antibody-related diseases. Neurol Neuroimmunol Neuroinflamm 5 : e501, 2018
 
5) Uchibori A, Gyohda A, Chiba A : Ca2+ -dependent anti-GQ1b antibody in GQ1bseronegative Fisher syndrome and related disorders. J Neuroimmunol 298 : 172-177, 2016
PubMed
6) Rajabally YA, Uncini A : Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 83 : 711-718, 2012
PubMed
7) van Koningsveld R, Steyerberg EW, Hughes RAC et al : A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 6 : 589-594, 2007
PubMed
8) Walgaard C, Lingsma HF, Ruts L et al : Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 76 : 968-975, 2011
PubMed
P.220 掲載の参考文献
9) Kuitwaard K, de Gelder J, Tio-Gillen AP et al : Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 66 : 597-603, 2009
PubMed
10) 海田賢一 : ギラン・バレー症候群の予後, 予後関連因子. Brain Nerve 67 : 1411-1419, 2015
 
11) Walgaard C, Lingsma HF, Ruts L et al : Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol 67 : 781-787, 2010
PubMed
12) Yamagishi Y, Suzuki H, Sonoo M, et al : Markers for Guillain-Barre syndrome with poor prognosis : a multi-center study. J Peripher Nerv Syst 22 : 433-439, 2017
PubMed
13) 山岸裕子, 楠進 : ギラン・バレー症候群の予後と予後予測因子. 臨床神経60 : 247-252, 2020
 
14) Nomura K, Kusunoki S : Japanese multicenter clinical trial of intravenous polyethylene glycol-treated immunoglobulin and comparison with previous clinical trial of sulfonated immunoglobulin in Guillain-Barre syndrome. Clin Exp Neuroimmunol 8 : Issue 3, 2017
 
15) Verboon C, van den Berg B, Cornblath DR et al : Original research : second IVIg course in Guillain-Barre syndrome with poor prognosis : the non-randomised ISID study. J Neurol Neurosurg Psychiatry 91 : 113-121, 2020
PubMed
P.221 掲載の参考文献
16) Walgaard C, Jacobs BC, Lingsma HF et al : Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS) : a double-blind, randomised, placebo-controlled trial. Lancet Neurol 20 : 275-283, 2021
PubMed
17) Susuki K, Rasband MN, Tohyama K et al : Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27 : 3956-3967, 2007
PubMed
18) Davidson AI, Halstead SK, Goodfellow JA et al : Inhibition of complement in Guillain-Barre syndrome : the ICA-GBS study. J Peripher Nerv Syst 22 : 4-12, 2017
PubMed
19) Misawa S, Kuwabara S, Sato Y et al : Safety and efficacy of eculizumab in Guillain-Barre syndrome : a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 17 : 519-529, 2018
PubMed
20) Wang Y, Shi Q, Lv H et al : IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barre syndrome. Exp Neurol 291 : 134-140, 2017
 
P.222 掲載の参考文献
21) Paterson RW, Brown RL, Benjamin L et al : The emerging spectrum of COVID-19 neurology : clinical radiological and laboratory findings. Brain 143 : 3104-3120, 2020
PubMed
22) De Sanctis P, Doneddu PE, Vigano L et al : Guillain-Barre syndrome-associated with SARS-CoV-2 infection. a systematic review. Eur J Neurol 27 : 2361-2370, 2020
PubMed
P.223 掲載の参考文献
1) van Doorn PA, Hadden RDM, Van den Bergh PYK : Elucidating autoimmune nodopathies and the CIDP spectrum. Brain 144 : 1043-1045, 2021
PubMed
2) Koike H, Katsuno M : Pathophysiology of chronic inflammatory demyelinating polyneuropathy : insights into classification and therapeutic strategy. Neurology Ther 9 : 213-227, 2020
PubMed
3) Herraets I, Rosmalen M van, Bos J et al : Clinical outcomes in multifocal motor neuropathy : a combined cross-sectional and follow-up study. Neurology 95 : e1979-1987, 2020
 
4) Al-Zuhairy A, Sindrup SH, Jakobsen J : Long-term follow-up of facilitated subcutaneous immunoglobulin therapy in multifocal motor neuropathy. J Neurol Sci 427 : 117495, 2021
PubMed
P.224 掲載の参考文献
5) Gentile L, Russo M, Rodolico C et al : Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy. Sci Rep-uk 11 : 9216, 2021
PubMed
6) Iijima M, Koike H, Hattori N et al : Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurology Neurosurg Psychiatry 79 : 1040, 2008.
PubMed
7) Bergh PYKV den, Doorn PA, Hadden RDM et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint Task Force? Second revision. J Peripher Nerv Syst 26 : 242-268, 2021
 
P.225 掲載の参考文献
8) Hayashi T, Nukui T, Piao J et al : Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Behav 11 : e02084, 2021
PubMed
9) Fukami Y, Iijima M, Koike H et al : Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. J Neurol 268 : 3835-3844, 2021
PubMed
10) Godelaine J, Schaepdryver MD, Bossuyt X et al : Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Commun 3 : fcab018, 2021
 
11) Breville G, Lascano AM, Roux-Lombard P et al : Interleukin 8, a biomarker to differentiate Guillain-Barre syndrome from CIDP. Neurol Neuroimmunol Neuroinflamm 8 : e1031, 2021
PubMed
12) Herraets IJT, Goedee HS, Telleman JA et al : Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. Neurology 94 : 10, 2020
 
13) Herraets IJT, Goedee HS, Telleman JA et al : Nerve ultrasound for diagnosing chronic inflammatory neuropathy : a multicenter validation study. Neurology 95 : e1745-1753, 2020
PubMed
14) Oudeman J, Eftimov F, Strijkers GJ et al : Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. Neurology 94 : e62-74, 2019
PubMed
15) Rosmalen MHJ van, Goedee HS, van der Gijp A et al : Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies. J Neurol 268 : 978-988, 2021
PubMed
P.226 掲載の参考文献
16) Shimizu S, Iijima M, Fukami Y et al : Efficacy and safety of rituximab in refractory CIDP with or without IgG4 autoantibodies (RECIPE) : protocol for a double-blind, randomized, placebo-controlled clinical trial. Jmir Res Protoc 9 : e17117, 2020
PubMed
17) Gingele S, Koch M, Saparilla AC et al : Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients : a prospective observational study under real-world conditions. Ther Adv Neurol Diso 14 : 175628642110091, 2021
 
P.227 掲載の参考文献
18) Yeh WZ, Dyck PJ, van den Berg LH et al : Multifocal motor neuropathy : controversies and priorities. J Neurology Neurosurg Psychiatry 91 : 140, 2020
PubMed
19) Oudeman J, Eftimov F, Strijkers GJ et al : Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. Neurology 94 : e62-74, 2019
PubMed
20) Loewenbruck KF, Werner R, Gunther R et al : One nerve suffices : a clinically guided nerve ultrasound protocol for the differentiation of multifocal motor neuropathy (MMN) and amyotrophic lateral sclerosis (ALS). J Neurol 268 : 1495-1507, 2021
PubMed
P.229 掲載の参考文献
1) 桑原聡 : Crow-Fukase症候群の病態と新規治療. 日内会誌 100 : 2275-2281, 2011
 
2) Suichi T, Misawa S, Beppu M et al : Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology 93 : e975-e983, 2019
PubMed
3) 三澤園子 : POEMS (クロウ-深瀬) 症候群. 医学のあゆみ 255 : 479-483, 2015
Medical*Online
P.230 掲載の参考文献
4) Marsh ES, Keddie S, Terris-Prestholt F et al : Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and -associated costs. J Neurol Neurosurg Psychiatry 92 : 172-176, 2021
PubMed
P.231 掲載の参考文献
5) Misawa S, Sato Y, Katayama K et al : Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15 : 1129-1137, 2016
PubMed
6) Suichi T, Misawa S, Nagashima K et al : Lenalidomide treatment for thalidomiderefractory POEMS syndrome : a prospective single-arm clinical trial. Intern Med 59 : 1149-1153, 2020
PubMed
7) Jurczyszyn A, Castillo JJ, Olszewska-Szopa M et al : POEMS syndrome : real world experience in diagnosis and systemic therapy-108 patients multicenter analysis. Clin Lymphoma Myeloma Leuk S2152-2650, 2021
PubMed
8) Mellors PW, Kourelis T, Go RS et al : Characteristics and risk factors for thrombosis in POEMS syndrome : a retrospective evaluation of 230 patients. Am J Hematol, 2021 [online ahead of print]
 
P.232 掲載の参考文献
9) Vallat JM, Duchesne M, Corcia P et al : The wide spectrum of pathophysiologic mechanisms of paraproteinemic neuropathy. Neurology 96 : 214-225, 2021
PubMed
10) Briani C, Visentin A, Cerri F et al : From pathogenesis to personalized treatments of neuropathies in hematological malignancies. J Peripher Nerv Syst 25 : 212-221, 2020
 
P.233 掲載の参考文献
11) Steck AJ : Anti-MAG neuropathy : from biology to clinical management. J Neuroimmunol 361 : 577725, 2021
PubMed
12) Koike H, Katsuno M : Paraproteinemia and neuropathy. Neurol Sci 42 : 4489-4501, 2021
PubMed
13) Hanggi P, Aliu B, Martin K et al : Decrease in serum anti-MAG autoantibodies is associated with therapy response in patients with anti-MAG neuropathy : retrospective study. Neurol Neuroimmunol Neuroinflamm 9 : e1109, 2021
PubMed
14) Vernino S, Hopkins S, Wang Z : Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 146 : 3-7, 2009
PubMed
15) Klein CM, Vernino S, Lennon VA et al : The spectrum of autoimmune autonomic neuropathies. Ann Neurol 53 : 752-758, 2003
PubMed
16) Nakane S, Mukaino A, Higuchi O et al : A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy. J Autoimmun 108 : 102403, 2020
PubMed
17) 中根俊成 : 自己免疫性自律神経節障害. "Annual Review 神経 2020" 鈴木則宏編. 中外医学社, 東京, pp322-332, 2020
 
18) Nakane S, Mukaino A, Ihara E et al : Autoimmune gastrointestinal dysmotility : the interface between clinical immunology and neurogastroenterology. Immunol Med 44 : 74-85, 2021
PubMed
P.234 掲載の参考文献
19) Nakane S, Mukaino A, Maeda Y et al : Extra-autonomic manifestations in autoimmune autonomic ganglionopathy : a Japanese survey. J Neurol Neurosurg Psychiatry 88 : 367-368, 2017
PubMed
20) Iodice V, Kimpinski K, Vernino S et al : Immunotherapy for autoimmune autonomic ganglionopathy. Auton Neurosci 146 : 22-25, 2009
PubMed
21) Schroeder C, Vernino S, Birkenfeld AL et al : Plasma exchange for primary autoimmune autonomic failure. N Engl J Med 353 : 1585-1590, 2005
PubMed
22) Winston N, Vernino S : Recent advances in autoimmune autonomic ganglionopathy. Curr Opin Neurol 23 : 514-518, 2010
PubMed
23) Gupta A, Harris S, Vernino S et al : Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy. Clin Auton Res 25 : 255-228, 2015
PubMed
24) Bouxin M, Schvartz B, Mestrallet S et al : Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy : case-report and literature review. J Neuroimmunol 326 : 28-32, 2019
PubMed
25) Iodice V, Kimpinski K, Vernino S et al : Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology 72 : 2002-2008, 2009
PubMed
P.236 掲載の参考文献
1) Gylfadottir SS, Itani M, Kroigard T et al : Diagnosis and prevalence of diabetic polyneuropathy : a cross-sectional study of Danish patients with type 2 diabetes. Eur J Neurol 27 : 2575-2585, 2020
PubMed
2) Mizokami-Stout KR, Li Z, Foster NC et al : T1D exchange clinic networ k. the contemporary prevalence of diabetic neuropathy in type 1 diabetes : findings from the T1D exchange. Diabetes Care 43 : 806-812, 2020
PubMed
3) Braffett BH, Gubitosi-Klug RA, Albers JW et al : Risk factors for diabetic peripheral neuropathy and cardio-vascular autonomic neuropathy in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes 69 : 1000-1010, 2020
 
P.237 掲載の参考文献
4) Mizukami H, Osonoi S, Takaku S et al : Role of glucosamine in development of diabetic neuropathy independent of the aldose reductase pathway. Brain Commun 2 : fcaa168, 2020
PubMed
5) Goncalves NP, Jager SE, Richner M et al : Schwann cell p75 neurotrophin receptor modulates small fiber degeneration in diabetic neuropathy. Glia 68 : 2725-2743, 2020
PubMed
6) Pinto MV, Ng PS, Howe BM et al : Lumbosacral radiculoplexus neuropathy : neurologic outcomes and survival in a population-based study. Neurology 96 : e2098-e2108, 2021
 
7) Teh K, Wilkinson ID, Heiberg-Gibbons F et al : Somatosensory network functional connectivity differentiates clinical pain phenotypes in diabetic neuropathy. Diabetologia 64 : 1412-1421, 2021
PubMed
8) Broadhead DY, Devenport SB : Sensorimotor polyneuropathy in a diabetic patient after rapid overcorrection of chronic hyperglycemia. J Investig Med High Impact Case Rep. 2021 9 : 23247096211051927, 2021
 
9) Jann S, Fazio R, Cocito D et al : High-dose intravenous immunoglobulin is effective in painful diabetic polyneuropathy resistant to conventional treatments. results of a double-blind, randomized, placebo-controlled, multicenter trial. Pain Med 21 : 576-585, 2020
PubMed
10) Lipone P, Ehler E, Nastaj M et al : Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin : a randomized controlled pilot study. CNS Drugs 34 : 1177-1189, 2020
PubMed
11) Ma J, Wang A, Jiang W et al : Clinical characteristics of paraneoplastic neurological syndrome -related to different pathological lung cancers. Thorac Cancer 12 : 2265-2270, 2021
 
P.238 掲載の参考文献
12) Shah S, Vazquez Do Campo R, Kumar N et al : Paraneoplastic myeloneuropathies : clinical, oncologic, and serologic accompaniments. Neurology 96 : e632-e639, 2021
PubMed
13) Sancho Saldana A, Mahdi-Rogers M, Hadden RD : Sensory neuronopathies : a case series and literature review. J Peripher Nerv Syst 26 : 66-74, 2021
PubMed
14) Fu P, He L, Tang N et al : A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies. J Clin Neurosci 89 : 336-342, 2021
PubMed
15) Beer R, O'Gorman C, Horwood K et al : A case of IVIg responsive paraneoplastic SOX1 peripheral neuropathy in a male with breast carcinoma. J Neuroimmunol 352 : 577492, 2021
 
16) Hean V, Camdessanche JP, Cathebras P et al : Paraneoplastic subacute sensory neuropathy with triple positive antineuronal antibodies -associated with small-cell lung cancer. BMJ Case Rep 13 : e235668, 2020
PubMed
17) Park IW, Kim YG, Ro S et al : Paraneoplastic demyelinating polyneuropathy associated with cardiac myxoma. Muscle Nerve 61 : E3-E5, 2020
PubMed
18) Holm-Yildiz S, Crone C, Borch TH et al : Metastatic melanoma presenting with subacute sensory neuronopathy. Muscle Nerve 64 : E5-E6, 2021
PubMed
P.239 掲載の参考文献
19) Hishikawa N, Takemoto M, Sato K et al : Sleep problems in subacute myelo-optico neuropathy (SMON). J Clin Neurosci 68 : 128-133, 2019
 
20) Calls A, Torres-Espin A, Navarro X et al : Cisplatin-induced peripheral neuropathy is associated with neuronal senescence-like response. Neuro Oncol 23 : 88-99, 2021
PubMed
21) Akin EJ, Alsaloum M, Higerd GP et al : Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain 144 : 1727-1737, 2021
PubMed
22) Kissoon T, Gururangan S, Sladky J : Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma. Neurooncol Pract 6 : 179-184, 2019
 
23) Suichi T, Misawa S, Beppu M et al : Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology 93 : e975-e983, 2019
PubMed
24) Suichi T, Misawa S, Nagashima K et al : Lenalidomide treatment for thalidomide-refractory POEMS syndrome : a prospective single-arm clinical trial. Intern Med 59 : 1149-1153, 2020
PubMed
25) Selvy M, Kerckhove N, Pereira B et al : Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life : a single center cross-sectional study. Front Pharmacol 12 : 637593, 2021
PubMed
26) Dubey D, David WS, Reynolds KL et al : Severe neurological toxicity of immune checkpoint inhibitors : growing spectrum. Ann Neurol 87 : 659-669, 2020
PubMed
27) Duong SL, Barbiero FJ, Nowak RJ et al : Neurotoxicities -associated with immune checkpoint inhibitor therapy. J Neurooncol 152 : 265-277, 2021
PubMed
28) Mikami T, Liaw B, Asada M et al : Neuroimmunological adverse events -associated with immune checkpoint inhibitor : a retrospective, pharmacovigilance study using FAERS database. J Neurooncol 152 : 135-144, 2021
PubMed
P.240 掲載の参考文献
29) Okada K, Seki M, Yaguchi H et al : Polyradiculoneuropathy -induced by immune checkpoint inhibitors : a case series and review of the literature. J Neurol 268 : 680-688, 2021
PubMed
30) Fan Q, Hu Y, Wang X et al : Guillain-Barre syndrome in patients treated with immune checkpoint inhibitors. J Neurol 268 : 2169-2174, 2021
PubMed
P.241 掲載の参考文献
1) Collins MP, Dyck PJ, Gronseth GS et al : Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of nonsystemic vasculitic neuropathy : executive summary. J Peripher Nerv Syst 15 : 176-184, 2010
 
2) Hadden RDM, Collins MP, Zivkovic SA et al : Vasculitic peripheral neuropathy : case definition and guidelines for collection, analysis, and presentation of immunisation safety data. Vaccine 35 : 1567-1578, 2017
PubMed
P.242 掲載の参考文献
3) Bischof A, Jaeger VK, Hadden RDM et al : Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides : insights from the DCVAS study. Neurol Neuroimmunol Neuroinflamm 6 : e615, 2019
PubMed
4) Nishi R, Koike H, Ohyama K et al : Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology 94 : e1726-e1737, 2020
PubMed
5) Nishi R, Koike H, Ohyama K et al : Association between IL-5 levels and the clinicopathologic features of eosinophilic granulomatosis with polyangiitis. Neurology 96 : 226-229, 2021
PubMed
P.243 掲載の参考文献
6) Zhang Z, Liu S, Guo L et al : Clinical characteristics of peripheral neuropathy in eosinophilic granulomatosis with polyangiitis : a retrospective single-center study in China. J Immunol Res, 3530768, 2020
 
7) Ng PS, Dyck PJ, Laughlin RS et al : Lumbosacral radiculoplexus neuropathy : incidence and the association with diabetes mellitus. Neurology 92 : e1188-e1194, 2019
PubMed
8) Pinto MV, Ng PS, Howe BM et al : Lumbosacral radiculoplexus neuropathy : neurologic outcomes and survival in a population-based study. Neurology 96 : e2098-e2108, 2021
 
9) Hui M, Meena AK, Rajasekhar L et al : Vasculitic neuropathy : a retrospective analysis of nerve biopsies and clinical features from a single tertiary care center. Ann Indian Acad Neurol 22 : 180-186, 2019
PubMed
10) Nathani D, Barnett MH, Spies J et al : Vasculitic neuropathy : comparison of clinical predictors with histopathological outcome. Muscle Nerve 59 : 643-649, 2019
PubMed
P.244 掲載の参考文献
11) Schneider C, Sprenger A, Weiss K et al : MRI detects peripheral nerve and adjacent muscle pathology in non-systemic vasculitic neuropathy (NSVN). J Neurol 266 : 975-981, 2019
PubMed
12) 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究班 (研究代表者 : 有村義宏), 難治性腎疾患に関する調査研究班 (研究代表者 : 丸山彰一), びまん性肺疾患に関する調査研究班 (研究代表者 : 本間栄) 編 : ANCA関連血管炎診療ガイドライン 2017. 診断と治療社, 東京, 2017
 
13) 厚生労働科学研究費補助金難治性疾患等政策研究事業 難治性血管炎に関する調査研究班 (研究代表者 : 針谷正祥) 編 : 抗リン脂質抗体症候群, 好酸球性多発血管炎性肉芽種症, 結節性多発動脈炎, リウマトイド血管炎の治療の手引き 2020. 診断と治療社, 東京, 2021
 
14) Collins MP, Hadden RD : The nonsystemic vasculitic neuropathies. Nat Rev Neurol 13 : 302-316, 2017
PubMed
P.245 掲載の参考文献
15) Lima K, Tavee J, Dua A : Combination rituximab and intravenous immunoglobulin for treatment of refractory vasculitic neuropathy : a case series. Rheumatology (Oxford) 60 : 4884-4887, 2021
PubMed
16) Quirins M, Theaudin M, Cohen-Aubart F et al : Nonsystemic vasculitic neuropathy : presentation and long-term outcome from a French cohort of 50 patients. Autoimmun Rev 20 : 102874, 2021
PubMed
17) Ramineni KK, Chandra SR, Mahadevan A et al : Clinical, electrophysiological and laboratory parameters, and outcome in patients with biopsy proven systemic and nonsystemic vasculitic neuropathy. Neurol India 67 : 62-70, 2021
 
P.247 掲載の参考文献
1) Billig JI, Kotsis SV, Chung KC et al : Variation in use of electrodiagnostic testing : analysis from the Michigan collaborative hand initiative for quality in surgery. J Hand Surg Am 46 : 169-177, 2021
 
2) Lu YT, Deol AK, Sears ED : The association between electrodiagnostic severity and treatment recommendations for carpal tunnel syndrome. J Hand Surg Am 46 : 92-98, 2021
PubMed
3) 園生雅弘 : 手根管症候群に望まれる診断基準とは. 1 既存の診断基準と診断基準のあり方・必要性. 末梢神経 30 : 200-202, 2019
 
P.248 掲載の参考文献
4) Miyaji Y, Kobayashi M, Oishi C et al : A new method to define cutoff values in nerve conduction studies for carpal tunnel syndrome considering the presence of false-positive cases. Neurol Sci 41 : 669-677, 2020
 
5) Rydberg M, Zimmerman M, Gottsater A et al : Diabetes mellitus as a risk factor for compression neuropathy : a longitudinal cohort study from southern Sweden. BMJ Open Diab Res Care 8 : e001298, 2020
PubMed
6) 三澤園子 : 糖尿病性多発神経障害の神経伝導検査. 脳神経内科 93 : 726-729, 2020
 
7) Olde Dubbelink TBG, De Kleermaeker FGCM, Beekman R et al : Wrist circumference-dependent upper limit of normal for the cross-sectional area is superior over a fixed cut-off value in confirming the clinical diagnosis of carpal tunnel syndrome. Front Neurol 12 : 625565, 2021
 
P.249 掲載の参考文献
8) Roomizadeh P, Eftekharsadat B, Abedini A et al : Ultrasonographic assessment of carpal tunnel syndrome severity. a systematic review and meta-analysis. Am J Phys Med Rehabil 98 : 373-381, 2019
PubMed
9) Cartwright MS, Hobson-Webb LD, Boon AJ et al : Evidence-based guideline : neuromuscular ultrasound for the diagnosis of carpal tunnel syndrome. Muscle Nerve 46 : 287-293, 2012
PubMed
10) Chompoopong P, Preston DC : Neuromuscular ultrasound findings in carpal tunnel syndrome with symptoms mainly in the nondominant hand. Muscle Nerve 63 : 661-667, 2021
PubMed
11) Li M, Jiang J, Zhou Q et al : Sonographic follow-up after endoscopic carpal tunnel release for severe carpal tunnel syndrome : a one-year neuroanatomical prospective observational study. BMC Musculoskelet Disord 20 : 157, 2019
PubMed
P.250 掲載の参考文献
12) Kitaoka H, Izumi C, Izumiya Y et al : JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 84 : 1610-1671, 2020
PubMed
13) Fosbol EL, Rorth R, Leicht BP at al : Association of carpal tunnel syndrome with amyloidosis, heat failure, and adverse cardio-vascular outcomes. J Am Coll Cardiol 74 : 15-23, 2019. Editorial comment. Ton VK, Patel S, Gottlieb SS : Carpal tunnel syndrome and future amyloidosis. Time to heed the warning sign. J Am Coll Cardiol 74 : 24-25, 2019
 
14) Milandri A, Farioli A, Gagliardi C et al : Carpal tunnel syndrome in cardiac amyloidosis : implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail 22 : 507-515, 2020. Editorial comment. Westin O, Fosbol E, Gustafsson F : Refining the role of carpal tunnel syndrome in cardiac amyloidosis. Eur J Heart Fail 22 : 516-518, 2020
 
15) Donnelly JP, Hanna M, Sperry BW et al : Carpal tunnel syndrome : a potential early, red-flag sign of amyloidosis. J Hand Surg Am 44 : 868-876, 2019
PubMed
P.251 掲載の参考文献
16) Sood RF, Kamenko S, McCreary E et al : Diagnosing systemic amyloidosis presenting as carpal tunnel syndrome. a risk nomogram to guide biopsy at time of carpal tunnel release. J Bone Joint Surg Am 103 : 1284-1294, 2021
PubMed
17) Baker NA, Dole J, Roll SC : Meta-synthesis of carpal tunnel syndrome treatment options : developing consolidated clinical treatment recommendations to improve practice. Arch Phys Med Rehabil 102 : 2261-2268, 2021
PubMed
18) Chen IJ, Chang KV, Wu WT et al : Ultrasound parameters other than the direct measurement of ulnar nerve size for diagnosing cubital tunnel syndrome : a systemic review and meta-analysis. Arch Phys Med Rehabil 100 : 1114-1130, 2019
 
19) Borders Jr SJ, Jenkins S, Bang K et al : Ulnar nerve subluxation and dislocation : a review of the literature. Neurosurg Rev 44 : 793-798, 2021
 
20) Rutter M, Grandizio LC, Malone WJ et al : The use of preoperative dynamic ultrasound to predict ulnar nerve stability following in situ decompression for cubital tunnel syndrome. J Hand Surg Am 44 : 35-38, 2019
PubMed
P.252 掲載の参考文献
21) Lee SK, Hwang SY, Kim SG et al : Analysis of the anatomical factors associated with cubital tunnel syndrome. Orthop Traumatol Surg Res 106 : 743-749, 2020
PubMed
P.254 掲載の参考文献
1) Kitaoka H, Izumi C, Izumiya Y et al : JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis. Circ J 84 : 1610-1671, 2020
PubMed
2) Waddington-Cruz M, Wixner J, Amass L et al : Characteristics of patients with late- vs. early-onset Val30Met transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther 10 : 753-766, 2021
PubMed
3) Benson MD, Berk JL, Dispenzieri A et al : Tissue biopsy for the diagnosis of amyloidosis : experience from some centres. Amyloid, 2021 [online ahead of print]
 
4) Singh V, Falk R, Di Carli MF et al : State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol 26 : 158-173, 2019
PubMed
P.255 掲載の参考文献
5) Ueda M, Sekijima Y, Koike H et al : Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies.J Neurol Sci 414 : 116813, 2020
PubMed
6) Yamashita T, Ueda M, Nomura T et al : Natural history and long-term effects of variant protein reduction in non-V30M ATTR amyloidosis. Neurology 93 : 714-716, 2019
PubMed
7) Rapezzi C, Elliott P, Damy T et al : Efficacy of tafamidis in patients with hereditary and wildtype transthyretin amyloid cardiomyopathy : further analyses from ATTR-ACT. JACC Heart Fail 9 : 115-123, 2021
PubMed
8) Monteiro C, Mesgazardeh J, Anselmo J et al : Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight 4 : e126526, 2019
PubMed
9) Landmesser U, Poller W, Tsimikas S et al : From traditional pharmacological towards nucleic acid-based therapies for cardio-vascular diseases. Eur Heart J 41 : 3884-3899, 2020
 
P.256 掲載の参考文献
10) Gonzalez-Duarte A, Berk JL, Quan D et al : Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol 267 : 703-712, 2020
 
11) Obici L, Berk JL, Gonzalez-Duarte A et al : Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid 27 : 153-162, 2020
PubMed
12) Adams D, Polydefkis M, Gonzalez-Duarte A et al : Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy : 12-month results of an open-label extension study. Lancet Neurol 20 : 49-59, 2021
PubMed
13) Coelho T, Yarlas A, Waddington-Cruz M et al : Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. J Neurol 267 : 1070-1079, 2020
PubMed
14) Brannagan TH, Wang AK, Coelho T et al : Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis : a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol 27 : 1374-1381, 2020
PubMed
15) Yarlas A, Lovley A, Brown D et al : Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study. J Neurol, 2021 [online ahead of print]
 
16) Magrinelli F, Fabrizi GM, Santoro L et al : Pharmacological treatment for familial amyloid polyneuropathy. Cochrane Database Syst Rev 4 : CD012395, 2020
PubMed
17) Dohrn MF, Auer-Grumbach M, Baron R et al : Chance or challenge, spoilt for choice? new recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy : the German/Austrian position and review of the literature. J Neurol 268 : 3610-3625, 2021
PubMed
18) Adams D, Algalarrondo V, Polydefkis M et al : Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis 16 : 411, 2021
 
P.257 掲載の参考文献
19) Fortanier E, Delmont E, Verschueren A et al : Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol 131 : 1129-1133, 2020
PubMed
20) Zouari HG, Ng Wing Tin S, Wahab A et al : Assessment of autonomic innervation of the foot in familial amyloid polyneuropathy. Eur J Neurol 26 : 94-e10, 2019
PubMed
21) Maia LF, Maceski A, Conceicao I et al : Plasma neurofilament light chain : an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid 27 : 97-102, 2020
PubMed
22) Ticau S, Sridharan GV, Tsour S et al : Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology 96 : e412-e422, 2021
 
23) Judge DP, Heitner SB, Falk RH et al : Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 74 : 285-295, 2019
PubMed
24) Habtemariam BA, Karsten V, Attarwala H et al : Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther 109 : 372-382, 2021
PubMed
25) Coelho T, Ando Y, Benson MD et al : Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-L (Rx) (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther 10 : 375-389, 2021
PubMed
P.258 掲載の参考文献
26) Gillmore JD, Gane E, Taubel J et al : CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385 : 493-502, 2021
PubMed
27) Buning H, Schambach A : A first step toward in vivo gene editing in patients. Nat Med 27 : 1515-1517, 2021
PubMed
28) Lim GB : Gene editing in patients with amyloidosis. Nat Rev Cardiol 18 : 611, 2021
PubMed
29) Onuora S : New treatments for amyloidosis. Nat Rev Rheumatol 17 : 510, 2021
PubMed
P.260 掲載の参考文献
1) Pipis M, Rossor AM, Laura M et al : Nextgeneration sequencing in Charcot-Marie-Tooth disease : opportunities and challenges. Nat Rev Neurol 15 : 644-656, 2019
PubMed
2) Laura M, Pipis M, Rossor AM et al : Charcot-Marie-Tooth disease and related disorders : an evolving landscape. Curr Opi Neurol 32 : 641-650, 2019
 
3) Barreto LC, Oliveira FS, Nunes PS et al : Epidemiologic study of Charcot-Marie-Tooth disease : a systematic review. Neuroepidemiology 46 : 157-165, 2016
PubMed
P.261 掲載の参考文献
4) Prukop T, Wernick S, Boussicault L et al : Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats. J Neurosci Res 98 : 1933-1952 : 2020
PubMed
5) Prukop T, Stenzel J, Wernick S et al : Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PloS one 14 : e0209752, 2019
 
P.262 掲載の参考文献
6) Attarian S, Young P, Brannagan TH et al : A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A. Orphanet J Rare Dis 16 : 433, 2021
PubMed
7) Boutary S, Caillaud M, El Madani M et al : Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A. Commun Biol 4 : 317, 2021
PubMed
8) Gautier B, Hajjar H, Soares S et al : AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A. Nat Commun 12 : 2356, 2021
 
9) Lee JS, Lee JY, Song DW et al : Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice. Nucleic Acids Res 48 : 130-140, 2020
PubMed
10) Lee JS, Kwak G, Kim HJ et al : miR-381 attenuates peripheral neuropathic phenotype caused by overexpression of PMP22. Exp Neurobiol 28 : 279-288, 2019
PubMed
11) Serfecz J, Bazick H, Al Salihi MO et al : Downregulation of the human peripheral myelin protein 22 gene by miR-29a in cellular models of Charcot-Marie-Tooth disease. Gene Ther 26 : 455-464, 2019
PubMed
12) Sahenk Z, Nagaraja HN, McCracken BS et al : NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 65 : 681-689, 2005
PubMed
13) Ozes B, Myers M, Moss K et al : AAV1. NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1. Gene Ther, 2021 [online ahead of print]
 
14) Ozes B, Moss K, Myers M et al : AAV1.NT-3 gene therapy in a CMT2D model : phenotypic improvements in Gars (P278KY/+) mice. Brain Commun 3 : fcab252, 2021
 
15) Fledrich R, Akkermann D, Schutza V et al : NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies. Nat Commun 10 : 1467, 2019
PubMed
P.263 掲載の参考文献
16) Scapin C, Ferri C, Pettinato E et al : Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot-Marie-Tooth type 1B mouse model. Hum Mol Genet 28 : 992-1006, 2019
 
17) Patzko A, Bai Y, Saporta MA et al : Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 135 (Pt 12) : 3551-3566, 2012
 
18) Chen Y, Podojil JR, Kunjamma RB et al : Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis. Brain 142 : 344-361, 2019
PubMed
19) Caillaud M, Msheik Z, Ndong-Ntoutoume GM et al : Curcumin-cyclodextrin/cellulose nanocrystals improve the phenotype of Charcot-Marie-Tooth-1A transgenic rats through the reduction of oxidative stress. Free Radic Biol Med 161 : 246-262, 2020
PubMed
20) Geisler S, Huang SX, Strickland A et al : Gene therapy targeting SARM1 blocks pathological axon degeneration in mice. J Exp Med 216 : 294-303, 2019
PubMed
P.264 掲載の参考文献
21) Glasser CE, Gartner MR, Wilson D et al : Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve 57 : 921-926, 2018
PubMed
22) Sociali G, Visigalli D, Prukop T et al : Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiol Dis 95 : 145-157, 2016
PubMed
23) Fledrich R, Abdelaal T, Rasch L et al : Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nat Commun 9 : 3025, 2018
 
P.265 掲載の参考文献
24) Fridman V, Suriyanarayanan S, Novak P et al : Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology 92 : e359-e370, 2019
PubMed
25) Murphy SM, Herrmann DN, McDermott MP et al : Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 16 : 191-198, 2011
PubMed
P.266 掲載の参考文献
1) Stevens RD, Marshall SA, Cornblath DR et al : A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med 37 : S299-308, 2009
PubMed
2) Latronico N, Bertolini G, Guarneri B et al : Simplified electrophysiological evaluation of peripheral nerves in critically ill patients : the Italian multi-centre CRIMYNE study. Crit Care 11 : R11, 2007
 
3) Koch S, Spuler S, Deja M et al : Critical illness myopathy is frequent : accompanying neuropathy protracts ICU dis- charge. J Neurol Neurosurg Psychiatry 82 : 287-293, 2011
 
P.267 掲載の参考文献
4) Appleton RT, Kinsella J, Quasim T : The incidence of intensive care unit-acquired weakness syndromes : a systematic review. J Intensive Care Soc 16 : 126-136, 2015
PubMed
5) Kasinathan A, Sharawat IK, Singhi P et al : Intensive care unit-acquired weakness in children : a prospective observational study using simplified serial electrophysiological testing (PEDCIMP Study). Neurocrit Care 34 : 927-934, 2021
PubMed
6) Frithiof R, Rostami E, Kumlien E et al : Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients : a prospective study. Clin Neurophysiol 132 : 1733-1740, 2021
PubMed
7) Santiago-Perez S, Espinosa-Garcia S, Martinez-Perez A et al : Neurophysiological findings in critical COVID-19 patients with peripheral nervous system manifestations. J Clin Neurophysiol, 2021
PubMed
8) Hameed S, Khan AF, Khan S : Electrodiagnostic findings in COVID-19 patients : a single center experience. Clin Neurophysiol 132 : 3019-3024, 2021
PubMed
9) Scarpino M, Bonizzoli M, Lazzeri C et al : Electrodiagnostic findings in patients with non-COVID-19- and COVID-19-related acute respiratory distress syndrome. Acta Neurol Scand 144 : 161-169, 2021
PubMed
10) Uncini A, Foresti C, Frigeni B et al : Electrophysiological features of acute inflammatory demyelinating polyneuropathy associated with SARS-CoV-2 infection. Neurophysiol Clin 51 : 183-191, 2021
PubMed
P.268 掲載の参考文献
11) Schweickert WD, Hall J : ICU-acquired weakness. Chest 131 : 1541-1549, 2007
PubMed
12) Latronico N, Bolton CF : Critical illness polyneuropathy and myopathy : a major cause of muscle weakness and paralysis. Lancet Neurol 10 : 931-941, 2011
 
P.269 掲載の参考文献
13) 厚生労働省 : 診療報酬算定資料 https://www.mhlw.go.jp/content/12400000/000603758.pdf (2021年12月30日閲覧)
 
14) Vander Berghe G, Wilmer A, Milants I et al : Intensitve insulin therapy in mixed medical/surgical intensive care units : benefit versus harm. Diabetes 55 : 3151-3159, 2006
 
15) Hermans G, De Jonghe B, Bruyninckx F et al : Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev 21 : CD006832, 2015
 
16) NICE-SUGAR Study Investigators, Finfer D, Chirttock DR et al : Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360 : 1283-1297, 2009
 
P.270 掲載の参考文献
17) Brunner R, Rinner W, Haberler C et al : Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis : a prospective, randomized, placebo-controlled, double-blinded trial. Critical Care 17 : R213, 2013
PubMed
18) Zayed Y. Kheiri B, Barbarawi M et al : Effects of neuromuscular electrical stimulation in critically ill patients : a systematic review and meta-analysis of randomised controlled trials Aust Crit Care 33 : 203-210, 2020
PubMed
19) Doiron KA, Hoffmann TC, Beller EM : Early intervention (mobilization or active exercise) for critically ill adults in the intensive care unit Cochrane Database Syst Rev 3 : CD010754, 2018
PubMed
20) Kou K, Momosaki R, Miyazaki S et al : Impact of nutrition therapy and rehabilitation on acute and critical illness : a systematic review. J UOEH 41 : 303-315, 2019
PubMed
21) Latronico N, Shehu I, Seghelini E : Neuromuscular sequelae of critical illness. Curr Opin Crit Care 11 : 381-390, 2005
PubMed
22) Fletcher SN, Kennedy DD, Ghosh IR et al : Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 31 : 1012-1016, 2003
PubMed
23) Guarneri B, Bertolini G, Latronico N : Long-term outcome in patients with critical illness myopathy or neuropathy : the Italian multicentre CRIMYNE study. J Neurol Neurosurg Psychiatry 79 : 838-841, 2008
PubMed
24) Koch S, Wollersheim T, Bierbrauer J et al : Long-term recovery in critical illness myopathy is complete, contrary to polyneuropathy. Muscle Nerve 50 : 431-436, 2014
PubMed
25) Garnacho-Montero J, Amaya-Villar R, Garcia-Garmendia JL et al : Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med 33 : 349-542, 2005
PubMed
26) Ali NA, O'Brien JM Jr, Hoffmann SP et al : Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med 178 : 261-268, 2008
PubMed
27) Brunello AG, Haenggi M, Wigger O et al : Usefulness of a clinical diagnosis of ICU-acquired paresis to predict outcome in patients with SIRS and acute respiratory failure. Intensive Care Med 36 : 66-74, 2010
PubMed
P.271 掲載の参考文献
28) 畑中裕己 : ICU (ICU acquired weakness) の診断. 臨床神経生理学 48 : 128-135, 2020
 
29) 畑中裕己 : ICU (ICU acquired weakness) の診断と治療. 脳神経内科 95 : 660-669, 2021
 

VIII章 筋疾患

P.274 掲載の参考文献
1) Narayanaswami P, Sanders DB, Wolfe GI et al : International consensus guidance for management of myasthenia gravis 2020 update. Neurology 96 : 114-122, 2021
 
P.275 掲載の参考文献
2) Imai T, Suzuki S, Nagane Y et al : Reappraisal of oral steroid therapy for myasthenia gravis. Front Neurol 11 : 868, 2020
PubMed
P.276 掲載の参考文献
3) Gronseth GS, Barohn R, Narayanaswami P : Practice advisory : thymectomy for myasthenia gravis (practice parameter update). Report of the guideline development, dissemination, and implementation. Subcommittee of the American Academy of Neurology. Neurology 94 : 705-709, 2020
 
4) Wolfe GI, Kaminski HJ, Aban IB et al : Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375 : 511-522, 2016
PubMed
5) Wolfe GI, Kaminski HJ, Aban IB et al : Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non- thymomatous myasthenia gravis : 2-year extension of the MGTX randomised trial. Lancet Neurol 18 : 259-268, 2019
PubMed
P.277 掲載の参考文献
6) Howard, Jr JF, Nowak RJ, Wolfe GI et al : Clinical effects of the self-administered subcutaneous complement inhibitor Zilucoplan in patients with moderate to severe generalized myasthenia gravis. results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol 77 : 1-11, 2020
 
7) 吉積一樹, 木村卓, 右近紳一郎他 : 浸潤性胸腺腫合併重症筋無力症クリーゼに対してエクリズマブが有効であった1例. 臨床神経学 60 : 865-868, 2020
 
8) Bril V, Benatar M, Andersen H et al : Efficacy and safety of Rozanolixizumab in moderate to severe generalized myasthenia gravis. a phase 2 randomized control trial. Neurology 96 : e853-e865, 2021
PubMed
P.278 掲載の参考文献
9) Di Stefano V, Lupica A, Rispoli MG et al : Rituximab in AChR subtype of myasthenia gravis : systematic review. J Neurol Neurosurg Psychiatry 91 : 392-395, 2020
PubMed
10) Dubey D, David WS, Reynolds KL et al : Severe neurological toxicity of immune checkpoint inhibitors : growing spectrum. Ann Neurol 87 : 659-669, 2020
PubMed
P.279 掲載の参考文献
11) 鈴木重明 : 免疫チェックポイント阻害薬に伴う神経系の免疫関連有害事象. 日内会誌 110 : 1611-1616, 2021
 
P.281 掲載の参考文献
1) Shruti MR, Donald BS, Vern CJ et al : Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia. Muscle Nerve 60 : 292-298, 2019
 
2) Alexander FL, Maarten JT, Martijn RT et al : Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome. Muscle Nerve 62 : 111-114, 2020
 
3) Shin JO : Assessment of the compound muscle action potential amplitude return time between exercises or tests in the repetitive nerve stimulation test for Lambert-Eaton myasthenic syndrome. Muscle Nerve 62 : 742-745, 2020
PubMed
P.282 掲載の参考文献
4) Paul M, Alexander FL, Paul G et al : Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort. Sci Rep 10 : 10546, 2020
 
5) Xuan S, Jiping T, Hui S et al : Anti-SOX1 antibodies in paraneoplastic neurological syndrome. J Clin Neurol 16 : 530-546, 2020
 
P.283 掲載の参考文献
6) Paul M, Paul G, Girija S et al : Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome. J Neuroimmunol 340 : 577149, 2020
 
7) Simizu F, Takeshita Y, Sano Y et al : GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain 142 : 2253-2264, 2019
 
P.284 掲載の参考文献
8) Gill AJ, Gandhy S, Lancaster E : Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. Muscle Nerve 63 : E18-E21, 2021
 
9) Perry S, Khema S, Bruce K et al : Amifampridine phosphate (firdapse) is effective in a confirmatory phase 3 clinical trial in LEMS. J Clin Neuromuscul Dis 20 : 111-119, 2019
 
P.285 掲載の参考文献
10) Alexander FL, Marion IB, Erik WZ et al : Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology 94 : e511-e520, 2020
 
P.286 掲載の参考文献
1) Tanboon J, Nishino I : Classification of idiopathic inflammatory myopathies : pathology perspectives. Curr Opin Neuro 32 : 704-714, 2019
PubMed
2) Uruha A, Goebel HH, Stenzel W : Updates on the immunopathology in idiopathic inflammatory myopathies. Curr Rheumatol Rep 23 : 56, 2021
PubMed
P.287 掲載の参考文献
3) Allenbach Y, Benveniste O, Stenzel W et al : Immune-mediated necrotizing myopathy : clinical features and pathogenesis. Nat Rev Rheumatol 16 : 689-701, 2020
PubMed
4) Xiong A, Yang G, Song Z et al : Rituximab in the treatment of immune-mediated necrotizing myopathy : a review of case reports and case series. Ther Adv Neurol Disord 14 : 1756286421998918, 2021
PubMed
5) Zhang H, Sun Y, Liu H et al : Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody : a case series. Rheumatology (Oxford, England), 2021
 
6) Kurashige T : Anti-HMGCR myopathy : clinical and histopathological features, and prognosis. Curr Opin Rheumatol 33 : 554-562, 2021
PubMed
7) Williams B, Horn MP, Banz Y et al : Cutaneous involvement in anti-HMGCR positive necrotizing myopathy. J autoimmun 123 : 102691, 2021
PubMed
8) Zhang L, Yang H, Lei J et al : Muscle pathological features and extra-muscle involvement in idiopathic inflammatory myopathies with anti-mitochondrial antibody. Semin Arthritis Rheum 51 : 741-748, 2021
 
P.288 掲載の参考文献
9) Opinc AH, Makowska JS : Antisynthetase syndrome-much more than just a myopathy. Semin Arthritis Rheum 51 : 72-83, 2021
PubMed
10) Cavagna L, Trallero-Araguas E, Meloni F et al : Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med 8 : 2013, 2019
 
11) Liu Y, Liu X, Xie M et al : Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review. Respiratory medicine 165 : 105920, 2020
PubMed
P.289 掲載の参考文献
12) Vulsteke JB, Satoh M, Malyavantham K et al : Anti-OJ autoantibodies : rare or underdetected? Autoimmun Rev 18 : 658-664, 2019
PubMed
13) Muro Y, Yamano Y, Yoshida K et al : Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. J Autoimmun 122 : 102680, 2021
 
14) Tanboon J, Inoue M, Hirakawa S et al : Pathologic features of anti-Mi-2 dermatomyositis. Neurology 96 : e448-e459, 2021
PubMed
P.290 掲載の参考文献
15) Romero-Bueno F, Diaz Del Campo P, Trallero-Araguas E et al : Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin in Arthritis Rheum 50 : 776-790, 2020
PubMed
16) Yamasaki Y, Kobayashi N, Akioka S et al : Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies : multicentre study. Rheumatology (Oxford, England) 60 : 4821-4831, 2021
 
17) Kotobuki Y, Tonomura K, Fujimoto M : Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis. Immunol Med 44 : 23-29, 2021
 
18) De Vooght J, Vulsteke JB, De Haes P et al : Anti-TIF1-γ autoantibodies : warning lights of a tumour autoantigen. Rheumatology (Oxford, England) 59 : 469-477, 2020
 
19) Ichimura Y, Konishi R, Shobo M et al : Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology (Oxford, England), 2021
 
20) Albayda J, Mecoli C, Casciola-Rosen L et al : A North American Cohort of Anti-SAE Dermatomyositis : Clinical phenotype, testing, and review of cases. ACR Open Rheumatol 3 : 287-294, 2021
 
P.291 掲載の参考文献
1) 日本神経学会監 : BQ1 筋強直性ジストロフィーとは. "筋強直性ジストロフィー診療ガイドライン 2020" 南江堂, 東京, pp2-11, 2020
 
P.292 掲載の参考文献
2) 松村剛, 高田博仁, 石垣景子他 : 本邦における筋強直性ジストロフィーの診療実態調査専門医対象全国調査. 臨床神経学 60 : 120-129, 2020
 
3) 高橋正紀, 山本理紗, 久保田智哉他 : 本邦における筋強直性ジストロフィーの患者実態調査患者対象全国調査. 臨床神経学60 : 130-136, 2020
 
4) Heatwole C, Luebbe E, Rosero S et al : Mexiletine in myotonic dystrophy type 1 : a randomized, double-blind, placebo-controlled trial. Neurology 9 : e228-e240, 2021
 
P.293 掲載の参考文献
5) 日本神経学会監 : FQ8-2 徐脈性不整脈に対する予防的なペースメーカ治療は予後を改善するか. "筋強直性ジストロフィー診療ガイドライン 2020" 南江堂, 東京, pp66-67, 2020
 
6) Itoh H, Hisamatsu T, Tamura T et al : Cardiac conduction disorders as markers of cardiac events in myotonic dystrophy type 1. J Am Heart Assoc 9 : e015709, 2020
PubMed
7) Creta A, Providencia R, Gossios T et al : A normal electrocardiogram does not exclude infra-hisian conduction disease in patients with myotonic dystrophy Type 1. JACC Clin Electrophysiol 7 : 1038-1048, 2021
 
8) 日本神経学会監 : BQ7-1 呼吸障害の特徴は何か. "筋強直性ジストロフィー診療ガイドライン 2020" 南江堂, 東京, pp56-57, 2020
 
9) Ashizawa T, Gagnon C, Groh WJ et al : Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract 8 : 507-520, 2018
PubMed
P.294 掲載の参考文献
10) 日本神経学会監 : BQ10-1 中枢神経障害の特徴はどのようなものか. "筋強直性ジストロフィー診療ガイドライン 2020" 南江堂, 東京, pp84-86, 2020
 
11) Lenzoni S, Bozzoni V, Burgio F et al : Recognition of emotions conveyed by facial expression and body postures in myotonic dystrophy (DM). Cortex 127 : 58-66, 2020
PubMed
12) Ates S, Deistung A, Schneider R et al : Characterization of iron accumulation in deep gray matter in myotonic dystrophy type 1 and 2 using quantitative susceptibility mapping and R2. Front Neurol 10 : 1320, 2019
PubMed
13) Serra L, Scocchia M, Meola G et al : Ventral tegmental area dysfunction affects decision-making in patients with myotonic dystrophy type-1. Cortex 128 : 192-202, 2020
PubMed
14) Langbehn KE, van der Plas E, Moser D et al : Cognitive function and its relationship with brain structure in myotonic dystrophy type 1. J Neurosci Res 99 : 190-199, 2021
PubMed
15) Koscik TR, van der Plas E, Gutmann L et al : White matter microstructure relates to motor outcomes in myotonic dystrophy type 1 independently of disease duration and genetic burden. Sci Rep 11 : 4886, 2021
PubMed
16) 日本神経学会監 : BQ2 診断・遺伝相談. "筋強直性ジストロフィー診療ガイドライン 2020" 南江堂, 東京, pp14-28, 2020
 
17) 松村剛, 秋澤叔香, 石垣景子 他 : 筋強直性ジストロフィー1 型の遺伝学的診療に関する臨床遺伝専門医対象調査. 臨床神経学 61 : 602-612, 2021
 
18) Senba H, Sueoka K, Sato S et al : The impact of parental unaffected allele combination on the diagnostic outcome in the preimplantation genetic testing for myotonic dystrophy type 1 in Japanese ancestry. Reprod Med Biol 19 : 265-269, 2020
 
P.295 掲載の参考文献
19) 日本神経学会監 : BQ13-1 筋強直性ジストロフィー女性が周産期 (妊娠中・産後) に気をつけることは何か. "筋強直性ジストロフィー診療ガイドライン 2020" 南江堂, 東京, pp114-116, 2020
 
20) 日本神経学会監 : BQ13-2 先天性筋強直性ジストロフィーの病態が成人型と異なるところは何か. "筋強直性ジストロフィー診療ガイドライン 2020" 南江堂, 東京, pp117-119, 2020
 
21) Johnson NE, Aldana EZ, Angeard N et al : Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1. Neurol Clin Pract 9 : 443-454, 2019
PubMed
22) 日本神経学会監 : BQ14-1 全身麻酔や鎮静を行ううえで問題となるべき点, またその要因は何か. "筋強直性ジストロフィー診療ガイドライン 2020" 南江堂, 東京, pp.128-130, 2020
 
23) Kim CS, Park JM, Park D et al : Opioid use may be -associated with postoperative complications in myotonic dystrophy type 1 with high-grade muscular impairment. Sci Rep 11 : 8, 2021
PubMed
P.296 掲載の参考文献
24) 日本神経学会監 : BQ12-1 腫瘍合併の頻度はどれくらいか. "筋強直性ジストロフィー診療ガイドライン 2020" 南江堂, 東京, pp104-106, 2020
 
25) Alsaggaf R, St George DMM, Zhan M et al : Benign tumors in myotonic dystrophy type I target disease-related cancer sites. Ann Clin Transl Neurol 6 : 1510-1518, 2019
PubMed
26) Pascual-Gilabert M, Lopez-Castel A, Artero R : Myotonic dystrophy type 1 drug development : a pipeline toward the market. Drug Discov Today 26 : 1765-1772, 2021
PubMed
27) Horrigan J, Gomes TB, Snape M et al : A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1). Pediatr Neurol 112 : 84-93, 2020
PubMed
P.298 掲載の参考文献
1) Komaki H, Takeshima Y, Matsumura T et al : Viltolarsen in Japanese Duchenne muscular dystrophy patients : a phase 1/2 study. Ann Clin Transl Neurol 7 : 2393-2408, 2020
PubMed
2) McDonald CM, Henricson EK, Abresch RT et al : Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy : a prospective cohort study. Lancet 391 : 451-461, 2018
PubMed
3) Clemens PR, Rao VK, Connolly AM et al : Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping : a phase 2 randomized clinical trial. JAMA Neurol 77 : 982-991, 2020
PubMed
P.299 掲載の参考文献
4) Pozsgai E, Griffin D, Potter R et al : Unmet needs and evolving treatment for limb girdle muscular dystrophies. Neurodegener Dis Manag 11 : 411-429, 2021
PubMed
5) Potter RA, Griffin DA, Sondergaard PC et al : Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. Human Gene Therapy : 749-762, 2018
PubMed
6) Shimizu-Motohashi Y, Komaki H, Motohashi N et al : Restoring dystrophin expression in Duchenne muscular dystrophy : current status of therapeutic approaches. J Pers Med 9 : 1, 2019
PubMed
7) Mendell JR, Sahenk Z, Lehman K et al : Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy. JAMA Neurology 77 : 1122, 2020
PubMed
8) Hamanaka K, Sikrova D, Mitsuhashi S et al : Homozygous nonsense variant in LRIF1 -associated with facioscapulohumeral muscular dystrophy. Neurology 94 : e2441-e2447, 2020
PubMed
9) Jia FF, Drew AP, Nicholson GA et al : Facioscapulohumeral muscular dystrophy type 2 : an update on the clinical, genetic, and molecular findings. Neuromuscul Disord, 2021
PubMed
P.300 掲載の参考文献
10) Le Gall L, Sidlauskaite E, Mariot V et al : Therapeutic strategies targeting DUX4 in FSHD. J Clin Med 9 : 2886, 2020
PubMed
11) LoRusso S, Johnson NE, McDermott MP et al : Clinical trial readiness to solve barriers to drug development in FSHD (Re-Solve) : protocol of a large, international, multi-center prospective study. BMC neurology 19 : 224, 2019
 
12) Kanagawa M, Toda T : Muscular dystrophy with ribitol-phosphate deficiency : a novel post-translational mechanism in dystroglycanopathy. J Neuromuscul Dis 4 : 259-267, 2017
PubMed
13) Cataldi MP, Lu P, Blaeser A et al : Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice. Nat commun 9 : 3448, 2018
 
14) Ortiz-Cordero C, Magli A, Dhoke NR et al : NAD+enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes. eLife 10 : e65443, 2021
 
15) Sengupta K, Mishra MK, Loro E et al : Genome editing-mediated utrophin upregulation in Duchenne muscular dystrophy stem cells. Mol Ther Nucleic Acids 22 : 500-509, 2020
PubMed
16) Choi E, Koo T : CRISPR technologies for the treatment of Duchenne muscular dystrophy. Mol Ther 29 : 3179-3191, 2021
PubMed
17) Dhoke NR, Kim H, Selvaraj S et al : A universal gene correction approach for FKRP-associated dystroglycanopathies to enable autologous cell therapy. Cell Reports 36 : 109360, 2021
 
18) Mercuri E, Muntoni F, Osorio AN et al : Safety and effectiveness of ataluren : comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res 9 : 341-360, 2020
PubMed
19) Michael E, Sofou K, Wahlgren L et al : Long term treatment with ataluren-the Swedish experience. BMC Musculoskeletal Disord 22 : 837, 2021
 
P.301 掲載の参考文献
20) Nakajima T, Sankai Y, Takata S et al : Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases : a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001). Orphanet J Rare Dis 16 : 304, 2021
PubMed
21) Dangouloff T, Boemer F, Servais L : Newborn screening of neuromuscular diseases. Neuromuscul Disord 31 : 1070-1080, 2021
PubMed
22) Matsumura T, Saito T, Mori M et al : Infection control in the respiratory care of coronavirus disease-19 patients with neuromuscular diseases. Neurol Clin Neurosci 9 : 159-165, 2021
PubMed
23) Matsumura T, Takada H, Kobayashi M et al : A web-based questionnaire survey on the influence of coronavirus disease-19 on the care of patients with muscular dystrophy. Neuromuscul Disord 31 : 839-846, 2021
 
24) Nishizawa H, Nakamura A : Changes in motor function in Duchenne muscular dystrophy patients after travel restrictions due to COVID-19. Muscle Nerve 64 : 357-361, 2021
PubMed
25) Natera-De Benito D, Aguilera-Albesa S, Costa-Comellas L et al : COVID-19 in children with neuromuscular disorders. J Neurol 268 : 3081-3085, 2021
PubMed
26) Levine H, Prais D, Aharoni S et al : COVID-19 in advanced Duchenne/Becker muscular dystrophy patients. Neuromuscul Disord 31 : 607-611, 2021
PubMed
27) Quinlivan R, Desikan M, Cruces F et al : Clinical outcome of SARS-CoV-2 infection in 7 adults with Duchenne muscular dystrophy attending a specialist neuromuscular centre. Neuromuscul Disord 31 : 603-606, 2021
PubMed
28) Dhont S, Callens R, Stevens D et al : Myotonic dystrophy type 1 as a major risk factor for severe COVID-19? Acta Neurol Belg 121 : 1761-1765, 2021
 
P.304 掲載の参考文献
1) Jitpimolmard N, Matthews E, Fialho D : Treatment updates for neuromuscular channelopathies. Curr Treat Options Neurol 22 : 34, 2020
PubMed
2) Sasaki R, Nakaza M, Furuta M et al : Mutation spectrum and health status in skeletal muscle channelopathies in Japan. Neuromuscul Disord 30 : 546-553, 2020
PubMed
3) Nakaza M, Kitamura Y, Furuta M et al : Analysis of the genetic background associated with sporadic periodic paralysis in Japanese patients. J Neurol Sci 412 : 116795, 2020
PubMed
4) Holm-Yildiz S, Witting N, Dahlqvist J et al : Permanent muscle weakness in hypokalemic periodic paralysis. Neurology 95 : e342-e352, 2020
PubMed
P.305 掲載の参考文献
5) Holm-Yildiz S, Krag T, Witting N et al : Vacuoles, often containing glycogen, are a consistent finding in hypokalemic periodic paralysis. J Neuropathol Exp Neurol 79 : 1127-1129, 2020
PubMed
6) Mazzanti A, Guz D, Trancuccio A et al : Natural history and risk stratification in Andersen-Tawil syndrome type 1. J Am Coll Cardiol 75 : 1772-1784, 2020
PubMed
P.306 掲載の参考文献
7) Sun J, Luo S, Suetterlin KJ et al : Clinical and genetic spectrum of a Chinese cohort with SCN4A gene mutations. Neuromuscul Disord 31 : 829-838, 2021
PubMed
8) Stunnenberg BC, LoRusso S, Arnold WD et al : Guidelines on clinical presentation and management of nondystrophic myotonias. Muscle Nerve 62 : 430-444, 2020
PubMed
9) Matthews E, Holmes S, Fialho D : Skeletal muscle channelopathies : a guide to diagnosis and management. Pract Neurol 21 : 196-204, 2021
PubMed
10) Desaphy JF, Altamura C, Vicart S et al : Targeted therapies for skeletal muscle ion channelopathies : systematic review and steps towards precision medicine. J Neuromuscul Dis 8 : 357-381, 2021
PubMed
P.307 掲載の参考文献
11) Modoni A, D'Amico A, Primiano G et al : Long-term safety and usefulness of mexiletine in a large cohort of patients affected by non-dystrophic myotonias. Front Neurol 11 : 300, 2020
 
12) Lorusso S, Kline D, Bartlett A et al : Openlabel trial of ranolazine for the treatment of paramyotonia congenita. Muscle Nerve 59 : 240-243, 2019
PubMed
13) Raja Rayan DL, Hanna MG : Managing pregnancy and anaesthetics in patients with skeletal muscle channelopathies. Neuromuscul Disord 30 : 539-545, 2020
PubMed
P.309 掲載の参考文献
1) Claeys KG : Congenital myopathies : an update. Dev Med Child Neurol 62 : 297-302, 2020
PubMed
2) Huang K, Bi FF, Yang H : A systematic review and meta-analysis of the prevalence of congenital myopathy. Front Neurol 12 : 761636, 2021
 
3) Papadimas GK, Xirou S, Kararizou E et al : Update on congenital myopathies in adulthood. Int J Mol Sci 21 : 3694, 2020
PubMed
P.310 掲載の参考文献
4) Huang K, Duan HQ, Li QX et al : Clinicopathological features of titinopathy from a Chinese neuromuscular center. Neuropathology : 349-356, 2020
 
5) Pagola-Lorz I, Vicente E, Ibanez B et al : Epidemiological study and genetic characterization of inherited muscle diseases in a northern Spanish region. Orphanet J Rare Dis 14 : 276, 2019
 
6) Theadom A, Rodrigues M, Poke G et al : A nationwide, population-based prevalence study of genetic muscle disorders. Neuroepidemiology 52 : 128-135, 2019
PubMed
7) Laitila J, Wallgren-Pettersson C : Recent advances in nemaline myopathy. Neuromuscul Disord 31 : 955-967, 2021
PubMed
P.311 掲載の参考文献
8) Pelin K, Wallgren-Pettersson C : Update on the genetics of congenital myopathies. Semin Pediatr Neurol 29 : 12-22, 2019
PubMed
9) Kiiski K, Lehtokari VL, Vihola AK et al : Dominantly inherited distal nemaline/cap myopathy caused by a large deletion in the nebulin gene. Neuromuscul Disord 29 : 97-107, 2019
PubMed
10) Blondelle J, Tallapaka K, Seto JT et al : Cullin-3 dependent deregulation of ACTN1 represents a new pathogenic mechanism in nemaline myopathy. JCI Insight 5 : e125665, 2019
PubMed
11) Saito Y, Nishikawa A, Iida A et al : ADSSL1 myopathy is the most common nemaline myopathy in Japan with variable clinical features. Neurology 95 : e1500-1511, 2020
PubMed
12) Ogasawara M, Nishino I : A review of core myopathy : central core disease, multiminicore disease, dusty core disease, and core-rod myopathy. Neuromuscul Disord 31 : 968-977, 2021
PubMed
13) Ogasawara M, Ogawa M, Nonaka I et al : Evaluation of the core formation process in congenital neuromuscular disease with uniform type 1 fiber and central core disease. J Neuropathol Exp Neurol 79 : 1370-1375, 2020
PubMed
14) Garibaldi M, Rendu J, Brocard J et al : 'Dusty core disease' (DuCD) : expanding morphological spectrum of RYR1 recessive myopathies. Acta Neuropathol Commun 7 : 3, 2019
PubMed
P.312 掲載の参考文献
15) Lornage X, Romero NB, Grosgogeat CA et al : ACTN2 mutations cause "multiple structured core disease" (MsCD). Acta Neuropathol 137 : 501-519, 2019
PubMed
16) Bouman K, Kusters B, De Winter JM et al : NEM6, KBTBD13-related congenital myopathy : myopathological analysis in 18 Dutch patients reveals ring rods fibers, cores, nuclear clumps, and granulo-filamentous protein material. J Neuropathol Exp Neurol 80 : 366-376, 2021
PubMed
17) Villar-Quiles RN, Catervi F, Cabet E et al : ASC-1 is a cell cycle regulator associated with severe and mild forms of myopathy. Ann Neurol 87 : 217-232, 2020
PubMed
18) Pellerin D, Aykanat A, Ellezam B et al : Novel recessive TNNT1 congenital corerod myopathy in French Canadians. Ann Neurol 87 : 568-583, 2020
PubMed
19) Garibaldi M, Fattori F, Pennisi EM et al : Novel ACTA1 mutation causes late-presenting nemaline myopathy with unusual dark cores. Neuromuscul Disord 31 : 139-148, 2021
PubMed
20) Reumers SFI, Erasmus CE, Bouman K et al : Clinical, genetic, and histological features of centronuclear myopathy in the Netherlands. Clin Genet 100 : 692-702, 2021
PubMed
21) Annoussamy M, Lilien C, Gidaro T et al : X-linked myotubular myopathy : a prospective international natural history study. Neurology 92 : e1852-1867, 2019
PubMed
22) Graham RJ, Muntoni F, Hughes I et al : Mortality and respiratory support in X-linked myotubular myopathy : a RECENSUS retrospective analysis. Arch Dis Child 105 : 332-338, 2020
 
23) Wilson JM, Flotte TR : Moving forward after two deaths in a gene therapy trial of myotubular myopathy. Hum Gene Ther 31 : 695-696, 2020
 
24) Cocanougher BT, Flynn L, Yun P et al : Adult MTM1-related myopathy carriers : classification based on deep phenotyping. Neurology 93 : e1535-1542, 2019
PubMed
P.313 掲載の参考文献
25) Naddaf E, Milone M, Kansagra A et al : Sporadic late-onset nemaline myopathy : clinical spectrum, survival, and treatment outcomes. Neurology 93 : e298-305, 2019
PubMed
26) Sewry CA, Laitila JM, Wallgren-Pettersson C : Nemaline myopathies : a current view. J Muscle Res Cell Motil 40 : 111-126, 2019
 
27) Jungbluth H, Muntoni F : Therapeutic aspects in congenital myopathies. Semin Pediatr Neurol 29 : 71-82, 2019
PubMed
28) Gohlke J, Tonino P, Lindqvist J et al : The number of Z-repeats and super-repeats in nebulin greatly varies across vertebrates and scales with animal size. J Gen Physiol 153 : e202012783.1-14, 2021
 
29) Jirka C, Pak JH, Grosgogeat CA et al : Dysregulation of NRAP degradation by KLHL41 contributes to pathophysiology in nemaline myopathy. Hum Mol Genet 28 : 2549-2560, 2019
PubMed
30) Rabai A, Reisser L, Reina-San-Martin B et al : Allele-specific CRISPR/Cas9 correction of a heterozygous DNM2 mutation rescues centronuclear myopathy cell phenotypes. Mol Ther Nucleic Acids 16 : 246-256, 2019
PubMed

IX章 神経系感染症

P.316 掲載の参考文献
1) Bodro M, Compta Y, Sanchez-Valle R : Presentations and mechanisms of CNS disorders related to COVID-19. Neurol Neuroimmnol Neuroinflamm 8 : e923, 2021
PubMed
P.317 掲載の参考文献
2) Lechien JR, Chiesa-Estomba CM, De Siati DR et al : Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19) : a multicenter European study. Eur Arch Otorhinolaryngol 277 : 2251-2261, 2020
PubMed
3) Moriguchi T, Harii N, Goto J et al : A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 94 : 55-58, 2020
PubMed
4) Bodro M, Compta Y, Llanso L et al : Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2-associated encephalitis. Neurol Neuroimmunol Neuroinflamm 7 : e821, 2020
 
5) Romero-Sanchez CM, Diaz-Maroto I, Fernandez-Diaz E et al : Neurologic manifestations in hospitalized patients with COVID-19 : the ALBACOVID registry. Neurology 95 : e1060-e1070, 2020
PubMed
P.318 掲載の参考文献
6) Frontera JA, Sabadia S, Lalchan R et al : A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City. Neurology 96 : e575-e586, 2021
PubMed
7) Liotta EM, Batra A, Clark JR et al : Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol 7 : 2221-2230, 2020
PubMed
8) Pilotto A, Masciocchi S, Volonghi I et al : Clinical presentation and outcomes of severe acute respiratory syndrome Coronavirus 2-related encephalitis : the ENCOVID multicenter study. J Infect Dis 223 : 28-37, 2021
PubMed
9) Poyiadji N, Shahin G, Noujaim D et al : COVID-19-associated acute hemorrhagic necrotizing encephalopathy : imaging features. Radiology 296 : E119-E120, 2020
PubMed
10) Dixon L, Varley J, Gontsarova A et al : COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. Neurol Neuroimmunol Neuroinflamm 7 : e789, 2020
 
11) Sotoca J, Rodriguez-Alvarez Y : COVID-19-associated acute necrotizing myelitis. Neurol Neuroimmunol Neuroinflamm 7 : e803, 2020
PubMed
12) Virhammar J, Kumlien E, Fallmar D et al : Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology 95 : 445-449, 2020
PubMed
13) Paterson RW, Brown RL, Benjamin L et al : The emerging spectrum of COVID-19 neurology : clinical, radiological and laboratory findings. Brain 143 : 3104-3120, 2020
PubMed
14) Utukuri PS, Bautista A, Lignelli A et al : Possible acute disseminated encephalomyelitis -related to severe acute respiratory syndrome coronavirus 2 infection. AJNR Am J Neuroradiol 41 : E82-E83. 2020
PubMed
15) Novi G, Rossi T, Pedemonte E et al : Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm 7 : e797, 2020
PubMed
16) Zanin L, Saraceno G, Panciani PP et al : SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien) 162 : 1491-1494, 2020
 
17) Pinto AA, Carroll LS, Nar V et al : CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19. Neurol Neuroimmunol Neuroinflamm 7 : e813, 2020
PubMed
P.319 掲載の参考文献
18) Bryce C, Grimes Z, Pujadas E et al : Pathophysiology of SARS-CoV-2 : the Mount Sinai COVID-19 autopsy experience. Mod Pathol 34 : 1456-1467, 2021
 
19) Solomon IH, Normandin E, Bhattacharyya S et al : Neuropathological features of Covid-19. N Engl J Med 383 : 989-992, 2020
PubMed
20) Panariello A, Bassetti R, Radice A et al : Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient : a case report. Brain Behav Immun 87 : 179-181, 2020
 
21) Burr T, Barton C, Doll E et al : N-methyld-aspartate receptor encephalitis associated with COVID-19 infection in a toddler. Pediatr Neurol 114 : 75-76, 2021
 
22) Benameur K, Agarwal A, Auld SC et al : Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, USA, 2020. Emerg Infect Dis 26 : 2016-2021, 2020
PubMed
23) IImura Y, Sugano H, Ueda T et al : Relapse of herpes simplex encephalitis by epilepsy surgery 35 years after the first infection : a case report and literature review. NMC Case Report Journal 8 : 235-240, 2021
PubMed
24) Toro J, Rivera JS, Moutran-Barroso H et al : Acute HSV and anti-NMDA encephalitis occurring as a neurosurgical complication. BMJ Case Rep 14 : e241136, 2021
PubMed
P.320 掲載の参考文献
25) Herlin LK, Hansen KS, Bodilsen J et al : Varicella zoster virus encephalitis in Denmark from 2015 to 2019-a nationwide prospective cohort study. Clin Infect Dis 72 : 1192-1199, 2021
PubMed
P.322 掲載の参考文献
1) Radmard S, Reid S, Ciryam P et al : Clinical utilization of the FilmArray meningitis/encephalitis (ME) multiplex polymerase chain reaction (PCR) assay. Front Neurol 10 : 281, 2019
PubMed
2) Boudet A, Pantel A, Carles MJ et al : A review of a 13-month period of FilmArray meningitis/encephalitis panel implementation as a first-line diagnosis tool at a university hospital. PLoS One 14 : e0223887, 2019
 
3) Nabower AM, Miller S, Biewen B et al : Association of the FilmArray meningitis/encephalitis panel with clinical management. Hosp Pediatr 9 : 763-769, 2019
PubMed
4) Hagen A, Eichinger A, Meyer-Buehn M et al : Comparison of antibiotic and acyclovir usage before and after the implementation of an on-site FilmArray meningitis/encephalitis panel in an academic tertiary pediatric hospital : a retrospective observational study. BMC Pediatr 20 : 56, 2020
 
5) Pfefferle S, Christner M, Aepfelbacher M et al : Implementation of the FilmArray ME panel in laboratory routine using a simple sample selection strategy for diagnosis of meningitis and encephalitis. BMC Infect Dis 20 : 170, 2020
PubMed
6) Wilson MR, Sample HA, Zorn KC et al : Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. N Engl J Med 380 : 2327-2340, 2019
PubMed
P.323 掲載の参考文献
7) Koelman DLH, Brouwer MC, Ter Horst L et al : Pneumococcal meningitis in adults : a prospective nationwide cohort studY over a 20-year period. Clin Infect Dis ciab477, 2021
 
8) Kloek AT, Brouwer MC, Schmand B et al : Long-term neurologic and cognitive outcome and quality of life in adults after pneumococcal meningitis. Clin Microbiol Infect 26 : 1361-1367, 2020
PubMed
9) Tubiana S, Varon E, Biron C et al : Community-acquired bacterial meningitis in adults : in-hospital prognosis, long-term disability and determinants of outcome in a multicentre prospective cohort. Clin Microbiol Infect 26 : 1192-1200, 2020
 
10) Sharew A, Bodilsen J, Hansen BR et al : The cause of death in bacterial meningitis. BMC Infect Dis 20 : 182, 2020
PubMed
11) van Kassel MN, van Haeringen KJ, Brouwer MC et al : Community-acquired group B streptococcal meningitis in adults. J Infect 80 : 255-260, 2020
 
12) Chekrouni N, Koelman DLH, Brouwer MC et al : Community-acquired Haemophilus influenzae meningitis in adults. J Infect 82 : 145-150, 2021
PubMed
13) van Ettekoven CN, Brouwer MC, Bijlsma MW et al : The FOUR score as predictor of outcome in adults with bacterial meningitis. Neurology 92 : e2522-e2526, 2019
PubMed
P.324 掲載の参考文献
14) Bodilsen J, Mens H, Midgley S et al : Enterovirus meningitis in adults : a prospective nationwide population-based cohort study. Neurology 97 : e454-e463, 2021
PubMed
15) Kies KD, Thomas AS, Binnicker MJ et al : Decrease in enteroviral meningitis : an unexpected benefit of coronavirus disease 2019 (COVID-19) mitigation? Clin Infect Dis 73 : e2807-e2809, 2021
PubMed
16) Cresswell FV, Tugume L, Bahr NC et al : Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis : a prospective validation study. Lancet Infect Dis 20 : 308-317, 2020
PubMed
17) Donovan J, Thu DDA, Phu NH et al : Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis : a prospective, randomised, diagnostic accuracy study. Lancet Infect Dis 20 : 299-307, 2020
PubMed
18) Martyn EM, Bangdiwala AS, Kagimu E et al : Cerebrospinal fluid bacillary load by Xpert MTB/RIF Ultra polymerase chain reaction cycle threshold value predicts 2-week mortality in human immunodeficiency virus-associated tuberculous meningitis. Clin Infect Dis 73 : e3505-e3510, 2021
PubMed
19) Donovan J, Cresswell FV, Thuong NTT et al : Xpert MTB/RIF Ultra for the diagnosis of tuberculous meningitis : a small step forward. Clin Infect Dis 71 : 2002-2005, 2020
PubMed
P.325 掲載の参考文献
20) Pormohammad A, Nasiri MJ, McHugh TD et al : A systematic review and meta-analysis of the diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis. J Clin Microbiol 57 : e01113-1118, 2019
PubMed
21) Lin A, Cheng B, Han X et al : Value of next-generation sequencing in early diagnosis of patients with tuberculous meningitis. J Neurol Sci 422 : 117310, 2021
 
22) Wen L, Li M, Xu T et al : Clinical features, outcomes and prognostic factors of tuberculous meningitis in adults worldwide : systematic review and meta-analysis. J Neurol 266 : 3009-3021, 2019
 
23) Wang MG, Luo L, Zhang Y et al : Treatment outcomes of tuberculous meningitis in adults : a systematic review and meta-analysis. BMC Pulm Med 19 : 200, 2019
 
24) Li K, Wang L, Wen L et al : Intrathecal therapy for tuberculous meningitis : propensity-matched cohort study. Neurol Sci, 2021
 
25) Temfack E, Rim JJB, Spijker R et al : Cryptococcal antigen in serum and cerebrospinal fluid for detecting cryptococcal meningitis in adults living with human immunodeficiency virus : systematic review and meta-analysis of diagnostic test accuracy studies. Clin Infect Dis 72 : 1268-1278, 2021
PubMed
P.326 掲載の参考文献
26) Ssebambulidde K, Bangdiwala AS, Kwizera R et al : Symptomatic cryptococcal antigenemia presenting as early cryptococcal meningitis with negative cerebral spinal fluid analysis. Clin Infect Dis 68 : 2094-2098, 2019
PubMed
27) Wan Y, Li X, Wang Y et al : Clinical characteristic of 15 cases of cryptococcal meningitis treated with Ommaya reservoir. Acta Neurol Belg 120 : 1139-1145, 2020
 
P.328 掲載の参考文献
1) 厚生労働省「HAM ならびにHTLV-1陽性難治性疾患に関する国際的な総意形成を踏まえた診療ガイドラインの作成」研究班, 「HTLV-1 関連脊髄症 (HAM) 診療ガイドライン 2019」作成委員会 : HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019. 日本神経学会, 日本神経治療学会, 日本神経免疫学会 他監. 南江堂, 東京, 2019
 
2) Araujo A, Bangham CRM, Casseb J et al : Management of HAM/TSP : systematic review and consensus-based recommendations 2019. Neurol Clin Pract 11 : 49-56, 2021
PubMed
3) Okuma K, Kuramitsu M, Niwa T et al : Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting : a collaborative study for performance evaluation of diagnostic assays in Japan. Retrovirology 17 : 26, 2020
 
P.329 掲載の参考文献
4) Kodama D, Tanaka M, Matsuzaki T et al : Anti-human T-cell leukemia virus type 1 (HTLV-1) antibody assays in cerebrospinal fluid for the diagnosis of HTLV-1-associated myelopathy/tropical spastic paraparesis. J Clin Microbiol 59 : e03230-20, 2021
PubMed
5) Tamaki K, Sato T, Tsugawa J et al : Cerebrospinal fluid CXCL10 as a candidate surrogate marker for HTLV-1-associated myelopathy/tropical spastic paraparesis. Front Microbiol 10 : 2110, 2019
PubMed
6) Yamauchi J, Sato T, Yagishita N et al : Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids. J Neurol Neurosurg Psychiatry 91 : 321-323, 2020
PubMed
P.330 掲載の参考文献
7) King-Robson J, Hampton T, Rosadas C et al : HTLV-1 encephalitis. Pract Neurol, 2021 [online ahead of print]
 
P.331 掲載の参考文献
8) Kalil RS, Vasconcellos I, Rosadas C et al : Association between high proviral load, cognitive impairment, and white matter brain lesions in HTLV-1-infected individuals. J Neurovirol, 2021 [online ahead of print]
 
9) Silva TR, Labanca L, Caporali JFM et al : Ocular vestibular evoked myogenic potential (VEMP) reveals mesencephalic HTLV-1-associated neurological disease. PLoS One 14 : e0217327, 2019
PubMed
10) Araujo AQC, Wedemann D : HTLV-1 associated neurological complex. what is hidden below the water? AIDS Rev 21 : 211-217, 2019
PubMed
11) Bonnan M, Olindo S, Signate A et al : NMOSD-like and longitudinal extensive HTLV1-associated myelitis are extremes that flank an overlooked continuum. Mult Scler J Exp Transl Clin 7 : 20552173211037361, 2021
PubMed
P.332 掲載の参考文献
12) Yamakawa N, Yagishita N, Matsuo T et al : Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet J Rare Dis 15 : 175, 2020
PubMed
13) Iijima N, Yamauchi J, Yagishita N et al : Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis : a nationwide registry study in Japan. Orphanet J Rare Dis 16 : 355, 2021
PubMed
14) Nagasaka M, Yamagishi M, Yagishita N et al : Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis. Proc Natl Acad Sci USA 117 : 11685-11691, 2020
PubMed
15) 古園麻衣, 松元陸, 眞弓芳子他 : HTLV-1関連脊髄症における疾患進行の予測因子. NEUROINFECTION 25 : 146-149, 2020
 
P.333 掲載の参考文献
16) Yamauchi J, Yamano Y, Yuzawa K : Risk of human T-cell leukemia virus type 1 infection in kidney transplantation. N Engl J Med 380 : 296-298, 2019
PubMed
17) Tamaki K, Mera H, Takeshita S et al : A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma : a case report and review of the literature. Medicine (Baltimore) 100 : e27450, 2021
PubMed
18) 郡山達男 : 神経疾患とモノクローナル抗体治療HTLV-1関連脊髄症 (HAM). Clinical Neuroscience 39 : 1560-1562, 2021
 
19) 佐藤知雄, 山野嘉久 : 神経疾患治療とモノクローナル抗体 抗CCR4抗体 モガムリズマブ. Clinical Neuroscience 39 : 1515-1517, 2021
 
P.334 掲載の参考文献
20) Enose-Akahata Y, Oh U, Ohayon J et al : Clinical trial of a humanized anti-IL-2/IL-15 receptor beta chain in HAM/TSP. Ann Clin Transl Neurol 6 : 1383-1394, 2019
 
P.335 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患政策研究事業・プリオン病及び遅発性ウイルス感染症に関する調査研究班, 同・プリオン病のサーベイランスと感染予防に関する調査研究班 : プリオン病診療ガイドライン 2020 (2020年3月発刊) http://prion.umin.jp/guideline/pdf/guideline_2020.pdf (2021年12月16日閲覧)
 
2) 厚生労働科学研究費補助金難治性疾患政策研究事業・プリオン病のサーベイランスと感染予防に関する調査研究班・日本神経学会 : プリオン病感染予防ガイドライン 2020 (2020年3月発刊) (2020年7月改訂) http://prion.umin.jp/guideline/pdf/cjd_2020v6.pdf (2021年12月16日閲覧)
 
P.336 掲載の参考文献
3) Jones E, Hunneirich H, Vire E et al : Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease : a genome-wide association study. Lancet Neurol 19 : 840-848, 2020
 
4) Hamaguchi T, Sakai K, Kobayashi A et al : Characterization of sporadic Creutzfeldt-Jakob disease and history of neurosurgery to identify potential iatrogenic cases. Emerg Infect Dis 26 : 1140-1146, 2020
PubMed
5) Raymond GJ, Race B, Orru CD et al : Transmission of CJD from nasal brushings but not spinal fluid or RT-QuIC product. Ann Clin Transl Neurol 7 : 932-944, 2020
PubMed
P.337 掲載の参考文献
6) Gill ON, Spencer Y, Richard-Loendt A et al : Prevalence in Britain of abnormal prion protein in human appendices before and after exposure to the cattle BSE epizootic. Acta Neuropathol 139 : 965-976, 2020
 
7) Brandel J-P, Vlaicu MB, Culeux A et al : Variant Creutzfeldt-Jakob disease diagnosed 7.5 years after occupational exposure. N Engl J Med 383 : 83-85, 2020
PubMed
8) Mikol J, Delmotte J, Jouy D al : Direct neural transmission of vCJD/BSE in macaque after finger incision. Acta Neuropathol 141 : 119-122, 2021
 
P.338 掲載の参考文献
9) Candelise N, Baiardi S, Franceschini A et al : Towards an improved early diagnosis of neurodegenerative diseases : the emerging role of in vitro conversion assays for protein amyloids. Acta Neuropathol Commun 8 : 117, 2020
PubMed
10) Giaccone G, Moda F : Applications for prion detection in peripheral tissues of patients with variant Creutzfeldt-Jakob disease. Biomolecules 10 : 405, 2020
PubMed
11) Orru CD, Groveman BR, Foutz A et al : Ring trial of 2nd generation RT-QuIC diagnostic tests for sporadic CJD. Ann Clin Transl Neurol 7 : 2262-2271, 2020
PubMed
12) Rhoads DD, Wrona A, Foutz A et al : Diagnosis of prion diseases by RT-QuIC results in improved surveillance Neurology 95 : e1017-e1026, 2020
 
13) Mammana A, Baiardi S, Rossi M et al : Detection of prions in skin punch biopsies of Creutzfeldt-Jakob disease patients. Ann Clin Transl Neurol 7 : 559-564, 2020
PubMed
14) Llorens F, Villar-Pique A, Schmitz M et al : Plasma total prion protein as a potential biomarker for neurodegenerative dementia : diagnostic accuracy in the spectrum of prion diseases. Neuropathol Appl Neurobiol 46 : 240-254, 2020
PubMed
15) Dabin LC, Guntoro F, Campbel T et al : Altered DNA methylation profiles in blood from patients with sporadic Creutzfeldt-Jakob disease. Acta Neuropathol 140 : 863-879, 2020
 
16) Norsworthy PJ, Thompson AGB, Mok TH et al : A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis. Nat Commun 11 : 3960, 2020
PubMed
17) Pascuzzo R, Oxtoby NP, Young AL et al : Prion propagation estimated from brain diffusion MRI is subtype dependent in sporadic Creutzfeldt-Jakob disease. Acta Neuropathol 140 : 169-181, 2020
PubMed
18) Bizzi A, Pascuzzo R, Blevins J et al : Evaluation of a new criterion for detecting prion disease with diffusion magnetic resonance imaging. JAMA Neurol 77 : 1141-1149, 2020
PubMed
19) Bizzi A, Pascuzzo R, Blevins J et al : Subtype diagnosis of sporadic Creutzfeldt-Jakob disease with diffusion magnetic resonance imaging. Ann Neurol 89 : 560-572, 2021
PubMed
P.339 掲載の参考文献
20) Hermann P, Appleby B, Brandel J-P et al : Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 20 : 235-246, 2021
PubMed
21) Hamaguchi T, Sanjo N, Ae R et al : MM2-type sporadic Creutzfeldt-Jakob disease : new diagnostic criteria for MM2-cortical type. J Neurol Neurosurg Psychiatry 91 : 1158-1165, 2020
PubMed
P.340 掲載の参考文献
22) Nakagaki T, Ishibashi D, Mori T et al : Administration of FK506 from late stage of disease prolongs survival of human prion-inoculated mice. Neurotherapeutics 17 : 1850-1860, 2020
PubMed
23) Bizat N, Parrales V, Laoues S et al : An in vivo Caenorhabditis elegans model for therapeutic research in human prion diseases. Brain 144 : 2745-2758, 2021
 
24) Minikel EV, Zhao HT, Le J et al : Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucl Acids Res 48 : 10615-10631, 2020
PubMed
25) Vallabh SM, Minikel EV, Schreiber SL et al : Towards a treatment for genetic prion disease : trials and biomarkers. Lancet Neurol 19 : 361-368, 2020
 
26) Minikel EV, Vallabh SM, Orseth MC et al : Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology 93 : e125-e134, 2019
PubMed
27) JACOP (Japanese Consortium of Prion Disease) http://jacop.umin.jp (2021年12月16日閲覧)
 
P.341 掲載の参考文献
1) Tan CS, Koralnik IJ : Progressive multifocal leukoencephalopathy and other disorders caused by JC virus : clinical features and pathogenesis. Lancet Neurol 9 : 425-437, 2010
PubMed
2) Amend KL, Turnbull B, Foskett N et al : Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 75 : 1326-1332, 2010
PubMed
P.342 掲載の参考文献
3) Yukitake M : Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis : a comprehensive review. Clin Exp Neuroimmunol 9 (Suppl 1) : 37-47, 2018
 
4) 厚生労働科学研究費補助金難治性疾患等政策研究事業「プリオン病及び遅発性ウイルス感染症に関する調査研究班」編 : 進行性多巣性白質脳症 (progressive multifocal leukoencephalopathy : PML) 診療ガイドライン 2020 http://prion.umin.jp/guideline/pdf/guideline_PML_2020.pdf (2021年12月19日閲覧)
 
5) Astrom KE, Mancall EL, Richardson EP Jr : Progressive multifocal leuko-encephalopathy ; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81 : 93-111, 1958
PubMed
6) Cortese I, Reich DS, Nath A : Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 17 : 37-51, 2021
PubMed
P.343 掲載の参考文献
7) Sahraian MA, Radue E-W, Eshaghi A et al : Progressive multifocal leukoencephalopathy : a review of the neuroimaging features and differential diagnosis. Eur J Neurol 19 : 1060-1069, 2012
 
8) Hodel J, Darchis C, Outteryck O et al : Punctate pattern : a promising imaging marker for the diagnosis of natalizumab-associated PML. Neurology 86 : 1516-1523, 2017
 
9) Aaron Boster A, Hreha S, Berger JR et al : Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis : a comparative study. Arch Neurol 66 : 593-599, 2009
PubMed
10) Hodel J, Outteryck O, Dubron C et al : Asymptomatic progressive multifocal leukoencephalopathy -associated with Natalizumab : diagnostic precision with MR imaging. Radiology 278 : 863-872, 2016
PubMed
11) Cinque P, Koralnik IJ, Gerevini S et al : Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 9 : 625-636, 2009
PubMed
12) Nakamichi K, Kawamoto M, Ishii J et al : Improving detection of JC virus by ultrafiltration of cerebrospinal fluid before polymerase chain reaction for the diagnosis of progressive multifocal leukoencephalopathy. BMC Neurol 19 : 252, 2019
 
13) 西條政幸 : 脳脊髄液中のJCウイルス (JCV) の検査支援による進行性多巣性白質脳症 (PML) のサーベイランス. 令和元年度プリオン病及び遅発性ウイルス感染症に関する調査研究班研究成果 http://prion.umin.jp/file/result_virus2019/saijo.pdf (2021年12月19日閲覧
 
P.344 掲載の参考文献
14) Berger JR, Aksamit AJ, Clifford DB et al : PML diagnostic criteria : consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80 : 1430-1438, 2013
PubMed
15) Nishiyama S, Misu T, Shishido-Hara Y et al : Fingolimod-associated PML with mild IRIS in MS. a clinicopathologic study. Neurol Neuroimmunol Neuroinflamm 5 : e415, 2018
 
16) Tan K, Roda R, Ostrow L et al : PML-IRIS in patients with HIV infection : clinical manifestations and treatment with steroids. Neurology 72 : 1458-1464, 2009
PubMed
17) Gasnault J, Costagliola D, Hendel-Chavez H et al : Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6 : e20967, 2011
PubMed
18) Landi D, De Rossi N, Zagaglia S et al : No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88 : 1144-1152, 201
 
P.345 掲載の参考文献
19) Antinori A, Cingolani A, Lorenzini P et al : Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy : data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 9 (Suppl 1) : 47-53, 2003
 
20) Tan CS, Chen Y, Viscidi RP et al : Discrepant findings in immune responses to JC virus in patients receiving natalizumab. Lancet Neurol 9 : 565-566, 2010
 
21) 雪竹基弘 : 進行性多巣性白質脳症 (概説と最近の話題). Neuroinfection 25 : 72-79, 2020
 
22) Berger JR : Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12 : 59-63, 2017
PubMed
23) ナタリズマブ安全性情報
 
24) フィンゴリモド安全性情報
 
P.346 掲載の参考文献
25) 阿江竜介 : 本邦で発症したフィンゴリモド治療に起因するPML患者の発病頻度-統計学的手法を用いた諸外国との比較-. 平成28年度プリオン病及び遅発性ウイルス感染症に関する調査研究班 研究成果 http://prion.umin.jp/file/result_virus2016/ae.pdf (2021年12月19日閲覧)
 
26) フマル酸ジメチル安全性情報
 
27) Marie Guille M, Rousset S, Bonneville F et al : IL-7 immunotherapy for progressive multifocal leukoencephalopathy in a patient with already controlled HIV-1 infection on antiretroviral therapy. AIDS 33 : 1954-1956, 2019
 
28) Giacomini PS, Rozenberg A, Metz I et al : Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 370 : 486-488, 2014
PubMed
29) Cortese I, Muranski P, Enose-Akahata Y et al : Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380 : 1597-1605, 2019
PubMed
30) Stefoski D, Balabanov R, Rasha Waheed R et al : Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol 6 : 923-931, 2019
 
P.347 掲載の参考文献
1) Romero-Sanchez CM, Diaz-Maroto I, Fernandez-Diaz E et al : Neurologic manifestations in hospitalized patients with COVID-19 : the ALBACOVID registry. Neurology 95 : e1060-e1070, 2020
PubMed
P.348 掲載の参考文献
2) Fridman S, Bullrich MB, Jimenez-Ruiz A et al : Stroke risk, phenotypes, and death in COVID-19 : systematic review and newly reported cases. Neurology 95 : e3373-e3385, 2020
 
3) Siepmann T, Sedghi A, Simon E et al : Increased risk of acute stroke among patients with severe COVID-19 : a multicenter study and meta-analysis. Eur J Neurol 28 : 238-247, 2021
PubMed
4) Graus F, Titulaer MJ, Balu R et al : A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15 : 391-404, 2016
PubMed
5) Espindola OM, Gomes YCP, Brandao CO et al : Inflammatory cytokine patterns associated with neurological diseases in coronavirus disease 2019. Ann Neurol 89 : 1041-1045, 2021
PubMed
6) Elkady A, Rabinstein AA : Acute necrotizing encephalopathy and myocarditis in a young patient with COVID-19. Neurology, 2020
 
7) Paterson RW, Brown RL, Benjamin L et al : The emerging spectrum of COVID-19 neurology : clinical, radiological and laboratory findings. Brain 143 : 3104-3120, 2020
PubMed
8) Hayashi M, Sahashi Y, Baba Y et al : COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci 415 : 116941, 2020
PubMed
9) Kishfy L, Casasola M, Banankhah P et al : Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19. J Neurol Sci 414 : 116943, 2020
PubMed
P.349 掲載の参考文献
10) Rabano-Suarez P, Bermejo-Guerrero L, Mendez-Guerrero A et al : Generalized myoclonus in COVID-19. Neurology 95 : e767-e772, 2020
PubMed
11) Shah PB, Desai SD : Opsoclonus myoclonus ataxia syndrome (OMAS) in the setting of COVID-19 infection. Neurology 96 : 33, 2021
 
12) Mendez-Guerrero A, Laespada-Garcia MI, Gomez-Grande A et al : Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology 95 : e2109-e2118, 2020
PubMed
13) Hull M, Parnes M, Jankovic J : Increased incidence of functional (psychogenic) movement disorders in children and adults amidst the COVID-19 Pandemic : a crosssectional study. Neurol Clin Pract, 2021
 
14) De Sanctis P, Doneddu PE, Vigano L et al : Guillain-Barre syndrome -associated with SARS-CoV-2 infection. a systematic review. Eur J Neurol 27 : 2361-2370, 2020
PubMed
15) Filosto M, Cotti Piccinelli S, Gazzina S et al : Guillain-Barre syndrome and COVID-19 : an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry 92 : 751-756, 2021
PubMed
16) Malik GR, Wolfe AR, Soriano R et al : Injury-prone : peripheral nerve injuries associated with prone positioning for COVID-19-related acute respiratory distress syndrome. Br J Anaesth 125 : e478-e480, 2020
PubMed
17) Tanboon J, Nishino I : COVID-19-associated myositis may be dermatomyositis. Muscle Nerve 63 : E9-E10, 2021
PubMed
P.350 掲載の参考文献
18) Matschke J, Lutgehetmann M, Hagel C et al : Neuropathology of patients with COVID-19 in Germany : a post-mortem case series. Lancet Neurol 19 : 919-929, 2020
 
19) Zheng J, Wong LR, Li K et al : COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589 : 603-607, 2021
PubMed
20) Wang L, Sievert D, Clark AE et al : A human three-dimensional neural-peri-vascular 'assembloid' promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology. Nat Med 27 : 1600-1606, 2021
 
21) Iba T, Levy JH, Connors JM et al : The unique characteristics of COVID-19 coagulopathy. Crit Care 24 : 360, 2020
PubMed
P.351 掲載の参考文献
22) Wang EY, Mao T, Klein J et al : Diverse functional autoantibodies in patients with COVID-19. Nature 595 : 283-288, 2021
PubMed
23) Nalbandian A, Sehgal K, Gupta A et al : Post-acute COVID-19 syndrome. Nat Med 27 : 601-615, 2021
PubMed
24) Couzin-Frankel J : The long haul. Science 369 : 614-617, 2020
 
25) Hosp JA, Dressing A, Blazhenets G et al : Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain 144 : 1263-1276, 2021
PubMed
26) Writing Committee for the COMEBAC Study Group, Morin L, Savale L et al : Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 325 : 1525-1534, 2021
 
27) Blomberg B, Mohn KG, Brokstad KA et al : Long COVID in a prospective cohort of home-isolated patients. Nat Med 27 : 1607-1613, 2021
 
P.352 掲載の参考文献
28) Pavord S, Scully M, Hunt BJ et al : Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 385 : 1680-1689, 2021
PubMed
29) Huynh A, Kelton JG, Arnold DM et al : Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 596 : 565-569, 2021
PubMed
30) Lunn MP, Cornblath DR, Jacobs BC et al : COVID-19 vaccine and Guillain-Barre syndrome : let's not leap to associations. Brain 144 : 357-360, 2021
 
31) Hull M, Mered Parnes M : Tics and Tik-Tok : functional tics spread through social media. Mov Disord Clin Pract, 2021
 
32) Kim DD, Kung CS, Perez DL : Helping the public understand adverse events associated with COVID-19 vaccinations : lessons learned from functional neurological disorder. JAMA Neurol 78 : 789-790, 2021
PubMed

X章 代謝性疾患

P.354 掲載の参考文献
1) Germain DP : Fabry disease. Orphanet J Rare Dis 5 : 30, 2010
PubMed
2) Azevedo O, Gago FM, Miltenberger-Miltenyi G et al : Fabry disease therapy : state-of-the-art and current challenges. Int J Mol Sci 22 : 206, 2020
 
P.355 掲載の参考文献
3) Hopkin RJ, Feldt-Rasmussen U, Germain DP et al : Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta : a Fabry Registry analysis stratified by phenotype. Mol Genet Metab Rep 25 : 100670, 2020
 
4) Banikazemi M, Bultas J, Waldek S et al : Agalsidase-beta therapy for advanced Fabry disease : a randomized trial. Ann Intern Med 146 : 77-86, 2007
PubMed
5) Beck M, Hughes D, Kampmann C et al : Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease : a Fabry Outcome Survey analysis. Mol Genet Metab Rep 3 : 21-27, 2015
PubMed
6) Tsuboi K, Yamamoto H : Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naive Fabry disease patients. BMC Pharmacol Toxicol 18 : 43, 2017
PubMed
7) Tsuboi K, Yamamoto H : Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α. Genet Med 16 : 766-772, 2014
 
8) Nakamura K, Kawashima S, Tozawa H et al : Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease : Phase I and II/III clinical studies. Mol Genet Metab 130 : 215-24, 2020
PubMed
9) McCafferty EH, Scott LJ : Migalastat : a review in Fabry disease. Drugs 79 : 543-554, 2019
 
10) Lenders M, Brand E : Fabry disease : the current treatment landscape. Drugs 81 : 635-645, 2021
PubMed
11) 日本先天代謝異常学会編 : ファブリー病診療ガイドライン 2020. 診断と治療社, 東京, 2021
 
12) Parini R, Pintos-Morell G, Hennermann JB et al : Analysis of renal and cardiac outcomes in male participants in the Fabry outcome survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age. Drug Des Devel Ther 14 : 2149-2158, 2020
PubMed
P.356 掲載の参考文献
13) Sheng S, Wu L, Nalleballe K et al : Fabry's disease and stroke : effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. J Clin Neurosci 65 : 83-86, 2019
PubMed
14) Sasa H, Nagao M, Kino K : Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease : post-marketing surveillance in Japan. Mol Genet Metab 126 : 448-459, 2019
PubMed
15) Stamerra CA, De Feo M, Castelli V et al : Effects of agalsidase-β administration on vascular function and blood pressure in familial Anderson-Fabry disease. Eur J Hum Genet 29 : 218-224, 2021
 
16) Fernandez P, Fernandez SO, Gonzalez JGM : Enzyme replacement therapy in pregnant women with Fabry disease : a case series. JIMD Rep 45 : 77-81, 2019
 
17) Narita I, Ohashi T, Sakai N et al : Efficacy and safety of migalastat in a Japanese population : a subgroup analysis of the ATTRACT study. Clin Exp Nephrol 24 : 157-166, 2020
 
P.357 掲載の参考文献
18) Lenders M, Nordbeck P, Kurschat C et al : Treatment of fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother 16 : pvab025, 2021
 
19) Tsukimura T, Tayama Y, Shiga T et al : Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy. Mol Genet Metab Rep 25 : 100650, 2020
PubMed
20) Hongo K, Harada T, Fukuro E et al : Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase a after 6 years of enzyme replacement therapy. Mol Genet Metab Rep 24 : 100623, 2020
 
21) Sawada J, Nakagawa N, Kano K et al : Characteristics of neurological symptoms in adult Japanese patients with Fabry disease. Intern Med 60 : 1819-1826, 2021
PubMed
P.358 掲載の参考文献
22) Korver S, Longo MGF, Lima MR et al : Determinants of cerebral radiological progression in Fabry disease. J Neurol Neurosurg Psychiatry 91 : 756-763, 2020
PubMed
23) Miwa K, Yagita Y, Sakaguchi M et al : Effect of enzyme replacement therapy on basilar artery diameter in male patients with Fabry disease. Stroke 50 : 1010-1012, 2019
PubMed
24) Sawada T, Kido J, Yoshida S et al : Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep 22 : 100562, 2020
PubMed
P.359 掲載の参考文献
25) Yoshida S, Kido J, Sawada T et al : Fabry disease screening in high-risk populations in Japan : a nationwide study. Orphanet J Rare Dis 15 : 220, 2020
PubMed
26) Afanasiev S, Telman G, Hadad R et al : Fabry disease in young ischemic stroke patients in northern Israel. J Stroke Cerebrovasc Dis 29 : 105398, 2020
 
27) 福田隆文, 伊川泰広, 三村卓矢他 : 尿中マルベリー小体が診断に有用だったFabry病3例. JJ Pediatric Society 123 : 866-872, 2019
 
28) Yonishi H, Namba-Hamano T, HamanoT et al : Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy. Nephrol Dial Transplant 24 : 1-10, 2020
 
P.360 掲載の参考文献
29) Laney DA, Germain DP, Oliveira JP et al : Fabry disease and COVID-19 : international expert recommendations for management-based on real-world experience. Clin Kidney J 13 : 913-925, 2020
PubMed
P.361 掲載の参考文献
1) Ng YS, Bindoff LA, Gorman GS et al : Consensus-based statements for the management of mitochondrial stroke-like episodes. Wellcome Open Res 4 : 201, 2019
PubMed
2) De Vries MC, Brown DA, Allen ME et al : Safety of drug use in patients with a primary mitochondrial disease : an international Delphi-based consensus. J Inherit Metab Dis 43 : 800-818, 2020
PubMed
3) Ng YS, Bindoff LA, Gorman GS et al : Mitochondrial disease in adults : recent advances and future promise. Lancet Neurol 20 : 573-584, 2021
PubMed
P.362 掲載の参考文献
4) Thompson K, Collier JJ, Glasgow RIC et al : Recent advances in understanding the molecular genetic basis of mitochondrial disease. J Inherit Metab Dis 43 : 36-50, 2020
PubMed
5) de Laat P, Rodenburg RR, Roeleveld N et al : Six-year prospective follow-up study in 151 carriers of the mitochondrial DNA 3243 A > G variant. J Med Genet 58 : 48-55, 2021
 
6) Ng YS, Martikainen MH, Gorman GS et al : Pathogenic variants in MT-ATP6 : a United Kingdom-based mitochondrial disease cohort study. Ann Neurol 86 : 310-315, 2019
PubMed
7) Stendel C, Neuhofer C, Floride E et al : Delineating MT-ATP6-associated disease : from isolated neuropathy to early onset neurodegeneration. Neurol Genet 6 : e393, 2020
PubMed
P.363 掲載の参考文献
8) Hikmat O, Naess K, Engvall M et al : Simplifying the clinical classification of polymerase gamma (POLG) disease based on age of onset ; studies using a cohort of 155 cases. J Inherit Metab Dis 43 : 726-736, 2020
 
9) Frazier AE, Thorburn DR, Compton AG : Mitochondrial energy generation disorders : genes, mechanisms, and clues to pathology. J Biol Chem 294 : 5386-5395, 2019
PubMed
10) Stenton SL, Prokisch H : Genetics of mitochondrial diseases : identifying mutations to help diagnosis. EBioMedicine 56 : 102784, 2020
PubMed
11) Rath S, Sharma R, Gupta R et al : MitoCarta 3.0 : an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res 49 : D1541-D1547, 2021
 
12) Wagner M, Berutti R, Lorenz-Depiereux B et al : Mitochondrial DNA mutation analysis from exome sequencing-a more holistic approach in diagnostics of suspected mitochondrial disease. J Inherit Metab Dis 42 : 909-917, 2019
PubMed
13) Chakrabarty S, Govindaraj P, Sankaran BP et al : Contribution of nuclear and mitochondrial gene mutations in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. J Neurol 268 : 2192-2207, 2021
PubMed
P.364 掲載の参考文献
14) Lin Y, Ji K, Ma X et al : Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders : a meta-analysis. Ann Clin Transl Neurol 7 : 1204-1213, 2020
PubMed
15) Formichi P, Cardone N, Taglia I et al : Fibroblast growth factor 21 and grow differentiation factor 15 are sensitive biomarkers of mitochondrial diseases due to mitochondrial transfer-RNA mutations and mitochondrial DNA deletions. Neurol Sci 41 : 3653-3662, 2020
PubMed
16) Lehtonen JM, Auranen M, Darin N et al : Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial disease. J Inherit Metab Dis 44 : 469-480, 2021
PubMed
17) Koga Y, Povalko N, Inoue E et al : A new diagnostic indication device of a biomarker growth differentiation factor 15 for mitochondrial diseases : from laboratory to automated inspection. J Inherit Metab Dis 44 : 358-366, 2021
PubMed
18) Ikawa M, Okazawa H, Yoneda M : Molecular imaging for mitochondrial metabolism and oxidative stress in mitochondrial diseases and neurodegenerative disorders. Biochim Biophys Acta Gen Subj 1865 : 129832, 2021
PubMed
19) Ikawa M, Okazawa H, Nakamoto Y et al : PET imaging for oxidative stress in neurodegenerative disorders associated with mitochondrial dysfunction. Antioxidants (Basel) 9 : 861, 2020
PubMed
20) Ikawa M, Povalko N, Koga Y : Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Curr Opin Clin Nutr Metab Care 23 : 17-22, 2020
PubMed
P.365 掲載の参考文献
21) Terada T, Obi T, Bunai T et al : In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease. Neurology 94 : e1592-e1604, 2020
PubMed
22) Catarino CB, von Livonius B, Priglinger C et al : Real-world clinical experience with idebenone in the treatment of leber hereditary optic neuropathy. J Neuroophthalmol 40 : 558-565, 2020
PubMed
23) Ohsawa Y, Hagiwara H, Nishimatsu SI et al : Taurine supplementation for prevention of stroke-like episodes in MELAS : a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 90 : 529-536, 2019
 
24) Russell OM, Gorman GS, Lightowlers RN et al : Mitochondrial diseases : hope for the future. Cell 181 : 168-188, 2020
PubMed
25) Pirinen E, Auranen M, Khan NA et al : Niacin cures systemic NAD (+) deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metab 31 : 1078-1090 e5, 2020
 
26) Newman NJ, Yu-Wai-Man P, Carelli V et al : Efficacy and safety of intravitreal gene therapy for leber hereditary optic neuropathy treated within 6 months of disease onset. Ophthalmology 128 : 649-660, 2021
PubMed
27) Mok BY, de Moraes MH, Zeng J et al : A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature 583 : 631-637, 2020
 
28) Jackson CB, Turnbull DM, Minczuk M et al : Therapeutic manipulation of mtDNA heteroplasmy : a shifting perspective. Trends Mol Med 26 : 698-709, 2020
PubMed
P.366 掲載の参考文献
29) Adashi EY, Rubenstein DS, Mossman JA et al : Mitochondrial disease : replace or edit? Science 373 : 1200-1201, 2021
PubMed
P.367 掲載の参考文献
1) Roberts EA, Schilsky ML : American Association for Study of Liver Diseases (AASLD) : Diagnosis and treatment of Wilson disease : an update. Hepatology 47 : 2089-2111, 2008
 
2) European Association for Study of Liver. EASL clinical practice guidelines : Wilson's disease. J Hepatol 56 : 671-685, 2012
PubMed
3) 日本小児栄養消化器肝臓学会, 日本移植学会, 日本肝臓学会他 : Wilson病診療ガイドライン 2015. 日本小児栄養消化器肝臓学会誌 29 : 63-119, 2015
 
4) 中井正人, 森川賢一, 大原正嗣他 : ウィルソン病における各診断ガイドラインの有用性の検討. 日消誌 114 : 839-845, 2017
 
P.368 掲載の参考文献
5) Hahn SH, Lee SY, Jang YJ et al : Pilot study of mass screening for Wilson's disease in Korea. Mol Genet Metab 76 : 133-136, 2002
PubMed
6) Xie J-J, Wu Z-Y : Wilson's disease in China. Neurosci Bull 33 : 323-330, 2017
 
7) Coffey AJ, Durkie M, Hague S et al : A genetic study of Wilson's disease in the United Kingdom. Brain 136 : 1476-1487, 2013
PubMed
8) Sridhar MS, Rangaraju A, Anbarasu K et al : Evaluation of Kayser-Fleischer ring in Wilson disease by anterior segment optical coherence tomography. Indian J Ophthalmol 65 : 354-357, 2017
PubMed
9) Telinius N, Ott P, Hjortdal J : Detection of Kayser-Fleischer ring using scheimpflug imaging. Acta Ophthalmol 95 : e248-249, 2017
PubMed
10) Albrecht P, Muller AK, Ringelstein M et al : Retinal neuro-degeneration in Wilson's disease revealed by spectral domain optical coherence tomography. PLoS ONE 7 : e49825, 2012
PubMed
11) Sinha S, Taly AB, Ravishankar S et al : Wilson's disease : cranial WRI observations and clinical correlation. Neuroradiology 48 : 613-621, 2006
 
12) Trocello JM, Woimant F, El Balkhi S et al : Extensive striatal, cortical, and white matter brain MRI abnormalities in Wilson disease. Neurology 81 : 1557, 2013
 
P.369 掲載の参考文献
13) Miyajima H : Aceruloplasminemia. Neuropathol 35 : 83-90, 2015
 
14) Dusek P, Skoloudik D, Maskova J et al : Brain iron accumulation in Wilson's disease : a longitudinal imaging case study during anticopper treatment using 7,0 T MRI and transcranial sonography. J Magn Reson Imaging 47 : 282-285, 2018
 
15) Hermann W : Classification and differential diagnosis of Wilson's disease. Ann Transl Med 7 (Suppl 2) : S63, 2019
 
16) EL Balkhi S, Poupon J, Trocello JM et al : Determination of ultrafiltrable and exchangeable copper in plasma : stability and reference values in healthy subjects. Anal Bioanal Chem 394 : 1477-1484, 2009
PubMed
17) EL Balkhi S, Trocello JM, Poupon J et al : Relative exchangeable copper : a new highly sensitive and highly specific biomarker for Wilson's disease diagnosis. Clin Chim Acta 412 : 2254-2260, 2011
 
18) Poujois A, Trocello JM, Djebrani-Oussedik N et al : Exchangeable copper : a reflection of the neurological severity in Wilson's disease. Eur J Neurol 24 : 154-160, 2017
 
P.370 掲載の参考文献
19) Antos A, Litwin T, Skowronska M et al : Pitfalls in diagnosing Wilson's disease by genetic testing alone : the case of a 47-yar-old woman with two pathogenic variants of the ATP7B gene. Neurol Neurochir Pol 54 : 478-480, 2020
 
20) Czlonkowska A, Rodo M, Wierzchowska-Ciok A et al : Accuracy of the radioactive copper incorporation test in the diagnosis of Wilson disease. Liver Int 38 : 1860-1866, 2018
PubMed
21) Pfeiffer RF : Diagnosing Wilson's disease under the sword of Damocles. Neurol Neurochir Pol 54 : 364-365, 2020
PubMed
22) Bandmann O, Weiss KH, Kaler SG : Wilson's disease and other neurological copper disorders. Lancet Neurol 14 : 103-113, 2015
PubMed
23) Stamelou M, Tuschl K, Chong WK et al : Dystonia with brain manganese accumulation resulting from SLC30A10 mutations : a new treatable disorder. Mov Disord 27 : 1317-1322, 2012
PubMed
24) Quadri M, Federico A, Zhao T et al : Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet 90 : 467-477, 2012
PubMed
25) Tuschl K, Clayton PT, Gospe SM Jr et al : Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet 90 : 457-466, 2012
 
P.371 掲載の参考文献
26) Di Toro Mammarella L, Mignarri A, Battisti C et al : Two-year follow-up after chelating therapy in a patient with adult-onset parkinsonism and hypermanganesaemia due to SLC30A10 mutations. J Neurol 261 : 227-228, 2014
 
27) Poujois A, Woimant F : Wilson's disease : a 2017 update. Clin Res Hepatol Gastroenterol 42 : 512-520, 2018
PubMed
28) Weiss KH, Thurik F, Gotthardt DN et al : Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol 11 : 1028-1035, 2013
PubMed
29) 清水教一 : ウィルソン病の診断と治療のポイント-日本版ガイドラインの発表をふまえて-. 臨床神経 59 : 565-569, 2019
 
P.372 掲載の参考文献
30) Aggarwal A, Bhatt M : Advances in treatment of Wilson disease. Tremor Other Hyperkinet Mov 28 : 525, 2018
 

XI章 頭痛

P.374 掲載の参考文献
1) Takeshima T, Wan Q, Zhang Y et al : Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea : a comprehensive review of the literature. J Headache Pain 20 : 111, 2019
PubMed
2) Kikui S, Chen Y, Todaka H et al : Burden of migraine among Japanese patients : a cross-sectional National Health and Wellness Survey. J Headache Pain 21 : 110, 2020
PubMed
P.375 掲載の参考文献
3) 日本神経学会, 日本頭痛学会, 日本神経治療学会監 : 頭痛の診療ガイドライン 2021. 医学書院, 東京, pp1-512, 2021
 
4) Labastida-Ramirez A, Rubio-Beltran E, Haanes KA et al : Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigemino-vascular system. Pain 161 : 1092-1099, 2020
 
5) Sakai F, Takeshima T, Homma G et al : Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 61 : 755-765, 2021
PubMed
6) Ueda K, Ye W, Lombard L et al : Realworld treatment patterns and patientreported outcomes in episodic and chronic migraine in Japan : analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20 : 68, 2019
PubMed
7) Edvinsson L, Haanes KA, Warfvinge K et al : CGRP as the target of new migraine therapies successful translation from bench to clinic. Nat Rev Neurol 14 : 338-350, 2018
PubMed
P.376 掲載の参考文献
8) American Headache Society : The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache 59 : 1-18, 2019
 
P.377 掲載の参考文献
9) Sacco S, Bendtsen L, Ashina M et al : European Headache Federation Guideline on the use of monoclonal antibodies acting on the calcitonin gene -related peptide or its receptor for migraine prevention. J Headache Pain 20 : 6, 2019
 
P.378 掲載の参考文献
10) Sakai F, Ozeki A, Skijarevsky V : Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine : a phase 2 randomized controlled clinical trial. Cephalalgia Reports 3 : 1-10, 2020
 
11) Hirata K, Takeshima T, Sakai F et al : A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf 20 : 721-733, 2021
PubMed
12) Sakai F, Suzuki N, Kim BK et al : Efficacy and safety of fremanezumab for episodic migraine prevention : multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61 : 1102-1111, 2021
PubMed
13) Sakai F, Suzuki N, Kim BK et al : Efficacy and safety of fremanezumab for chronic migraine prevention : multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61 : 1092-1101, 2021
PubMed
14) Ashina M, Saper J, Cady R et al : Eptinezumab in episodic migraine : a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40 : 241-254, 2020
 
15) Lipton RB, Goadsby PJ, Smith J et al : Efficacy and safety of eptinezumab in patients with chronic migraine : PROMISE-2. Neurology 94 : e1365-e1377, 2020
PubMed
P.379 掲載の参考文献
16) Takeshima T, Sakai F, Hirata K et al : Erenumab treatment for migraine prevention in Japanese patients : efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 61 : 927-935, 2021
PubMed
17) Sakai F, Takeshima T, Tatsuoka Y et al : Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Headache 61 : 653-661, 2021
PubMed
18) Tepper SJ, Diener HC, Ashina M et al : Erenumab in chronic migraine with medication overuse : subgroup analysis of a randomized trial. Neurology 92 : e2309-e2320, 2019
PubMed
P.380 掲載の参考文献
19) Goadsby PJ, Dodick DW, Ailani et al : Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults : a double-blind, randomised phase 2b/3 trial. Lancet Neurol 19 : 727-737, 2020
 
20) Ailani J, Lipton RB, Goadsby PJ et al : Atogepant for the preventive treatment of migraine. N Engl J Med 19 : 695-706, 2021
 
P.381 掲載の参考文献
1) 日本神経学会, 日本頭痛学会, 日本神経治療学会監 : 頭痛の診療ガイドライン 2021. 医学書院, 東京, 2021
 
P.382 掲載の参考文献
2) Schiller J, Karst M, Kellner T et al : Combination of acupuncture and medical training therapy on tension type headache : results of a randomised controlled pilot study. Cephalalgia 41 : 879-893, 2021
 
P.384 掲載の参考文献
3) Kroll LS, Callesen HE, Carlsen LN et al : Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. a systematic review and meta-analysis. J Headache Pain 22 : 96, 2021
 
4) Saha FJ, Pulla A, Ostermann T et al : Effects of occlusal splint therapy in patients with migraine or tension-type headache and comorbid temporomandibular disorder : a randomized controlled trial. Medicine (Baltimore) 98 : e16805, 2019
PubMed
5) Danilov AB, Danilov AB, Kurushina OV et al : Safety and efficacy of melatonin in chronic tension-type headache : a postmarketing real-world surveillance program. Pain Ther 9 : 741-750, 2020
PubMed
P.385 掲載の参考文献
6) Roland SB, Pripp AH, Msomphora MR et al : The efficacy of botulinum toxin A treatment for tension-type or cervicogenic headache : a systematic review and meta-analysis of randomized, placebo-controlled trials. Scand J Pain 21 : 635-652, 2021
PubMed
P.386 掲載の参考文献
1) Peng KP, Takizawa T, Lee MJ : Cluster headache in Asian populations : similarities, disparities, and a narrative review of the mechanisms of the chronic subtype. Cephalalgia 40 : 1104-1112, 2020
 
P.387 掲載の参考文献
2) Kikui S, Sugiyama H, Danno D et al : Chronic cluster headache with a pediatric onset : the first japanese case report. Intern Med 59 : 2937-2940, 2020
PubMed
3) Sjostrand C, Alexanderson K, Josefsson P et al : Sickness absence and disability pension days in patients with cluster headache and matched references. Neurology 94 : e2213-e2221, 2020
PubMed
4) Harder AVE, Winsvold BS, Noordam R et al : Genetic susceptibility loci in genomewide association study of cluster headache. Ann Neurol 90 : 203-216, 2021
PubMed
5) O'Connor E, Fourier C, Ran C et al : Genome wide association study identifies risk loci for cluster headache. Ann Neurol 90 : 93-202, 2021
 
P.388 掲載の参考文献
6) Fourier C, Ran C, Sjostrand C et al : The molecular clock gene cryptochrome 1 (CRY1) and its role in cluster headache. Cephalalgia 41 : 1374-1381, 2021
PubMed
P.389 掲載の参考文献
7) Wei DY, Goadsby PJ : Comprehensive clinical phenotyping of nitroglycerin infusion-induced cluster headache attacks. Cephalalgia 41 : 913-933, 2021
PubMed
8) Imai N, Kitamura E : Differences in clinical features of cluster headache between drinkers and nondrinkers in Japan. PLoS One 14 : e0224407, 2019
PubMed
9) Moller M, Mehnert J, Schroeder CF et al : Noninvasive vagus nerve stimulation and the trigeminal autonomic reflex : an fMRI study. Neurology 94 : e1085-e1093, 2020
PubMed
P.390 掲載の参考文献
10) Lambru G, Rantell K, Levy A et al : A prospective comparative study and analysis of predictors of SUNA and SUNCT. Neurology 93 : e1127-e1137, 2019
 
11) Lambru G, Rantell K, O'Connor E et al : Trigeminal neuro-vascular contact in SUNCT and SUNA : a cross-sectional magnetic resonance study Brain 143 : 3619-3628, 2020
 
12) International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia 40 : 129-221, 2020
PubMed
13) 日本口腔顔面痛学会, 日本頭痛学会訳 : 国際口腔顔面痛分類 第1版. 日本口腔顔面痛学会誌 13 : 131-217, 2021
 
14) Ziegeler C, May A : Facial presentations of migraine, TACs, and other paroxysmal facial pain syndromes. Neurology 93 : e1138-e1147, 2019
PubMed
P.391 掲載の参考文献
15) Obermann M, Nagel S, Ose C et al : Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache : a multicentre, double-blind, randomised controlled trial. Lancet Neurol 20 : 29-37, 2021
PubMed
16) Tso AR, Brudfors M, Danno D et al : Machine phenotyping of cluster headache and its response to verapamil. Brain 144 : 655-664, 2021
PubMed
17) Monta A, Redon S, Fabre C et al : A retrospective observation on 105 patients with chronic cluster headache receiving indomethacin. Neurol Sci 42 : 4175-4182, 2021
PubMed
P.392 掲載の参考文献
18) Summ O, Andreou AP, Akerman S et al : Differential actions of indomethacin : clinical relevance in headache. Pain 162 : 591-599, 2021
PubMed
P.393 掲載の参考文献
1) 光藤尚 : 体位性頻脈症候群と低髄液圧症の関係-交感神経機能亢進に注目して-. 自律神経 57 : 56-57, 2020
 
P.394 掲載の参考文献
2) Upadhyaya P, Ailani J : A review of spontaneous intracranial hypotension. Curr Neurol Neurosci Rep 19 : 22, 2019
 
3) D'Antona L, Jaime Merchan MA, Vassiliou A et al : Clinical presentation, investigation findings, and treatment outcomes of spontaneous intracranial hypotension syndrome : a systematic review and meta-analysis. JAMA Neurol 78 : 329-337, 2021
PubMed
4) Carroll IR, Friedman DI : Neuroimaging for spontaneous intracranial hypotension turned on its side. Neurology 96 : 415-416, 2021
PubMed
5) 日本神経学会, 日本頭痛学会, 日本神経治療学会監 : 頭痛の診療ガイドライン 2021. 医学書院, 東京, 2021
 
6) Hani L, Fung C, Jesse CM et al : Insights into the natural history of spontaneous intracranial hypotension from infusion testing. Neurology 95 : e247-e255, 2020
PubMed
7) Villamil F, Ruella M, Perez A et al : Traumatic vs spontaneous cerebrospinal fluid hypotension headache : our experience in a series of 137 cases. Clin Neurol Neurosurg 198 : 106140, 2020
 
P.396 掲載の参考文献
8) Schievink WI, Maya M, Prasad RS et al : Spontaneous spinal cerebrospinal fluidvenous fistulas in patients with orthostatic headaches and normal conventional brain and spine imaging. Headache 61 : 387-391, 2021
PubMed
9) 田村直俊, 光藤尚 : 脳脊髄液減少症の歴史的展望-Schaltenbrandの業績を中心に-. 自律神経 56 : 162-169, 2019
 
10) Graf N, Fernandes Santos AM, Ulrich CT et al : Clinical symptoms and results of autonomic function testing overlap in spontaneous intracranial hypotension and postural tachycardia syndrome : a retrospective study. Cephalalgia Reports 1 : 1-6, 2018
 
11) Kato Y, Hayashi T, Arai N et al : Spontaneous intracranial hypotension associated with postural tachycardia syndrome. Intern Med 58 : 2569-2571, 2019
PubMed
12) Sjulstad AS, Odeh F, Baloch FK et al : Occurrence of postdural puncture headachea randomized controlled trial comparing 22G Sprotte and Quincke. Brain Behav 10 : e01886, 2020
PubMed
P.397 掲載の参考文献
13) Jespersen MS, Jaeger P, Agidius KL et al : Sphenopalatine ganglion block for the treatment of postdural puncture headache : a randomised, blinded, clinical trial. Br J Anaesth 124 : 739-747, 2020
 
14) Kim DK, Brinjikji W, Morris PP et al : Lateral decubitus digital subtraction myelography : tips, tricks, and pitfalls. AJNR Am J Neuroradiol 41 : 21-28, 2020
PubMed
15) Farb RI, Nicholson PJ, Peng PW et al : Spontaneous intracranial hypotension : a systematic imaging approach for CSF leak localization and management based on MRI and digital subtraction myelography. AJNR Am J Neuroradiol 40 : 745-753, 2019
PubMed
16) Schievink WI, Maya MM, Moser FG et al : Lateral decubitus digital subtraction myelography to identify spinal CSF-venous fistulas in spontaneous intracranial hypotension. J Neurosurg Spine 13 : 1-4, 2019
 
17) Kim DK, Carr CM, Benson JC et al : Diagnostic yield of lateral decubitus digital subtraction myelogram stratified by brain MRI findings. Neurology 96 : e1312-e1318, 2021
PubMed
18) Dobrocky T, Grunder L, Breiding PS et al : Assessing spinal cerebrospinal fluid leaks in spontaneous intracranial hypotension with a scoring system based on brain magnetic resonance imaging findings. JAMA Neurol 76 : 580-587, 2019
PubMed
19) Luetzen N, Dovi-Akue P, Fung C et al : Spontaneous intracranial hypotension : diagnostic and therapeutic workup. Neuroradiology 63 : 1765-1772, 2021
PubMed
P.398 掲載の参考文献
20) 嘉山孝正監, 「脳脊髄液減少症の非典型例及び小児例の診断・治療法開拓に関する研究班」編 : 脳脊髄液漏出症診療指針. 中外医薬社, 東京, 2019
 
21) Jones MR, Shlobin NA, Dahdaleh NS : Spontaneous spinal cerebrospinal fluid leak : review and management algorithm. World Neurosurg 150 : 133-139, 2021
PubMed
P.400 掲載の参考文献
1) Headache Classification Committee of the International Headache Society : The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38 : 1-211, 2018
 
2) 日本頭痛学会・国際頭痛分類委員会訳 : 国際頭痛分類 第3版. 医学書院, 東京, 2018
 
3) Gambeta E, Chichorro JG, Zamponi GW : Trigeminal neuralgia : an overview from pathophysiology to pharmacological treatments. Mol Pain 16 : 1744806920901890, 2020
PubMed
4) Jones MR, Urits I, Ehrhardt KP et al : A comprehensive review of trigeminal neuralgia. Curr Pain Headache Rep 23 : 74, 2019
PubMed
5) Magown P, Ko AL, Burchiel KJ : The spectrum of trigeminal neuralgia without neuro-vascular compression. Neurosurgery 85 : E553-e559, 2019
 
6) Di Stefano G, Yuan JH, Cruccu G et al : Familial trigeminal neuralgia-a systematic clinical study with a genomic screen of the neuronal electrogenisome. Cephalalgia 40 : 767-777, 2020
PubMed
7) Panchagnula S, Sularz AK, Kahle KT : Familial trigeminal neuralgia cases implicate genetic factors in disease pathogenesis. JAMA Neurol 76 : 9-10, 2019
PubMed
P.401 掲載の参考文献
8) Ferraro D, Annovazzi P, Moccia M et al : Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia : an Italian multi-centre study. Mult Scler Relat Disord 37 : 101461, 2020
PubMed
9) Di Stefano G, Maarbjerg S, Truini A : Trigeminal neuralgia secondary to multiple sclerosis : from the clinical picture to the treatment options. J Headache Pain 20 : 20, 2019
 
10) Bendtsen L, Zakrzewska JM, Abbott J et al : European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol 26 : 831-849, 2019
PubMed
P.402 掲載の参考文献
11) Farajzadeh A, Bathaie SZ, Arabkheradmand J et al : Different pain states of trigeminal neuralgia make significant changes in the plasma proteome and some biochemical parameters : a preliminary cohort study. J Mol Neurosci 66 : 524-534, 2018
PubMed
12) Parascandolo E, Levinson K, Rizzoli P et al : Efficacy of erenumab in the treatment of trigeminal neuralgia : a retrospective case series. Neurol Clin Pract 11 : 227-231, 2021
PubMed
P.403 掲載の参考文献
13) Moore D, Chong MS, Shetty A et al : A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia. Br J Anaesth 123 : e385-e396, 2019
 
14) Mazzucchi E, Brinzeu A, Sindou M : Arachnoiditis as an outcome factor for micro-vascular decompression in classical trigeminal neuralgia. Acta Neurochir (Wien) 161 : 1589-1598, 2019
 
P.404 掲載の参考文献
15) Hughes MA, Jani RH, Fakhran S et al : Significance of degree of neuro-vascular compression in surgery for trigeminal neuralgia. J Neurosurg, 1-6, 2019
 
16) Jafree DJ, Zakrzewska JM : Long-term pain relief at five years after medical, repeat surgical procedures or no management for recurrence of trigeminal neuralgia after micro-vascular decompression : analysis of a historical cohort. Br J Neurosurg 33 : 31-36, 2019
PubMed
17) Park SH, Chang JW : Gamma knife radiosurgery on the trigeminal root entry zone for idiopathic trigeminal neuralgia : results and a review of the literature. Yonsei Med J 61 : 111-119, 2020
 
18) Somaza S, Montilla EM, Mora MC : Gamma knife radiosurgery on the trigeminal ganglion for idiopathic trigeminal neuralgia : results and review of the literature. Surg Neurol Int 10 : 89, 2019
PubMed
P.405 掲載の参考文献
1) 日本神経学会, 日本頭痛学会, 日本神経治療学会監 : 頭痛の診療ガイドライン 2021. 医学書院, 東京, 2021
 
P.406 掲載の参考文献
2) Pilato F, Distefano M, Calandrelli R : Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome : clinical and radiological considerations. Front Neurol 11 : 34, 2020
PubMed
3) Singhal AB, Topcuoglu MA, Fok JW et al : Reversible cerebral vasoconstriction syndromes and primary angiitis of the central nervous system : clinical, imaging, and angiographic comparison. Ann Neurol 79 : 882-894, 2016
PubMed
4) Choi HA, Lee MJ, Choi H et al : Characteristics and demographics of reversible cerebral vasoconstriction syndrome : a large prospective series of Korean patients. Cephalalgia 38 : 765-775, 2018
PubMed
5) Rocha E, Singhal AB : Current treatment options in cardio-vascular medicine : update on reversible cerebral vasoconstriction syndrome. Curr Treat Options Cardiovasc Med 22 : 1-13, 2020
 
6) Centers for Disease Control and Prevention : National Center for Health Statistics. International classification of diseases, tenth revision, clinical modification (ICD-10-CM). Updated January 26, 2021 cdc.gov/nchs/icd/icd10cm.htm (2021年6月18日閲覧)
 
7) Thavamani A, Umapathi KK, Puliyel M et al : Epidemiology, comorbidities, and outcomes of posterior reversible encephalopathy syndrome in children in the United States. Pediatr Neurol 103 : 21-26, 2020
PubMed
8) Singhal AB, Topcuoglu MA : Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology 88 : 228-236, 2017
PubMed
9) de Boysson H, Parienti JJ, Mawet J et al : Primary angiitis of the CNS and reversible cerebral vasoconstriction syndrome : a comparative study. Neurology 91 : e1468-e1478, 2018
PubMed
10) Caria F, Zedde M, Gamba M et al : The clinical spectrum of reversible cerebral vasoconstriction syndrome : the Italian Project on Stroke at Young Age (IPSYS). Cephalalgia 39 : 1267-1276, 2019
PubMed
11) Coffino SW, Fryer RH : Reversible cerebral vasoconstriction syndrome in pediatrics : a case series and review. J Child Neurol 32 : 614-623, 2017
 
P.407 掲載の参考文献
12) 日本頭痛学会・国際頭痛分類委員会訳 : 国際頭痛分類 第3版. 医学書院, 東京, 2018
 
13) Wolff V, Ducros A : Reversible cerebral vasoconstriction syndrome without typical thunderclap headache. Headache 56 : 674-687, 2016
PubMed
14) Topcuoglu MA, Singhal AB : Hemorrhagic reversible cerebral vasoconstriction syndrome : features and mechanisms. Stroke 47 : 1742-1747, 2016
PubMed
15) Topcuoglu MA, Kursun O, Singhal AB : Coexisting vascular lesions in reversible cerebral vasoconstriction syndrome. Cephalalgia 37 : 29-35, 2017
PubMed
P.408 掲載の参考文献
16) Rocha EA, Topcuoglu MA, Silva GS et al : RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome. Neurology 92 : e639-e647, 2019
PubMed
17) Topcuoglu MA, Chan ST, Silva GS et al : Cerebral vasomotor reactivity in reversible cerebral vasoconstriction syndrome. Cephalalgia 37 : 541-547, 2017
PubMed
18) Hsu WH, Wang SJ, Chao YM et al : Urine metabolomics signatures in reversible cerebral vasoconstriction syndrome. Cephalalgia 40 : 735-747, 2020
PubMed
19) Chen SP, Chang YA, Chou CH et al : Circulating microRNAs associated with reversible cerebral vasoconstriction syndrome. Ann Neurol 89 : 459-473, 2021
PubMed
P.409 掲載の参考文献
20) Willard N, Honce JM, Kleinschmidt-DeMasters BK : PRES : review of histological features. J Neuropathol Exp Neurol 77 : 100-118, 2018
PubMed
21) Parikh NS, Schweitzer AD, Young RJ et al : Corticosteroid therapy and severity of vasogenic edema in posterior reversible encephalopathy syndrome. J Neurol Sci 380 : 11-15, 2017
PubMed
P.410 掲載の参考文献
22) Wu P, Haththotuwa R, Kwok CS et al : Preeclampsia and future cardio-vascular health : a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 10 : e003497, 2017
 
23) John S, Singhal AB, Calabrese L et al : Long-term outcomes after reversible cerebral vasoconstriction syndrome. Cephalalgia 36 : 387-394, 2016
PubMed
24) Boitet R, de Gaalon S, Duflos C et al : Long-term outcomes after reversible cerebral vasoconstriction syndrome. Stroke 51 : 670-673, 2020
PubMed

XII章 てんかん

P.412 掲載の参考文献
1) 日本神経学会監 : CQ1-1 てんかんとはなにか. "てんかん診療ガイドライン 2018". 医学書院, 東京, pp2-3, 2018
 
2) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 22 : 489-501, 1981
PubMed
3) Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30 : 389-399, 1989
PubMed
P.413 掲載の参考文献
4) Fisher RS, Cross JH, French JA et al : Operational classification of seizure types by the International League Against Epilepsy : position paper of the ILAE commission for classification and terminology. Epilepsia 58 : 522-530, 2017
PubMed
5) Pellinen J, Tafuro E, Yang A et al : Focal nonmotor versus motor seizures : the impact on diagnostic delay in focal epilepsy. Epilepsia 61 : 2643-2652, 2020
PubMed
6) 日本神経学会監 : CQ3-2 新規発症の部分てんかんでの選択薬はなにか. "てんかん診療ガイドライン 2018". 医学書院, 東京, pp27-28, 2018
 
7) 日本神経学会監 : CQ3-3 新規発症の全般てんかんでの選択薬はなにか. "てんかん診療ガイドライン 2018". 医学書院, 東京, pp29-30, 2018
 
8) Janmohamed M, Lawn N, Spilsbury K et al : Starting a new anti-seizure medication in drug-resistant epilepsy : add-on or substitute? Epilepsia 62 : 228-237, 2021
PubMed
9) Doerrfuss JI, Kowski AB, Holtkamp M : Etiology-specific response to antiseizure medication in focal epilepsy. Epilepsia 62 : 2133-2141, 2021
PubMed
P.414 掲載の参考文献
10) Seshachala BB, Jose M, Lathikakumari AM et al : Valproate usage in pregnancy : an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia 62 : 1141-1147, 2021
PubMed
11) Vajda FJE, O'Brien TJ, Graham JE et al : Pregnancy after valproate withdrawal-Fetal malformations and seizure control. Epilepsia 61 : 944-950, 2020
PubMed
12) Pennell PB, French JA, May RC et al : Changes in seizure frequency and antiepileptic therapy during pregnancy. N Engl J Med 383 : 2547-2556, 2020
PubMed
13) Sen A, Jette N, Husain M et al : Epilepsy in older people. Lancet 395 : 735-748, 2020
PubMed
P.415 掲載の参考文献
14) Alsfouk BAA, Hakeem H, Chen Z et al : Characteristics and treatment outcomes of newly diagnosed epilepsy in older people : a 30-year longitudinal cohort study. Epilepsia 61 : 2720-2728, 2020
PubMed
15) Devinsky O, Patel AD, Cross JH et al : Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 378 : 1888-1897, 2018
PubMed
16) Patel S, Grinspoon R, Fleming B et al : The long-term efficacy of cannabidiol in the treatment of refractory epilepsy. Epilepsia 62 : 1594-1603, 2021
 
17) Contento M, Bertaccini B, Biggi M et al : Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs. Epilepsia 62 : 2159-2170, 2021
PubMed
18) Wiebe S, Blume WT, Girvin JP et al : A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 345 : 311-318, 2001
PubMed
19) Barba C, Cossu M, Guerrini R et al : Temporal lobe epilepsy surgery in children and adults : a multicenter study. Epilepsia 62 : 128-142, 2021
PubMed
P.416 掲載の参考文献
20) Abou-Al-Shaar H, Brock AA, Kundu B et al : Increased nationwide use of stereoencephalography for intracranial epilepsy electroencephalography recordings. J Clin Neurosci 53 : 132-134, 2018
PubMed
21) Petrik S, San Antonio-Arce V, Steinhoff BJ et al : Epilepsy surgery : late seizure recurrence after initial complete seizure freedom. Epilepsia 62 : 1092-1104, 2021
PubMed
22) Kohlhase K, Zollner JP, Tandon N et al : Comparison of minimally invasive and traditional surgical approaches for refractory mesial temporal lobe epilepsy : a systematic review and meta-analysis of outcomes. Epilepsia 62 : 831-845, 2021
PubMed
23) Kawai K, Tanaka T, Baba H et al : Outcome of vagus nerve stimulation for drugresistant epilepsy : the first three years of a prospective Japanese registry. Epileptic Disord 19 : 327-338, 2017
 
24) Razavi B, Rao VR, Lin C et al : Real-world experience with direct brain-responsive neurostimulation for focal onset seizures. Epilepsia 61 : 1749-1757, 2020
PubMed
25) Salanova V, Sperling MR, Gross RE et al : The SANTE study at 10 years of follow-up : effectiveness, safety, and sudden unexpected death in epilepsy. Epilepsia 62 : 1306-1317, 2021
PubMed

XIII章 神経 ( 脳神経内科 ) 系疾患における新たな治療・新薬の動向

P.418 掲載の参考文献
1) Burgos AM, Saver JL : Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke : meta-analysis of 5 randomized trials. Stroke 50 : 2156-2162, 2019
PubMed
2) Sevigny J, Chiao P, Bussiere T et al : The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537 : 50-56, 2016
 
P.419 掲載の参考文献
3) Hattori N, Tsuboi Y, Yamamoto A et al : Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease : a randomized, double-blind, placebo-controlled, phase II/III study. Parkinsonism Relat Disord 75 : 17-23, 2020
 
4) Hattori N, Mochizuki H, Hasegawa K et al : Ropinirole patch versus placebo, ropinirole extended-release tablet in advanced Parkinson's disease. Mov Disord 35 : 1565-1573, 2020
PubMed
5) Takeda A, Takahashi R, Tsuboi Y et al : Randomized, controlled study of opicapone in Japanese Parkinson's patients with motor fluctuations. Mov Disord 36 : 415-423, 2021
PubMed
6) Halpern CH, Santini V, Lipsman N et al : Three-year follow-up of prospective trial of focused ultrasound thalamotomy for essential tremor. Neurology 93 : e2284-e2293, 2019
PubMed
7) Benedict RHB, Tomic D, Cree BA et al : Siponimod and cognition in secondary progressive multiple sclerosis : EXPAND secondary analyses. Neurology 96 : e376-e386, 2021
PubMed
8) Hauser SL, Bar-Or A, Cohen JA et al : Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383 : 546-557, 2020
PubMed
P.420 掲載の参考文献
9) Pittock SJ, Berthele A, Fujihara K et al : Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381 : 614-625, 2019
PubMed
10) Yamamura T, Kleiter I, Fujihara K et al : Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381 : 2114-2124, 2019
PubMed
11) Traboulsee A, Greenberg BM, Bennett JL et al : Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder : a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19 : 402-412, 2020
 
12) Cree BAC, Bennett JL, Kim HJ et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019
PubMed
13) Oyama M, Okada K, Masuda M et al : Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord 13 : 1756286420904207, 2020
PubMed
14) Howard JF Jr., Bril V, Vu T et al : Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20 : 526-536, 2021
PubMed
P.421 掲載の参考文献
15) Sakai F, Takeshima T, Homma G et al : Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 61 : 755-765, 2021
PubMed
16) Sakai F, Ozeki A, Skljarevski V : Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine : a phase 2 randomized controlled clinical trial. Cephalalgia Reports 3 : 2515816320932573, 2020
 
17) Sakai F, Suzuki N, Kim BK et al : Efficacy and safety of fremanezumab for episodic migraine prevention : multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61 : 1102-1111, 2021
PubMed
18) Sakai F, Suzuki N, Kim BK et al : Efficacy and safety of fremanezumab for chronic migraine prevention : multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61 : 1092-1101, 2021
PubMed
19) Takeshima T, Sakai F, Hirata K et al : Erenumab treatment for migraine prevention in Japanese patients : Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 61 : 927-935, 2021
PubMed
P.422 掲載の参考文献
20) Vossler DG, Knake S, O'Brien TJ et al : Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures : a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry 91 : 1067-1075, 2020
 
21) Yamamoto T, Lim SC, Ninomiya H et al : Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission : the open-label Study 342 (FREEDOM Study). Epilepsia Open 5 : 274-284, 2020
PubMed
22) Mercuri E, Deconinck N, Mazzone ES et al : Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2) : a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 21 : 42-52, 2022
PubMed
P.423 掲載の参考文献
23) Adams D, Gonzalez-Duarte A, O'Riordan WD et al : Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 379 : 11-21, 2018
PubMed
24) Kastritis E, Palladini G, Minnema MC et al : Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med 385 : 46-58, 2021
PubMed
25) Ohsawa Y, Hagiwara H, Nishimatsu SI et al : Taurine supplementation for prevention of stroke-like episodes in MELAS : a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 90 : 529-536, 2019
 

XIV章 神経 ( 脳神経内科 ) 系疾患における新たな診断技術・臨床検査の動向

P.427 掲載の参考文献
1) 井上学 : 急性期脳梗塞におけるperfusion imagingの有用性, 脳循環代謝 30 : 29-33, 2018
 
2) Dula AN, Mlynash M, Zuck ND et al : Neuroimaging in ischemic stroke is different between men and women in the DEFUSE 3 cohort. Stroke 51 : 481-488, 2020
PubMed
3) Mittal S, Oliveros S, Li J et al : AI filter improves positive predictive value of atrial fibrillation detection by an implantable loop recorder. JACC Clin Electrophysiol 7 : 965-975, 2021
PubMed
4) Perez MV, Mahaffey KW, Hedlin H et al : Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med 381 : 1909-1917, 2019
PubMed
5) Samaniego EA, Roa JA, Hasan D : Vessel wall imaging in intracranial aneurysms. J Neurointerv Surg 11 : 1105-1112, 2019
PubMed
6) Ahmed TF, Ahmed A, Imtiaz F : History in perspective : how Alzheimer's disease came to be where it is? Brain Res 1758 : 147342, 2021
PubMed
P.428 掲載の参考文献
7) Beyer L, Brendel M : Imaging of tau pathology in neurodegenerative diseases : an update. Semin Nucl Med 51 : 253-263, 2021
PubMed
8) Tagai K, Ono M, Kubota M et al : High-contrast in vivo imaging of tau pathologies in Alzheimer's and Non-Alzheimer's disease tauopathies. Neuron 109 : 42-58. e8, 2021
 
9) Barthelemy NR, Li Y, Joseph-Mathurin N et al : A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med 26 : 398-407, 2020
PubMed
10) Pereira JB, Janelidze S, Stomrud E et al : Plasma markers predict changes in amyloid, tau, atrophy and cognition in nondemented subjects. Brain 144 : 2826-2836, 2021
PubMed
P.429 掲載の参考文献
11) Tolosa E, Garrido A, Scholz SW et al : Challenges in the diagnosis of Parkinson's disease. Lancet Neurol 20 : 385-397, 2021
PubMed
12) Mitchell T, Archer DB, Chu WT et al : Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp 40 : 5094-5107, 2019
PubMed
13) Rossi M, Candelise N, Baiardi S et al : Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140 : 49-62, 2020
PubMed
14) Ono M, Takahashi M, Shimozawa A et al : In vivo visualization of propagating α-synuclein pathologies in mouse and marmoset models by a bimodal imaging probe, C05-05. bioRxiv, 2020
 
15) Uehara Y, Ueno S, Amano-Takeshige H et al : Non-invasive diagnostic tool for Parkinson's disease by sebum RNA profile with machine learning. Sci Rep 11 : 18550, 2021
PubMed
16) Shefner JM, Al-Chalabi A, Baker MR et al : A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 131 : 1975-1978, 2020
PubMed
P.430 掲載の参考文献
17) Hardiman O : Major advances in amyotrophic lateral sclerosis in 2020. Lancet Neurol 20 : 14-15, 2021
PubMed
18) Tansarli GS, Chapin KC : Diagnostic test accuracy of the BioFire (R) FilmArray(R) meningitis/encephalitis panel : a systematic review and meta-analysis. Clin Microbiol Infect 26 : 281-290, 2019
 
19) Chen B, Lopez Chiriboga AS, Sirven JI et al : Autoimmune encephalitis-related seizures and epilepsy : diagnostic and therapeutic approaches. Mayo Clin Proc 96 : 2029-2039, 2021
PubMed
P.431 掲載の参考文献
20) Fujihara K : Neuromyelitis optica spectrum disorders : still evolving and broadening. Curr Opin Neurol 32 : 385-394, 2019
PubMed
21) Marignier R, Hacohen Y, Cobo-Calvo A et al : Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20 : 762-772, 2021
PubMed
22) Nakahara J : Visualization of myelin for the diagnosis and treatment monitoring of multiple sclerosis. Adv Exp Med Biol 1190 : 249-256, 2019
PubMed
23) Sanz Diaz CT, de Las Heras Florez S, Carretero Perez M et al : Evaluation of kappa index as a tool in the diagnosis of multiple sclerosis : implementation in routine screening procedure. Front Neurol 12 : 676527, 2021
PubMed
24) Kim H, Lee EJ, Kim S et al : Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. Mult Scler 2 : 13524585211024978, 2021
 
25) Frykman H, Kumar P, Oger J : Immunopathology of autoimmune myasthenia gravis : implications for improved testing algorithms and treatment strategies. Front Neurol 11 : 596621, 2020
PubMed
26) de Meel RHP, Keene KR, Wirth MA et al : Repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis. Neurology 94 : e1693-e1701, 2020
PubMed
P.432 掲載の参考文献
27) Van den Bergh PYK, van Doorn PA, Hadden RDM et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint Task Force-Second revision. Eur J Neurol 28 : 3556-3583, 2021
PubMed
28) Capodivento G, De Michelis C, Carpo M et al : CSF sphingomyelin : a new biomarker of demyelination in the diagnosis and management of CIDP and GBS. J Neurol Neurosurg Psychiatry 92 : 303-310, 2021
PubMed
29) Miyazaki T, Nakajima W, Hatano M et al : Visualization of AMPA receptors in living human brain with positron emission tomography. Nat Med 26 : 281-288, 2020
PubMed
P.433 掲載の参考文献
30) Chamanzar A, Haigh SM, Grover P et al : Abnormalities in cortical pattern of coherence in migraine detected using ultra high-density EEG. Brain Commun 3 : fcab061, 2021
PubMed

書評

最近チェックした商品履歴

Loading...